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Abstract
Naturally occurring macromolecules such as proteins and DNA adopt very specific 
conformations and three dimensional arrangements which allow them to perform 
their sophisticated functions in nature. Unnatural oligomers can also adopt well 
defined conformations and these have been termed ‘foldamers’. This project is 
concerned with the design and synthesis of |3-peptide foldamers which are 
assembled from nucleoside derived (3-amino acids. It was hoped that the 
combination of the inherent helix folding properties of peptides and the associated 
characteristics of nucleosides would allow us to create novel foldamers with specific 
recognition properties. The structure of the [3-amino acids involves conversion of the 
3-hydroxyl group of the nucleoside sugar into an amino group (with retention of 
configuration) and oxidation of the 5'-hydroxymethylene group to a carboxylic acid.
Beginning with the natural nucleosides thymidine and 2-deoxyadenosine, 
syntheses of 4 different nucleoside [3-amino acid monomers was accomplished. The 
syntheses were based around the use of S'-azido^'-deoxynucleosides as key 
synthetic intermediates and also required optimisation of protecting groups to 
prevent side reactions associated with cleavage of the glycosidic bond, in general, 
the preferred protecting group strategy involved the S'-amino group being either 
protected with a fiuorenylmethoxycarbonyl (Fmoc) group or being masked as an 
azide. The benzhydryl group also proved useful in the protection of the carboxylic 
acid function for couplings in solution.
The synthesis of the (3-peptides was investigated by both solid-phase peptide 
synthesis and standard couplings in solution. A range of peptide dimers, trimers and 
a tetramer were prepared, but the isolated yields of the final products were low due 
to difficulties with purification.
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Chapter 1: Introduction
1.1 Introduction
Within the natural world, a large proportion of complex processes are carried out by 
macromolecules. Each of these molecules adopts a highly ordered structure which 
is specifically adapted to a unique role. These macrostructures are extremely 
kinetically and thermodynamically stable and this stability can be attributed to the 
presence of a high number of H-bond donors and acceptors in most cases. Some of 
the most important examples of these highly ordered structures are peptides and 
deoxyribonucleic acid (DNA); both these molecules exhibit high levels of hydrogen 
bonding including inter- and intra- molecular bonding which attributes to and allows 
them to keep their distinct structures. Over the past 60 years, the interest in these 
types of molecular structures and their mimics has proved to be a major and 
important area of research.
1.2 DNA Structure 
1.2.1 Primary structure
Although DNA was first isolated in the late 1800’s,1 its true biological function was 
only demonstrated by Avery and co-workers in 1944.2 Early studies of the molecule 
had given a basic understanding of the chemical content of DNA.3,4 However very 
little was known about its higher order structure and how this contributed to its 
function until the publication by Watson and Crick of its double helix structure in 
1953.5 This realisation that structure, as well as the chemical content of a molecule, 
was important for biological activity was the starting point for an extremely 
interesting area of research.
In order to explore the higher order structures of DNA, the primary structure must 
first be examined. The features of the individual nucleotide units are ultimately 
responsible for the complex helical structure formed by DNA and each unit consists 
of a furanose sugar, a heterocyclic base and a phosphate ester.
The bases are either monocyclic pyrimidines (cytosine and thymine, uracil in the 
case of ribonucleic acid) or bicyclic purines (guanine and adenine) and these 
hydrogen bond with each other in a highly specific manner. Adenine is always 
paired with thymine (or uracil in RNA) through 2 hydrogen bonds and guanine with 
cytosine through 3 hydrogen bonds, making this the stronger of the 2 base pairs 
(Figure 1.1). Watson-Crick base pairing is the dominating pattern in double stranded
10
nucleic acid structures. However, other hydrogen bonding arrangements such as 
Hoogsteen pairing are often found in multi-stranded structures (Figure 1.1).6,7
T*A C*G G*G
Figure 1.1: Watson-Crick base pairing for T-A (left), C-G (middle) and Hoogsteen 
base pairing for G-G as seen in G-quadruplexes (right).
The heterocyclic base is attached to the furanose sugar at the anomeric centre (CT) 
and exclusively adopts the p-configuration. The pyrimidine bases are connected to 
the sugar by the AM atom and the purines by A/-9. The bond formed between the 
sugar and base is termed the glycosidic bond and the molecule is collectively known 
as a nucleoside. When esterified with a phosphate ester at the 5'-hydroxyl group, 
these compounds are then termed nucleotides (Figure 1.2). These monomers are 
then joined together in a manner where a phosphodiester bond is formed between 
the S'-position of one and the 3'-position of its neighbour.
O—P—O
Figure 1.2: A Nucleoside (left) a Nucleotide (right) In DNA X=H, in RNA X=OH.
The major structure defining features of the nucleosides are the pucker adopted by 
the furanose sugar ring and the position of the base with respect to the rest of the 
sugar. Studies into nucleoside structure based on pseudorotations have identified 
two interconverting sugar conformations which are termed the C3'-endo 
conformation and the C2'-endo conformation (Figure 1.3). The endo terminology 
refers to the displacement of the C2' or C3' atom out of the C1 '-04-C4' plane of the 
furanose ring, with the endo face being the side on which the heterocyclic base
ll
resides. The other side is termed the exo face. The terms ‘North’ (N) and ‘South’ (S) 
are also used to describe the C3'-e/?cfo and C2'-endo conformations, respectively 
and are based upon their geographical positions on the pseudorotational cycle.8 
Conveniently, the ‘N’ and ‘S’ notation also represents the approximate shape of the 
C4r“C3r-C2,-CT bonds in each conformation.
Figure 1.3: Simplified furanose sugar puckers CS’-Endo “North" (left) and CT-Endo
“South” (right).
The preferred sugar conformation of a nucleoside is determined by a number of 
factors including the orientation of the base and electronic effects in the ring system 
itself. In DNA, the south-type sugar pucker is generally preferred.9 A major 
contributing factor in the adoption of the south conformation is a favourable gauche 
interaction (60° dihedral angle when looking along the C3'-C4' bond) between the 
ribose ring oxygen (04') and the oxygen presiding at C3' (OS').10
Figure 1.4: Nucleoside conformations of guanosine: sterically favourable “antf 
(left), sterically disfavoured “syn" (middle) and favoured "syn” conformation for 8-
oxo-G (right).
The bases in nucleosides can be orientated in two directions with respect to the 
sugar and are termed ‘antF and ‘syrf (Figure 1.4). The ‘ant? conformation is usually 
preferred and describes the situation when the major bulk of the base is orientated 
away from the sugar ring; this reduces any unfavourable steric interactions. This 
conformation is adopted exclusively by the pyrimidines choosing to have the smaller 
H6 above the plane of the ring and avoiding any steric clash between the bulkier 02 
and H3'. Adenine also prefers the 'ant? conformation. However, it has been shown
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that, in certain cases, guanine can prefer to adopt the ‘syri conformation. It has 
been shown that substitutions at the 8-position of the guanine base, such as the 
formation of 8-oxo-G in oxidatively damaged DNA,11 can result in a favouring of the 
‘syn' conformation. The introduction of halogens at C8 to give 8-bromo-G,12 8- 
chloro-G and 8-iodo-G13 also causes the nucleoside to favour the ‘syn’ 
conformation. This characteristic of guanine can result in the formation of unusual 
structures in G-rich sequences, such as in G-quadruplexes which will be explained 
in more detail later in this chapter.
1.2.2 Secondary structure
The original structure of DNA, proposed by Watson and Crick, was a right-handed 
double helix comprised of two single strands of DNA running anti-parallel and held 
together by the formation of hydrogen bonding between the bases on opposite 
strands. As well as base pairing, an additional stabilising effect is tt-tt stacking 
between the heterocyclic bases in the helix (Figure 1.5). 14
Figure 1.5: A double DNA helix (adapted from reference 15).15
In the 1970’s, the development of automated nucleotide synthesis allowed for a 
huge leap in oligonucleotide structural studies. It became possible to obtain 
oligonucleotides of defined sequence and high enough purity for preparation of 
crystals allowing single crystal diffraction studies to be performed.16,17
13
At this time, it was already known that DNA exhibited a great deal of structural 
diversity. However, this was the first time where these structures, termed A-, B- and 
Z- forms could be studied in detail (Figure 1.6). Although different, these helical 
forms all possess the same structural features; a major groove and a minor groove 
which run down the helical axis and are opposite to each other.18
A-DNA B-DNA Z-DNA
Figure 1.6: A-, B- and Z-DNA forms showing a side on view of the helix (top) and a 
view down the helical axis (bottom). The sugar phosphate backbone is shown as a
ribbon (taken from reference 18).18
A-DNA was first observed in dehydrated DNA samples19,20 and it is a right-handed 
helix consisting entirely of C3'-endo nucleoside units with 11 base pairs per helical 
turn. The major groove of this DNA type is comparatively slim, at 2.7A, but it is 
extremely deep (13.5A). This slim wide major groove produces a wide shallow 
minor groove, having a width of 11.0A but a depth of only 2.8A. In A-DNA, the 
stacked base pairs are tilted slightly sideways in order to maintain a normal van der 
Waals’ separation this results in a helix which is 26A across.14 A-DNA can be found 
in RNA duplexes21 and DNA-enzyme complexes.22
B-DNA, also a right-handed helix, is the predominating form under standard 
physiological conditions and, unlike A-DNA, C2'-endo nucleoside units form the 
majority of the structure. In contrast to A-DNA, B-DNA has a wide major groove and 
slim minor groove. The major groove has a width and depth of 11.7A and 8.8A, 
respectively, whereas the minor groove has a width and depth of 5.7A and 7.5A,
14
respectively. This structure has 10 base pairs per helical turn and a diameter of 
20A.14
Z-DNA, a left-handed helix, is the most uncommonly seen form of DNA and it 
adopts an unusual structure. The true function of Z-DNA is not yet fully understood 
and it is regarded as more of a transient feature in a cellular environment than a 
permanent one.23 It has been postulated that Z-DNA plays a role in the regulation of 
gene transcription24 and a number of Z-DNA binding proteins have also been 
identified, including the ELS protein which is responsible for the pathogenicity of 
poxviruses.25
The A-, B- and Z-forms of DNA, mentioned above, are the most intently studied and 
biologically relevant structures. However, the diversity of DNA extends further. A 
whole range of other DNA forms have been observed, although they are usually 
formed under very specific conditions or through specific chemical modifications.
For example, L-DNA is formed when the natural deoxyribose sugar is replaced with 
u-deoxyribose. This imparts a resistance to nucleases into the DNA structure26 and 
is sometimes termed ‘mirror-DNA’ as it is the mirror image of natural DNA. H-DNA is 
an intramolecular triple helical structure that forms under low pH conditions. H-DNA 
is thought to play a role in gene expression and only occurs in poly(purine): 
poly(pyrimidine) rich strands.27 The range of structures found in DNA is so diverse 
that there are only 5 letters remaining to describe new forms that may be found in 
the future.28
1,2.3 Higher order structures
As methods for examining the structure of nucleic acids improved a number of 
multiple stranded structures began to emerge. Interest has grown in these higher 
order structures as their biological function and relevance becomes more apparent. 
Of particular interest are G-quadruplexes and intercalated motifs (i-motifs).
G-quadruplexes (sometimes termed tetraplexes, Figure 1.7) are found in G-rich 
strands of DNA and are square-like conformations of four guanine bases, termed 
tetrads, interacting by Hoogsteen hydrogen bonding in the presence of a 
monovalent metal ion.29,30 These tetrads can be formed by 4 or 2 interacting strands 
and can even be formed by intramolecular interactions within the same strand; the 
latter is the most commonly found topology in nature.31 G-quadruplexes of particular
15
interest are those which form at the end of eukaryotic chromosomes termed 
telomeres. In humans, the telomeric sequence is single stranded, 100-200 
nucleotides in length and is a TTAGGG repeating sequence.32 Human telomeres 
are maintained by the enzyme telomerase and this has been implicated in up to 
85% of cancers. However, formation of G-quadruplexes has been shown to inhibit 
the activity of this enzyme.33 More recently it has been observed that G- 
quadruplexes also play a role in the control and regulation of gene transcription. 
Studies have shown that subjecting genetic sequences that contain G-quadruplexes 
to small molecules or proteins that specifically target the tetrads can disturb genetic 
transcription.34 This makes G-quadruplexes a very attractive target for both 
biological and chemical research.
N—H
H—N
Figure 1.7: A G-tetrad (above) and folding topologies of G-quadruplexes (below)
(adapted from reference 31 ).31
Interestingly, the C-rich strands complementary to the G-rich strands that form 
quadruplexes, can form their own complex higher order structure termed the i- 
motif.35 Formation of the i-motif is pH dependent and consists of two parallel strands
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which are held together by hemi-protonated C-C+ base pairs.36 Two duplexes can 
then interact in an anti-parallel fashion to form a complex quadruplex structure; this 
is the only known structure involving systematic base intercalation (Figure 1.8). As 
with the G-quadruplex the four interacting strands can be sourced from 4,35 237 or a 
single strand of DNA.38 The biological function of the i-motif is not yet fully 
understood although recent research has shown that it too may have an important 
role in gene expression. A study of the oncogene bcl-2 found that deletion or 
mutation of a G-C rich region of the gene upstream from its P1 promoter site, which 
is known to play a large role in its transcription, caused an increase in transcription. 
This indicates that this G-C rich region and its ability to form higher order DNA 
structures must have a role in the regulation of gene expression.39 Further research 
into this complex structure and its role in biology is of great interest in the scientific 
community and as techniques for the study of genetics become more advanced the 
information on the importance of higher order structures is being published.
(6:2:6) i-Motif
Figure 1.8: Hemi-protonated cytosine bases found in the i-motif (left) and a 
representation of a single stranded i-motif showing the systematic base intercalation
(right), (adapted from reference 39).39
Higher order DNA structures are also being utilised in the area of nanotechnology 
where they have found a number of applications ranging from nanostructured 
materials to nanomachinery.40,41 G-Quadruplex motifs have been used in the 
formation of ion selective membrane channels42 and DNA logic switches modulated 
by the presence of metal ions.43 Both the G-quadruplex and i-motif have been 
employed in the formation of microfilms and microcapsules which, with further 
investigation, may have a use in selective binding of therapeutic proteins.44 The i- 
motif alone has found applications in many areas, an example of which is the 
formation of nanoswitches such as those used in molecular machines known as 
DNA tweezers which are activated by a change in pH.45 The research into DNA and
17
its structure is vast and diverse and continues to be of great interest in all areas of 
science and technology.
1.3 Peptide nucleic acid
1.3.1 History and primary structure
Peptide nucleic acid (PNA) is a DNA mimic in which the deoxyribose phosphate 
backbone has been replaced with a pseudo peptide backbone. In the original design 
of PNA (aegPNA), this backbone is made up of A/-(2-aminoethyl)glycine units where 
the nucleobases are attached to the glycine nitrogen by a carbonyl methylene linker 
(Figure 1.9).
“-An*
H
Figure 1.9: The original aegPNA backbone, B=nucleobase.
Since the introduction of aegPNA 20 years ago by Nielsen et al.,46 there has been a 
vast amount of time and effort dedicated to this area in many fields of science from 
pure chemistry47 and biology48 to genetics49 and nanotechnology.50 PNA was 
originally designed as a DNA duplex binding ligand which would mimic a triplex­
forming oligonucleotide and bind in the major groove of a DNA double helix through 
Hoogsteen type base pairing. It was designed based on the bonding pattern seen in 
oligonucleotides known as the “6 + 3 rule”, that is, 6 bonds between neighbouring 
nucleotides and 3 bonds separating the backbone and heterocyclic base. It was 
found however that the PNA backbone was a much better substitute for a normal 
oligonucleotide backbone than expected.46 The publication of this realisation 
sparked a frenzy of interest in this type of oligomer, particularly within the fields of 
antisense and antigene drug discovery.51
From a chemical point of view, PNA has a variety of interesting properties. PNA is 
acid stable and will not suffer from loss of the base even under the most harshly 
acidic conditions;52 cleavage of the glycosidic bond is of major concern in DNA and 
its other mimics. PNA is stable to mildly basic conditions but will undergo acyl 
transfer reactions under strongly basic conditions.53 For this reason, some of the 
preferred methods of PNA synthesis are the Boc- or Fmoc- solid phase strategies,
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removal of Boc protection requires acidic conditions and Fmoc removal requires 
only extremely mild basic conditions.54
From a biological point of view PNA is an attractive target because of its stability in 
the presence of both peptidase and nuclease enzymes.55 Various PNAs have been 
tested in the presence of mammalian and bacterial peptidases and been found to be 
stable.56 In addition, in tests carried out using nuclease and DNase enzymes no 
degradation was observed.57 For these reasons PNA is considered an attractive 
potential drug candidate.
It is thought that the reason why PNA is able to mimic DNA so effectively is due to 
the balance between the inherent flexibility of the molecule and the conformational 
constraint provided by the amide groups. This allows the molecule to adapt to 
variations in the structural features in the DNA target. It has been observed that any 
increase in the conformational freedom in aegPNA, by either elongation of the 
backbone or side chains, results in a loss of stability in PNA/DNA and PNA/RNA 
duplexes.58
LysPNA ArgPNA
Figure 1.10: Modifications to the PNA backbone that increase aqueous solubility,
(adapted from reference 51 ).51
The neutral nature of the pseudo peptide backbone also means that the 
electrostatic repulsion that is experienced between the two anionic strands in DNA 
and RNA does not occur in the PNA duplexes. While the neutral nature of the 
backbone might be an advantage, in terms of energy, it does bring about problems 
with aqueous solubility.51 Common strategies that have been used to overcome its 
poor solubility include incorporation of hydrophilic amino acids, such as lysine 
(lysPNA), at the ends of the molecule,59 incorporation of arginine residues which 
contain the guanidinium group (argPNA) into the backbone60 and conjugation with 
cationic ligands61 (Figure 1.10). All these methods have helped to improve solubility 
without compromising hydrogen bonding ability or specificity.
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1.3.2 Secondary structures of PNA
During PNA duplex and triplex formation studies, it has been observed that the PNA 
strand can associate with its complementary oligonucleotide strand in either a 
parallel or antiparallel fashion, with the latter being the more stable. In comparison 
to an oligonucleotide sequence, the C-terminus of PNA is considered to be the 3- 
end and the 5’-end the A/-terminus. PNAs, like DNA and RNA, also follow the 
Watson and Crick rules for hydrogen bonding.55
PNA: DNA heteroduplexes are considerably more stable than the corresponding 
DNA duplexes and an increase in Tm of around 1K/base has been observed.62 The 
helix tends to take on a form very similar to B-form DNA; the sugar pucker remains 
in the CT-endo conformation and the helical rise remains the same. However, the 
helix does contain some elements of an A-form helix and some differences from the 
standard DNA helix form.63 Whilst the helix is still right-handed64 there are 
approximately 13 bases per helical turn in the PNA:DNA heteroduplex rather than 
the 10 seen in a standard DNA helix, the major groove is wider and, as a 
consequence of this, the minor groove is narrower and more shallow than A-form 
DNA. The amides of the PNA backbone are all orientated towards the solvent and in 
the trans conformation. It is interesting to note, however, that there is no observed 
hydrogen bond formation between the carbonyl and amide groups in the PNA 
backbone. The carbonyl groups within the nucleobase linker are all directed towards 
the C-teminus of the PNA strand.62
PNA:RNA duplexes are even more stable than PNA:DNA duplexes with a Tm 
increase of around 1.5K per base65. The PNA:RNA duplex is a right-handed helix 
with very similar properties to naturally occurring RNA, which usually takes on an A- 
form helix in which the sugar conformation adopted is CZ'-endo. The amides of the 
PNA backbone switch geometry in this case to the cis conformation and again no 
hydrogen bonding is observed.62
20
Figure 1.11: A PNA:RNA duplex and a PNA:DNA duplex (left) shown with side view 
(top) and a view down the helical axis (bottom) (taken from reference 68)68 and a 
PNA:PNA duplex (right) again shown as a side view and a view down the helical
axis (taken from reference 67).67
PNA can also hybridise with itself to form a PNA:PNA duplex which is a unique 
structure unobserved in nature; this has been termed “P-form” (Figure 1.11).66 The 
two PNA strands associate through Watson-Crick interactions and produce a helix 
with a width of 28A and 18 bases per turn, a lot more than the 11 seen in A-form 
DNA or 10 in B-form.67 As a direct consequence of this, the helix has an extremely 
deep, wide major groove and shallow, narrow minor groove. Similarly to the 
PNA:DNA duplex, the backbone amide bonds are in the trans conformation and the 
amides of the nucleobase linker are orientated towards the C-teminus of the 
strands.62
Although originally designed as a (DNA)2:PNA triplex forming strand, it has been 
found that this type of triplex only occurs in cases where a C-rich PNA strand and 
GC-rich DNA duplex are present.46 For other single stranded sequences, the usual 
triplex structure is of the form (PNA)2:DNA and (PNA)2:RNA strands have also been 
observed,69 both exhibit equally high stability. PNAs rich in pyrimidines form 
triplexes with double stranded DNA in the (PNA)2:DNA format but do so by an 
unusual binding mode known as strand displacement or triplex invasion. One strand 
of the DNA duplex is displaced to form a loop and a triplex is formed inside the host
21
duplex, the PNA is bound to the DNA strand by both Watson-Crick and Hoogsteen 
base pairing and the triplex forms an unusual uP-helix” (Figure 1.12).68
3'
C-terminus
PNA
5' Watson-Crick 
strand, /V-Terminus
DNA
Figure1.12: A representation of strand displacement in a DNA duplex by a PNA 
duplex (left), (adapted from reference 68)68 and a (PNA)2:DNA P-helix (right) 
showing a side view (top) and view down the helical axis (bottom), (taken from
reference 68)68
Although PNA forms excellent hybrid molecules with both DNA and RNA, the 
deviations away from the ideal B-form and A-form helix suggest that there is room 
for improvement. This has been attempted using various modifications of the PNA 
monomers in an effort to induce additional conformational constraint in the PNA 
backbone.51 The most successful modifications have come from the introduction of 
cyclic motifs to the backbone. The highest rate of success has been demonstrated 
by the introduction of cyclopentyl (cypPNA)70 and pyrrolidine (pyrPNA)71 motifs 
(Figure 1.13). However, during research with these monomers, it has been found 
that the stereochemistry of such a constrained backbone, as well as other factors, 
do play an important role in host binding ability. The pyrrolidine derived analogues 
showed a distinct preference for antiparallel DNA binding over RNA or 
complementary binding,71 and cyclopentyl analogues showed binding, with a slight 
gain of stability compared to aegPNA, only when in the trans- configuration,72
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Significant work has already been carried out in the field of PNA structure and 
potential functions and interest in this type of molecule remains high today. Further 
research into perfecting the structure, increasing aqueous solubility and cell 
permeability may lead to some extremely important biological applications in the 
future.
pyrPNAcypPNA
Figure 1.13: Modifications to the PNA backbone to induce conformational
constraint.
1.4 g-Peptides
In nature, there are twenty commonly occurring amino acids which exhibit an a- 
arrangement of the functional groups, that is, the carboxylic acid and amine moiety 
are both attached to the same carbon atom. When condensed together, these form 
peptides and these peptides have the ability to hydrogen bond due to a high 
proportion of hydrogen bond donors and acceptors. This hydrogen bonding can be 
both intermolecular, which gives rise to p-sheet and associated structures, and 
intramolecular, which gives rise to a-helix structures.
The key to secondary structure in peptides is the planar peptide bond which was 
first published in 1951 by Pauling et al.73 This was based on earlier work, in the 
1930’s, by Astbury74 who proposed that two different forms of protein, a and p, 
existed in natural fibres. This proposal was based on a difference in x-ray diffraction 
patterns between stretched and none stretched wool fibres. Although the findings 
from this study were not accurate, they were the first major step in the examination 
of peptide secondary structure. The first to identify that the models proposed by 
Astbury were inaccurate was Neurath in a paper from 1940.75 It was shown that the 
models contained clashes of atoms and were therefore not feasible.
23
The planar peptide bond model proposed by Pauling was based on resonance 
structures. It was suggested that all the atoms of the bond must be in the same 
plane in order for the entire structure to be stabilised by resonance (Figure 1.14).
Figure 1.14: Amide bond resonance forms.
The planarity of the amide bond constrains the entire peptide chain which in turn 
means that there are only limited sites where intramolecular hydrogen bonding can 
occur. Based on this hypothesis, in collaboration with Corey and Branson,73 two 
helical structures were proposed, modelled on the results of crystal structure 
studies. Pauling et al. constructed helices with planar amide groups and an 
observed hydrogen bond length of 2.72A. They found there were only two 
possibilities, one with 3.7 residues per helical turn and one with 5.1; these were 
eventually termed an a-helix76 and a y-helix,73 respectively. However, to this date, a 
y-helix has never been observed (Figure 1.15).
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Figure 1.15: Pauling’s a-helix (left) and y-helix (right), (taken from reference 77).77
A major flaw in the work of Pauling et at. was the handedness of the helix. In the 
structure proposed, the helix was shown to be left-handed and made up of D-amino 
acids. We now know that the converse is true and a-helices are right-handed and 
consist of naturally occurring L-amino acids.78 The modern day a-helix is also known 
to have a distance of 1.5A between adjacent amino acids, 3.6 amino acid residues 
per turn and a pitch of 5.4A. The hydrogen bonding in this type of helix exists in an [
/ + 4 ->/ ] fashion which denotes that the backbone N-H of one residue forms a 
hydrogen bond to the carbonyl of the amino acid 4 residues previous.79 Variations of 
this type of hydrogen bonding in an a-helix exist but they are rare and make up only 
a small amount of amino acid structures. These include the 310 helix80 81 (a tighter 
helix) and the u-helix79,82 (a looser helix).
The helix forming propensity of a peptide depends largely on the amino acid 
sequence present; some amino acids have a higher propensity for helix formation 
than others. In 1974, Chou et al.83 derived a helix propensity scale based on 
observations from crystal structures which could be used to predict the folding 
properties of a peptide based only on the amino acid sequence. Structural 
prediction of this type has been an extremely active area of research over the past
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30 years and more recent helix propensity scales allow a-helices to be predicted 
with up to 60% accuracy.84,85 It has been found that the amino acids with the 
highest helix forming propensity are alanine, uncharged glutamic acid, leucine and 
methionine whereas the lowest are proline, due to its lack of an amide proton, and 
glycine because of its high flexibility.83 This supports earlier research which 
suggested that Ala, Leu and Glu were the most commonly found amino acid 
residues in helices.84 Despite the immense amount of time and effort dedicated to 
the study of a-helices, the relationship between all the complex factors involved in 
folding is not yet fully understood.86
Figure 1.16: Hydrogen bonding patterns in different types of a-helix.
In the same year as the publication of the a-helix structures, Pauling et al. also 
published the first work on p-sheets.87 The P-sheet secondary structure is only 
marginally less common than the a-helix and is associated with the formation of 
aggregates and fibrils observed in human diseases such as Alzheimer’s.88 This 
observation makes p-sheets an important area of research.
p-Sheets are networks of polypeptides (termed p-strands) joined together by 
intermolecular hydrogen bonds. The P-strands adopt a slightly extended 
conformation with a distance of 3.5A between adjacent amino acids which is similar 
to a helix with only 2 residues per turn. The ‘pleating’ of the sheets is due to the sp3 
angle of the side chain bearing carbon causing the neighbouring carbon atoms to be 
either above or below the plane of the sheet(Figure 1.17).89,90
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Figure 1.17: ‘Pleating’ in (3-sheets (taken from reference 91 ).91
The two modern day (3-sheet structures are termed parallel and anti-parallel92 
(Figure 1.18). The parallel form of the (3-sheet is more pleated than its anti-parallel 
counterpart and is less commonly found. The parallel sheets are rarely found with 
less than 5 interacting strands ordered C-terminus to C-terminus and are uniform in 
nature with a consistent pattern of 12-membered hydrogen bonded rings. Anti­
parallel p-sheets, on the other hand, can be found with as few as 2 interacting 
strands ordered in an AMerminus to C-terminus fashion and have a repeating 
pattern of 10-membered and 14-membered hydrogen bonded rings.93
Figure 1.18: Hydrogen bonding in p-Sheets: parallel (left) and anti-parallel (right)
Naturally occurring macromolecules demonstrate such an array of complex 
secondary structures, which contribute to their important functions, that it is 
therefore of no surprise that research into mimics of these structural motifs is such a 
huge area. Unnatural mimetics of peptides and related structures which adopt well 
defined secondary structures have been termed ‘foldamers’.94
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1.5 Foldamers
Foldamers are described as ‘a synthetic polymer with a strong tendancy to adopt a 
specific compact conformation’.94 Over the past 20 years, research into foldamers 
has progressed rapidly and applications ranging from biomimetics95 to 
nanotechnology96 have been demonstrated. The range of structures and backbones 
which have been shown to adopt compact folded motifs is extremely diverse and 
constantly expanding with amino acids,97 aromatic oligoamides,98 carbohydrates99 
and polyisocyanates100 included in the scope of this area. The following sections will 
concentrate on p-amino acids, carbohydrate and nucleic acid base-containing 
foldamers.
1.6 B-Peptides 
1.6.1 Introduction
There have been countless studies into synthetic oligomers, but the most intensely 
studied are the p-peptides and their folding properties are the best understood, p- 
Peptides are made up of unnatural p-amino acids which have an additional 
methylene spacer between the amine and carboxylic acid functional groups 
compared to their corresponding a-derivatives (Figure 1.19).
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a-amino acid p-amino acid
Figure 1.19: Amino acids.
p-Amino acids are much less abundant in nature than their a-counterparts; the only 
natural p-amino acid commonly found is p-alanine found in the dipeptides carnosine 
and anserine.101 p-Peptides have a number of attractive properties which make 
them good candidates for development into therapeutic agents. This will be 
discussed within this chapter.
The introduction of the extra methylene group in p-amino acids results in two 
possible sites for substitution, the C2 and C3 positions. Amino acids which are 
substituted on C2, the carbon adjacent to the carbonyl carbon, are termed p2-amino
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acids and amino acids substituted on C3, the same carbon that carries the amine, 
are termed (33-amino acids. Most substituted p-amino acids prefer to reside in a 
gauche conformation around the C2-C3 bond, the one exception to this being a syn- 
C2-C3-disubstituted derivative which prefers an anti-periplanar conformation. In 
order for peptides to fold, the gauche conformation is required and as a result of this 
syn-C2-C3-disubstituted amino acids tend to form sheet- like structures.102
Gauche conformation Anti-periplanar conformation
Figure 1.20: Substitution patterns in p-amino acids (top) and conformations about
the C2-C3 bond (bottom).
The first to coin the term ‘foldamer’ was Gellman,94 who has played a pivotal role in 
the determination of folding patterns in p-peptides. One of the main reasons for 
folding in a-peptides is the lack of nearest neighbour interactions leading to a 
preference for interactions between hydrogen bond donors and acceptors that are 
non-adjacent.103 Early model studies by Gellman et a!., on both p- and y-amino acid 
oligomers, showed that the latter formed a preference for nearest neighbour 
interactions whereas the former did not, suggesting that p-peptides showed more 
promise for folding studies.104 Over almost three decades of work on p-peptide 
foldamers, a large array of structures have been observed including pleated 
sheets,105 turns,106 helices107 and more. The unnatural peptides experience much 
more structural diversity within these classes than their natural analogues e.g. p- 
peptides can from helices with hydrogen bonded rings containing between 8 and 14 
members (Figure 1.21) whereas the dominant form in natural a-helices is the 13 
membered hydrogen bonded ring.
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14-helix
Figure 1.21: Helices found in p-peptides.
Early research by Seebach et al. into naturally occurring polyhydroxybutyrates 
(PHB’s, Figure 1.22) and their synthetic analogues showed that these structures 
adopted a 14-helix with 3 residues per hydrogen bonded turn (3-rhelix) and that 
replacement of the backbone oxygens with nitrogen was highly tolerated.108 This led 
to experiments using the p-analogues of valine, lysine and leucine assembled into a 
(3-hexapeptide of the form (H-3-HVal-(3HAIa-p-HLeu)2-OH. It was found that this 
hexapeptide also formed a 14-helix with 3 amino acid residues per turn. However, 
although circular dichroism spectra showed similarities between the hexapeptide 
and a-peptides which adopt a p-sheet conformation, NMR studies in cfe-pyridine 
revealed that the hydrogen bonds were in fact intra- not intermolecular.109,110 For 
comparison, peptides made up from the naturally occurring a-amino acids form a 
13-helix with 3.6 amino acid residues per hydrogen bonded turn (S.ei-helixJ.The 
major difference between natural and unnatural peptides is the direction of the helix; 
the unnatural helix dipole runs towards the C-terminus, the opposite of what is 
observed in the natural helix.111
CH3 O
H
Figure 1.22: General structure of a polyhydroxybutyrate.
This was considered a surprising result due to the fact that, for an a-peptide to form 
a stable secondary structure in solution, it must contain between 15-20 residues 
whereas the unnatural peptides exhibited secondary structure with only 6.112 It had 
been expected that the extra carbon atom in the P-amino acid structure would 
provide the peptide with additional flexibility and, thus, it had been proposed that a
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lot more residues would be required in order for these peptide molecules to form 
ordered secondary structures.
1.6.2 Conformationallv-constrained B-peptides
The expectation of increased flexibility is reflected in the work of Gellman et at. 
conducted at around the same time on conformationally-constrained (B-peptides.114 
Previous studies on p-alanine peptides had shown that this increased flexibility and 
lack of side chains caused the oligomer to be unordered in solution, although it 
formed p-sheet motifs in the solid state.113 Gellman postulated that reducing the 
number of degrees of freedom available to the peptide would help to induce helical 
folding. This was achieved by incorporating the C2 and C3 carbons of the backbone 
into a cyclohexane ring and utilising a frans-arrangement of the functional 
groups(Figure 1.23), thus trapping the amino acid in its gauche conformation. This 
design was first investigated by computer modelling which indicated that a stable 
helix could be derived from a 10 residue oligomer and that this arrangement formed 
a 14-helix. This was subsequently investigated experimentally and oligomers of 
frans-aminocyclohexanecarboxylic acid (frans-ACHC, Figure 1.23) of various 
lengths were synthesised. A crystal structure of the hexamer revealed that the 
computer modelling was in fact accurate. These constrained oligomers did indeed 
form a 14-helix that was shown to be extremely stable in solution.114
Based on this result, it was postulated that a reduction in ring size should result in a 
smaller hydrogen bonded ring and hence a tighter helix. This hypothesis was 
investigated using a hexamer of frans-aminocyclopentenecarboxylic acid (trans- 
ACPC, Figure 1.23). Interestingly, it was found from 2D-NMR studies that this 
oligomer did indeed form a tighter 12-helix which was stable in organic 
solvents.107,115
a\\NH2
rCOOH 
Trans-ACHC
Figure 1.23: Confomnationally constrained amino acids developed by Gellman.
Since the discovery that p-peptide secondary structure formation could be controlled 
by relatively small changes to the backbone, there have been countless studies into 
backbone variation. Examples of these include oxetane,116 cyclobutane117 and
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cyclopropane118 motifs. The first to investigate 4-membered cyclic amino acid 
monomers was Fleet and co-workers. They found through 2D-NMR studies that a 
hexamer compound of a c/s-oxetane-p-amino acid monomer (Figure 1.24) provided 
a left-handed 10-helix, when present as a solution in either chloroform or 
benzene.116 More recently, studies have shown that the corresponding oligomer 
made from the carbocyclic derivative, c/s-aminocyclobutanecarboxylic acid (c/s- 
ACBC, Figure 1.24), exhibited only nearest neighbour interactions and thus did not 
adopt a helical conformation.119 However, changing the relative positions of the 
functional groups from cis- to trans- induced a conformational change, presumably 
to the gauche conformation. Dipeptides of trans-ACBC and mixed ACBC showed a 
preference for an 8-helix structure120 whereas hexamers and octamers of trans- 
ACBC showed a preference for longer range hydrogen bonding and the formation of 
a 12-helix in cfe-pyridine was observed. 117
.COOH
"'""nh2
Trans-ACBC
Figure 1.24: Oxetane (left) and cyclobutane (right) derived p-amino acids.
Seebach et al. have shown that when achiral cyclopropane amino acids (Figure 
1.25) are assembled into peptides, they form a ribbon like arrangement of 8- 
membered hydrogen bonded ring.118 This deviation away from the traditional 
conformational constraint about the C2-C3 bond has shown just how adaptable 
these peptides are. It is also interesting to note that when the 3-membered 
cyclopropane ring was replaced with a cyclohexane (Figure 1.25) the shape 
adjusted from an 8-helix to a 10-helix.121 8-Helices have been observed in a number 
of oligomers and are thought to be the result of steric and electronic effects which 
favour nearest neighbour type interactions over longer range interactions.
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Figure 1.25: Cyclopropane (left) and cyclohexane derived p-amino acids
1.6.3 Mixed helix forming B-peptides
It has been observed that while homo-oligomers tend to adopt a highly ordered 
regular helix, oligomers with mixed residues can form what is termed a ‘mixed helix’. 
The most well known example of this is the 10/12 helix. p-Peptides with an 
alternating p2- and p3-substitution pattern are known to adopt this type of 
conformation with the amides attached to the unsubstituted methylene groups 
hydrogen bonding to each other forming a 10-membered ring and the amides 
attached to the carbons bearing side chains adopting 12-membered rings (Figure 
1.26).122 These structures have been studied by 2D-NMR and circular dichroism in 
both pyridine and methanol and it has been found that there are two types of amide 
bond alignments in this type of helix. The 10-atom ring amides are orientated almost 
perpendicular to the helical axis and the 12 atom ring amides are orientated with the 
helical axis. This results in a reduced helix dipole compared to the uniformly aligned 
12 and 14 helices.122
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Figure 1.26: Structure of the 10/12-helix with an expanded view showing orientation 
of 10-atom ring amides (green) and 12-atom ring amides (purple), (taken from
reference 102)102.
It has been postulated that the 10/12-helix is favoured when residues with 
intercalating side chains are placed 3 residues apart and this has encouraged 
computational modelling of these types of oligomer. Applying these techniques to 
oligomers of P-alanine predicted that 10/12-helix formation was favoured over a 14- 
helix.123 Introduction of a single methyl group at either the (32 or p3 positions allowed 
for six patterns of dipeptide repeat, (S)-p2/(S)-(32, (S)-p2/(R)-p2, (S)-p2/(S)-p3, (S)- 
p2/(R)-p3, (S)-p3/(S)-p3 and (S)-p3/(R)-p3 and each of these were modelled. Results 
of the study indicated that there seemed to be no additional stabilisation effect to the 
10/12 helix but rather a destabilising effect on the unfavoured conformations, in 
most cases the 14-helix.123 The predictions gained from this study are yet to be 
tested experimentally but could provide a useful tool in the design of specific 
helices.
1.6.4 Problems with B-peotides
A common problem encountered with P-peptides is with their aqueous solubility107 
and a number of methods have been devised to tackle this issue. One of the first 
strategies devised to overcome this problem involved simply adding a charged 
component to the peptide backbone. Gellman et al. were the first to attempt this 
strategy by adding amino groups in an alternating fashion to the cylcohexane moiety 
of the frans-ACHC hexamer mentioned earlier (Figure 1.27).124 This hexamer could
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bear a charge of +3 at pH <7 and indeed did have good aqueous solubility. 
However, it produced poor resolution in NMR studies.
o
Figure 1.27: Gellman’s hexamer with alternating charges (top) and hexamer with 
2:1 cyclic to acyclic residues (bottom).
A hexamer with a 2:1 cyclic to acyclic residue ratio produced much better resolution 
in NMR studies in an aqueous acetate buffer at pH 3.9 and the long range coupling 
constants indicated that it did indeed form a 14-helix in aqueous solution.124 This 
was supported by a characteristic CD maximum at 215nm, which is comparable to 
the frans-ACHC CD spectral findings. The CD spectrum for the fully cyclic charged 
hexamer also produced a strong maximum at 215nm which indicated 14-helix 
formation, although without the corresponding NMR data this could not be 
confirmed for certain.124
A second strategy developed to overcome this problem was to replace the trans- 
ACRC carbocycle with the charged pyrrolidine analogue fra/7s-3-aminopyrrolidine-4- 
carboxylic acid (frans-APC, Figure 1.28).125 This both retained the structural rigidity 
of the original oligomer and improved aqueous solubility as it formed a helix which 
was ampiphilic in nature. This type of oligomer has been shown to have excellent 
antibacterial properties against a number of bacteria strains and also excellent 
selectivity for bacterial cells over mammalian.125
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Figure 1.28: rrans-aminopyrrolidinecarboxylic acid
1.6.5 Sheet structures
As well as forming helices, (3-peptides can also mimic another important class of 
biologically active motifs, namely p-sheets. These unnatural peptides can adopt one 
of two types of anti-parallel arrangements, whereas the natural a-peptides that can 
only form one. This variation exists because of the ability of P-peptides to reside in 
two conformations about the C2-C3 torsion angle, ‘anti’ and ‘gauche’. When all the 
residues in the peptide adopt the ‘anti’ conformation, the sheet is said to be type I. 
This type of sheet results in a net dipole due to the parallel arrangement of the 
carbonyl groups. When all the residues of the peptide adopt the ‘gauche’ 
conformation, the sheet is said to be type II. This sheet has little or no net dipole 
due to the anti-parallel arrangement of the carbonyl groups; this is comparable to 
the naturally occurring a-peptides which adopt a p-sheet motif.126
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Figure 1.29: Two types of p-sheet structures observed in p-peptides.
As mentioned previously, early work on poly-p-alanine showed that this peptide 
tended to form sheet structures in its crystalline form, but was relatively disordered 
in solution.113 Sheet secondary structures have also been observed in other poly-p- 
amino acids. Work by Gellman et at. has provided an important insight into the 
preparation of p-peptides with sheet-like conformations. A hybrid molecule 
containing two C2, C3-disubstituted amino acid residues was shown to adopt a 
hairpin-like, type I anti-parallel sheet conformation both in organic solvents and the 
solid state. The molecule contained a central i-proline-glycolic acid segment which 
assisted the p-turn conformation and initiated the formation of an anti-parallel sheet 
containing both 10-membered and 14-membered hydrogen bonded rings (Figure 
1.30, A).126 One of the key structural features of the two p-amino acids required for 
generation of this sheet conformation, is the syn arrangement of the C2 and C3 
substituents. This promoted an ‘anti’ torsion angle about the C2-C3 bond. 
Replacement of the disubstituted residues with p-alanine led to the formation of a 
type II non-polar sheet while incorporation of two p3-substituted amino acids 
induced an equilibrium between the two types of p-sheet. This research suggested 
that p-amino acids with a syn- C2, C3 disubstitution pattern would have the highest 
propensity for p-sheet formation.
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Further to this finding, a similar p-sheet motif has been synthesised from entirely p- 
amino acid residues by replacing the i-proline-glycolic acid segment of A with a 
heterochiral nipecotic acid dipeptide (Figure 1.30, B). The conformational constraint 
of the heterochiral nipecotic dipeptide fragment induced p-sheet formation. 
However, it was found that if a homochiral dipeptide (i.e. having the same 
configuration at carbons 1 and 2 in Figure 1.30, B) was used instead interaction of 
the two terminal amino acid residues was inhibited, thus preventing sheet 
formation.127
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Figure 1.30: P-Peptide hairpin type structures by Gellman (A and B) and Seebach
(C)
Research by Seebach et al. provided more evidence for the formation of p-peptide 
hairpins in organic solvents by preparing hexapeptides in which the first and last two 
amino acid residues were syn- C2, C3 disubstituted (Figure 1.30, C).128 Interestingly, 
this group reported that a turn-inducing dipeptide containing a C2- followed by a C3- 
substituted p-amino acid provided a different reverse turn motif to that observed in 
the work of Gellman with the nipecotic acid dipeptides. A 10-membered hydrogen 
bonded ring was observed by Seebach whereas Gellman’s peptide gave a 12- 
membered hydrogen bonded ring. This discovery, once again, highlights the 
greater conformational diversity of the p-peptides as opposed to their natural 
congeners, in which only one type of reverse turn (p-tum) is commonly observed.102
More recently, it has been found that conformational control can be exerted on 
certain peptides whilst in aqueous solution by using metal cations such as zinc. This 
type of conformational control is dependent on the nature of the amino acid residues 
and where they are placed in the in the peptide chain. A p-octapeptide has been
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synthesised with terminal p-histidine and p-cysteine residues.129 These residues 
show a high affinity for zinc cations, through interaction with the imidazole A/-atoms 
in the case of histidine and the thiol in the case of cysteine. The peptide was 
examined by NMR in methanol (with S-protection of the terminal p-cysteine residue 
to prevent any disulphide formation) and it was found to form a 14-helix. Upon 
deprotection and isolation with ZnCI2 in an aqueous environment, the peptide was 
seen to undergo a switch from a helical structure to a hairpin-like structure 
containing a 10- and two 14-membered hydrogen bonded rings. It is believed that 
interaction of the two terminal amino acid residues with the zinc cation induced and 
stabilised this change.129 This research highlights new avenues and applications for 
p-peptides which could prove to be important in the future.
1.6.6 Cyclic B-peptides
As well as linear P-peptides, studies have also been carried out on a number of 
cyclic p-peptides. Various groups have undertaken research on these types of 
peptides and have shown that they can undergo molecular stacking to form column 
type structures through hydrogen bonding interactions between the amine group of 
one macrocycle with the carbonyl groups of another. They can also exhibit sheet­
like structures through different hydrogen bonding interactions.
Figure 1.31: Cyclic tetrapeptide
One of the first investigations into cyclic p-peptides was carried out by Seebach et 
al. in which a series of methyl-substituted cyclic tetrapeptides (Figure 1.31) were 
synthesised and studied by powder diffraction. The results suggested that the rings 
did indeed stack on top of each other in an ordered fashion and were stabilised by 
hydrogen bonding interactions between the rings.130
More recently, conformationally constrained cyclic tripeptides have been 
synthesised. It has been found that these also exhibit the same type of
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intermolecular hydrogen bonding to give tubular structures when crystallised from a 
mixture of formic acid and water (Figure 1.32).131 Interestingly however, it was found 
that when the concentration of the peptide was increased, rather than crystals, a 
fibrous material was observed. This was later confirmed to be a sheet-like structure 
by electron diffraction analysis.
A B C
Figure 1.32: Cyclic p-tripeptides (A) assembled into tubular form (B) and sheet form
(C) (taken from reference 131).131
Further to this, Seebach also demonstrated that cyclic (3-peptides may also provide 
good synthetic analogues of naturally occurring hormones. This group synthesised 
a mimic of the hormone somatostatin which has many important biological 
functions, one of which is the regulation and release of growth hormone.132 A 
synthetic analogue of this hormone (octreotide, Figure 1.33) already exists and is 
used therapeutically to treat certain cancers.133 However, this analogue is made of 
a-amino acids and this results in it having an extremely short half life in vivo of just 
90 minutes.
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Figure 1.33: Octreotide (left) and a (3-peptide mimic of Somatostatin (right).
The mimic synthesised by Seebach at al. (Figure 1.33) was shown to bind to 
various somatostatin receptors with affinity comparable to somatostatin itself. 
Subsequent NMR studies of both the existing synthetic hormone and this analogue 
showed significant, although not perfect, spacial overlap of the side chains which 
are essential for biological activity.134 The results of this study indicate that, with 
further research, there may be a potential for p-peptides to be used as therapeutic 
agents within the area of artificial hormones.
1.6.7 Higher order structures in B-peptides
An ultimate goal of the study of p-peptides is to enable the construction of complex 
higher order structures, particularly artificial proteins. Significant progress has been 
made towards this goal with several groups publishing promising results. 
Conformational order in complex structures is a requirement in order to develop 
foldamers with sophisticated biological functions such as catalysis. Research by 
Gellman et al. has identified helix bundle motifs in peptides that contain alternating 
a- and P- amino acid residues and also in what they term a ‘block’ strategy which 
contains a mixture of both a-peptide helices and a/p-peptide helices which 
associate together to form a helix bundle.135,136
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Figure 1.34: A synthetic p-peptide octamer (peptide helices shown in purple) that 
displays a hydrophobic core (shown in green) (taken from reference 138).138
Work by Schepartz et al. indicated that helices containing only p3-amino acid 
residues can also assemble in this way. They observed that a 12-residue helix 
forming foldamer self-associated in aqueous solution, to from an octameric bundle 
held together only by non-covalent inter-residue interactions. This bundle also 
displayed similar properties to those associated with an a-helix bundle such as a 
hydrophobic core (Figure 1.34).137-138 These studies indicate that, clearly, there is 
potential for synthetic mimics of natural biopolymers that may, in the future, provide 
some extremely desirable functions.
1.7 Carbohydrate containing foldamers
Carbohydrates have many important roles in biology ranging from energy storage to 
featuring as essential units in glycoproteins and hormones. They have, therefore, 
featured in much chemical and biological research, one of which is in the area of 
foldamers. There is a vast number of examples of foldamers that contain 
carbohydrate derivatives ranging from the 4 membered oxetanes,116 mentioned 
previously, to pyranose-based carbohydrate analogues. In particular, carbohydrate 
amino acid derivatives have been shown to play a useful role in the construction of 
peptiomimetics,139 the assembly of combinatorial libraries140 and they have also 
produced interesting biological results when incorporated into peptides.141
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Figure 1.35: Furanose-based oligomer that forms a 16-helix.
Work by Fleet et al. has shown that oligomers of furanose dervied amino acids can 
form highly ordered structures in solution (Figure 1.35). An octamer of C-glycosyl a- 
D-lyxofuranose amino acids was synthesised and it was shown through NMR 
studies, to adopt a strongly helical structure in solution; a 16-helix.142 Interestingly, 
shorter oligomers were shown to be disordered in solution which suggests that, in 
this case, more residues are required to induce a secondary structure.
It has also been shown that oligomers utilising pyranose carbohydrate amino acids 
can exhibit secondary structures in solution with as little as 4 residues. However, the 
secondary structure is stabilised by elongation of the chains. Work by Gervay et al. 
demonstrated the first pyranose carbohydrate oligomer containing amide bonds for 
which secondary structure was observed.143 However, full elucidation of the 
interactions involved and conformation of the secondary structure was not published 
until 2 years later. This group found that the secondary structure appeared to vary 
with oligomer length; for the shorter oligomers, for example a tetramer, a 16-helix 
was observed whereas with longer oligomers, an octamer, a 22-helix was 
observed.144 A promising property of these oligomers is that they are water soluble 
and seemed to keep their complex secondary structure when in aqueous solution.
The area of p-peptides derived from carbohydrate p-amino acids has also received 
much attention and numerous examples of these oligomers exist.145 An interesting 
example of this comes from a recent paper by Andreini et al. in which a p-peptide 
with spirocyclic disubstitution and A/, O-acetal functionality at the p-carbon of the 
backbone is presented. Studies by NMR and CD in deuterated DMSO indicated that 
even short oligomers of 4 residues in length adopt secondary structure and there 
was strong evidence for the formation of 8-membered hydrogen bonded rings.146
This research has been, and still is, extremely informative and important in terms of 
examining the possibilities of synthetic peptidomimetics. Carbohydrates have been 
placed in a position of particular importance due to their contribution to the ridigity
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and stability of secondary structures, which are not only limited to helices but 13- 
turns147 and others. One particular interesting feature is the fact that the 
polyhydroxylated backbone offers the opportunity for custom synthesis of 
hydrophobic or hydrophilic derivatives, which is known to be of particular importance 
in protein tertiary structure assembly.142
1.8 Nucleobase-containing foldamers
Oligomers that combine the folding properties of peptides and specific recognition 
properties of nucleic acids have also have been of interest over recent years. 
Although most of the work into these types of foldamers has focused on PNA, there 
are a few notable examples of true polypeptides functionalised with nucleobases. 
The first example of a nucleobase-functionalised amino acid dates back to 1969 
when Doel et al. synthesised a series of adenine, thymine and cytosine a-amino 
acids.148 However, had these amino acids been sequenced into an oligomer, it is 
unlikely that association with a complementary oligonucleotide strand would have 
been successful due to reduced spacial distance between the nucleobases in the 
peptide.The most successful oligonucleotide mimics are those with a backbone 
isosteric to that observed in a natural oligonucleotide strand.
One of the first examples of a successful oligonucleotide binding nucleopeptide was 
reported in 1997 by Yamazaki et at.. This group synthesised a tetrapeptide made up 
of u-a-amino acids functionalised with adenine alternately spaced with glycine, 
serine, threonine or tyrosine. They found that the peptide, although short, bound to 
poly d(T) and poly d(U) sequences with a binding affinity higher than that found with 
a natural d(A) tetranucleotide. It is thought that the increase in binding affinity was 
due to a lack of electrostatic repulsion between the neutral peptide and negatively 
charged oligonucleotide backbones.149
Diederichsen et al. demonstrated that combining the helix-forming properties of (3- 
peptides and association properties of nucleobases can lead to interesting 
results.150 Using the knowledge that ^-substituted peptides tend to form a 14-helix 
with 3 residues per turn, this group assembled peptides with a nucleobase side 
chain substitution every 3 residues.
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p-Peptide
14-helix
|5-Peptide
14-helix
Figure 1.36: A model of base pairing in an anti-parallel (3-peptide duplex 
functionalised with nucleobase side chains every 3 residues, (taken from reference
151).151
This substitution pattern resulted in one side of the helix being occupied by only 
nucleobases (Figure 1.36).150 When in solution, anti-parallel duplex formation 
through the Watson-Crick base pairing of complementary sequences was observed 
for A-T, T-T, C-C+, T-C, T-G pairs.151 Although GCGC sequences were self 
recognising and displayed the strongest binding affinity of all base pairs, homo(G) 
and homo (C) sequences displayed no specific interactions.152
Previous work within our group has shown that oligomers made up of a thymidine 
derived (3-amino acid form an 8-helix in solution.153 Oligomers of 4 residues in length 
were studied by NMR and, when in a solution of cfe-pyridine, were found to 
assemble into a helix in which the thymine nucleobases were located on the outside 
of the helical chain. An overall ‘zig zag’ arrangement of the carbocyclic rings in the 
chain resulted in a pattern of alternating nucleobases being found on alternating 
‘sides’ of the helix (Figure 1.37).153 This result indicates that, in the future, peptides 
of this nature may be able to associate through base pairing to their complementary 
strands in a manner similar to that reported by Diederichsen.
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Figure 1.37: A thymidine derived (3-amino acid (centre) and the oligomers 
assembled by our group (left) and the oligomers assembled by Chandrasekhar et al. 
(taken from references 153, 154 and 155)155
Further to this, Chandrasekhar et al. have shown that oligomers made up of the 
same thymidine-derived (3-amino acid alternated with a-amino acids also formed a 
helical secondary structure. A mixed helix of an 11/8 nature was formed by these 
molecules and, similar to the work of our group, the nucleobases were all still found 
on the outside of the helix. However, this time the nucleobases were located in a 
‘radial’ fashion around the helical axis rather than on alternating ‘sides’.154 Although 
not yet perfected, evidence from these and other studies point to nucleobase 
association becoming a useful tool in molecular design in the future.
1.9 Project aims
The primary goal of this project was to synthesise nucleoside (3-amino acids from 
their natural nucleoside starting materials and assemble them into peptides. It was 
hoped that combining the helix forming properties of cyclic (3-amino acids with the 
characteristics of nucleobases would provide novel foldamers with specific
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recognition properties. Monomers were designed with protecting groups which were 
compatible with both solid and solution phase peptide synthesis so that both 
methods of oligomer assembly could be investigated. Work in this thesis 
concentrates on the synthesis of thymidine, 5-methyl-2'-deoxycytosine and 2'- 
deoxyadenosine amino acid derivatives and their assembly into peptides.
Figure 1.38: Basic synthesis of an oligomer, B=nucleobase.
The peptides were specifically designed to posses both a 5'- carboxylic acid and 3'- 
amine terminus so that the possible formation of cyclic structures that may 
associate through base stacking interactions could be explored.
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Chapter 2: Results and Discussion 1
Synthesis of Nucleoside Derived B-Amino Acid
Monomers
48
2.1 Proposed route for the synthesis of nucleoside g-amino acids
The overall planned synthesis of the required modified nucleoside monomer began 
with the parent nucleosides. The synthesis proceeded through several steps which 
commenced with protection of the 5'-hydroxyl group and any functionality included 
in the nucleobase. This was followed by a double inversion of stereochemistry at the 
3'-position to introduce the azide functionality with overall retention of configuration. 
In general, all the synthetic routes involved reduction of the azide to form the amine 
and oxidation of the 5-hydroxyl group to form the carboxylic acid (Figure 2.1). 
Finally, protection of either the amine or acid functionality provided a monomer 
which could be used for either coupling in solution or on a solid-phase resin. In 
particular, the synthetic work reported herein has focussed on (3-amino acids 
associated with the nucleobases 5-methyl cytosine, thymine and adenine (Figure 
2.1) and these will be addressed in turn.
HO.
PG
OH
NHFmoc NHFmocNHFmoc
Figure 2.1: General reaction scheme outlining the synthesis of a nucleoside (3- 
amino acid (B=nucleobase and PG=protecting group) and also showing the target 
p-amino acids (T = thymine, 5-MeC = cytidine, A = adenine, Bz = benzoyl, Alloc = 
allyloxycarbonyl and Fmoc = 9-fluorenylmethoxycarbonyl)
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2.2 Synthesis of thymidine-derived B-amino acid monomers
Synthesis of a thymidine amino acid monomer protected with Fmoc at the 3'-amino 
group (3) has been reported previously by this group156 (Figure 2.2). This amino 
acid has also been synthesised by other groups; however, each reported synthesis 
varies in both the chemical route to the product and the intended use of the
157,158monomer.
o o o
OH N3 NHFmoc
(1) (2) O)
Figure 2.2: Synthesis of the target thymidine P-amino acid monomer (3)
In this case, the monomer was intended for use with solid-phase peptide synthesis 
conditions, but was deemed to also be suitable for coupling reactions in solution.
The synthesis of this monomer utilised the pharmaceutically important compound 3'- 
azido-3'-deoxythymidine (AZT, Figure 2.2, (2)). AZT was one of the first approved 
treatments for HIV and is still used in combination with other drugs today. 
Consequently, this compound has been studied intensively in order to find efficient 
routes of synthesis.159
Routes to AZT, including synthesis from carbohydrate derivatives,160 
crotonaldehyde161 and 3,3-diethoxypropionate,162 exist in the literature but these can 
be quite complex. By far the most efficient method of synthesis of this compound 
begins with the parent nucleoside and goes via preparation of an 
anhydronucleoside intermediate (Scheme 2.1, 5). This method employs a double 
Sn2 reaction at the 3'-position of the deoxyribose ring, with overall retention of 
stereochemistry. The second of these reactions is carried out using an azide 
nucleophile to introduce this functionality at the 3'-position (7).
Anhydronucleosides have been obtained by a number of methods all of which rely 
on transformation of the 3'-hydroxyl group into a good leaving group (Scheme 2.1). 
Activation of the 3'-hydroxyl group can be achieved either in situ, immediately 
followed by cyclisation in a ‘one-pot’ reaction, or the activated intermediate can be 
isolated and purified before cyclisation is carried out. Generation of the activated
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intermediate in situ is usually performed using either fluorinating reagents163 or in a 
Mitsunobu-style reaction164 and the most commonly used isolatable intermediates 
are S'-O-methansuifony! derivates (4).165 The anhydronucleoside intermediate can 
then be directly opened by azide165 or, as demonstrated by Horwitz166 and Lin,167 a 
second S'-xylo-O-methanesulfonyl derivative (6) can be synthesised and isolated, 
prior to displacement with azide.
Ns (7) (6)
Scheme 2.1: Routes to AZT using direct opening of anhydrothymidine165 (blue) and 
isolation of second active intermediate as demonstrated by Horwitz166/Lin167 (pink).
For our investigations, the method of AZT synthesis chosen was the elegant double 
Mitsunobu reaction developed by Czernecki et ai. (Scheme 2.2).164 The initial step in 
this reaction was protection of the 5-hydroxyl group using p-methoxybenzoic acid 
and this was followed immediately by a second Mitsunobu reaction to give the 5-0- 
protected -2, 3-anhydrothymidine target (8). The white powder obtained required no 
further purification after washing with plenty of diethyl ether and was afforded in high 
yield (84%). indications of successful Z.S'-anhydro formation included an unusually 
high 1H NMR shift for H3r at 5.40 ppm (thymidine H3' appears at 4.10 ppm) and a 
downfield shift of C3' in the 13C NMR spectrum from 71.0 ppm in thymidine to 77.5 
ppm in the 2, S'-anhydrothymidine compound.
Ring opening of the 2, S'-anhydronucleoside (8) was achieved by treatment with 
lithium azide in anhydrous DMF at 125°C. Lithium azide was chosen due to its
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enhanced solubility in polar organic solvents compared to other azide salts such as 
sodium azide.168 Anhydrous lithium azide is not commercially available, but can be 
easily prepared from a salt exchange reaction between sodium azide and lithium 
sulfate. The lithium azide and sodium sulfate by-product can be difficult to separate 
entirely and, for this reason, a large excess of the prepared lithium azide was used 
in this reaction.
'O i) PPh3> DIAD, 
Anisic acid, DMF,
p-OMeBzO.
ii) PPh3, DIAD,
DMF, 5°C
125°C
p-OMeBzO.
84% over 2 steps
Scheme 2.2: Synthesis of AZT from thymidine (p-OMeBz = para-methoxybenzoyl)
Azides show a characteristic peak in the IR spectrum at around 2100cm 1. Analysis 
of the product (9) by IR gave a peak at 2103cm 1, which confirmed the presence of 
an azide group. This was supported by further analysis. The 1H NMR spectrum 
confirmed an upheld shift of the H3' proton from 5.40 ppm in the starting material (8) 
to 4.32 ppm in the azido compound and the 13C NMR spectrum gave an upheld shift 
for C3' from 77.5 ppm in the starting material to 61.6 ppm in the product. 
Comparison of the 13C NMR spectrum of the azido compound to that of the parent 
nucleoside, thymidine (1), also pointed positively to a successful reaction. The C3' 
signal was again upheld from its original shift reported for (1) and this was as 
expected due to an increased shielding effect of an azide compared to that of a 
hydroxyl group.
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During the reaction, formation of a small amount of a more polar product was 
observed. This was isolated during purification and was found to be AZT (2). This 
slight loss of the S'-Oprotecting group suggested that it was not entirely suited to 
the harsh conditions required for the opening of the 2, 3'-anhydronucleoside. It was 
decided tha,t in order to minimise loss of the product, the protected azido 
nucleoside (9) would be carried through the deprotection step crude. This gave an 
increase in yield from 78% over two steps for the method utilizing isolation of the 
protected azido intermediate as compared to 84% when the intermediate was not 
isolated.
Removal of the S'-O-p-methoxybenzoyl protecting group of (9) was carried out 
under basic conditions using powdered sodium methoxide in aqueous methanol 
followed by neutralisation with Amberlite™ H+ resin. Removal of the protecting 
group was confirmed by 1H NMR spectroscopy by the disappearance of the 
characteristic aromatic proton signals associated with the protecting group. This 
route afforded AZT (2) in a 45% yield over 3 steps starting from thymidine (1).
The next step in the synthesis of the protected thymidine amino acid was reduction 
of the azide moiety (Scheme 2.3), Although many reduction methods exist, and 
some of these will be discussed in more detail later in this chapter, the method 
chosen here was catalytic hydrogenation using palladium on activated carbon. This 
provided a simple and efficient route to the S'-amino nucleoside (10) in a 74% yield 
and without the need for further purification. Analysis of the compound by IR 
spectroscopy indicated successful reduction due to disappearance of the 
characteristic azide peak and this was also confirmed in the 1H NMR spectrum of 
compound (10) by an upfield shift of the H3' proton of around 1 ppm.
Protection of the 3'-amino nucleoside with Fmoc was then carried out by treatment 
of (10) with potassium carbonate in a 33% aqueous 1,4-dioxane solution followed 
by addition of Fmoc chloride at low temperature. Addition of water to the solution 
was expected to afford the hydrophobic compound (11) as an amorphous solid 
which could simply be isolated by filteration from the reaction mixture. However, it 
was found that a sticky solid formed rather than the expected powder so extra 
purification by flash chromatography was required to obtain the product in sufficient 
purity for analysis. It was observed, in the NMR spectrum, that the deshielding 
effect of the protecting group caused a significant downfield shift of the H3' proton; 
from 3.33 ppm in the starting material to 4.25 ppm in the product. This, coupled with
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the appearance of characteristic aromatic protons, confirmed that protection had 
been successful.
H2, Pd/C, HO. 
MeOH 
74%
K2CO3, FmocCI 
(2:1) 1,4 dioxane:water 
45%
TEMPO, BAIB, 
1:1 MeCN:water 
40%
NHFmoc NHFmoc
(3) (11)
Scheme 2.3: Route to the final protected thymidine-derived p-amino acid.
The final step in this reaction sequence was the oxidation of the S'-hydroxyl group of 
(11) to a carboxylic acid. Although nucleosides can tolerate a wide range of 
oxidation conditions, as will be discussed later in this chapter, mild, metal free 
oxidations are generally preferred. The milder conditions offer efficient routes to the 
desired level of oxidation without over reaction or the requirement for complicated 
purification techniques. For the purposes of this study an oxidation system utilizing 
the nitroxyl radical, 2,2,6,6-tetramethylpiperidinoxyl (TEMPO), was chosen. TEMPO, 
along with other nitroxyl radicals, has been identified as a useful reagent for 
oxidations as it can be used under a variety of conditions and with a number of co­
reagents. It is also compatible with a large range of substrates and is highly 
selective for oxidation of primary alcohols.169,170 TEMPO can be used in oxidations 
either in stoichiometric or catalytic quantities, however it has been identified that the 
active species required for oxidation is not the TEMPO itself but an oxoammonium 
species.171 If used stoichiometrically, the oxoammonium species can either be
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generated in situ using another oxidant172 or can be prepared separately and 
isolated.173
The catalytic use of TEMPO has been intensively studied as the catalytic cycle for 
regeneration of the radical species has proved to be mechanistically interesting. The 
mechanism by which the active oxoammonium species is generated depends upon 
the pH of the reaction. Two pathways for the generation of the oxoammonium 
intermediate and regeneration to the radical species exist; below pH 3 
disproportionation is favoured and above pH 3 syn-proportionation is the favoured 
cycle (Figure 2.3).169 Disproportionation is induced by acidic conditions where two 
molecules of the radical species generate one molecule of the active oxoammonium 
salt and one molecule of a hydroxylamine by-product. Once the oxoammonium salt 
has oxidised the alcohol, a second molecule of the hydroxylamine by-product is 
formed. Both are converted back to the radical species by the co-oxidant so that the 
cycle can begin again until full oxidation of the alcohol has taken place.
o
Figure 2.3: TEMPO oxidation catalytic cycles showing disproportionation (blue) and
syn-proportionation (pink).
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Above pH 3, syn-proportionation of the oxoammonium and hydroxylamine species 
occurs to give two molecules of TEMPO radical which can then be oxidised by the 
co-oxidant to the active oxoammonium salt. The mechanism for the formation of the 
aldehyde is not yet fully understood. However, three intermediates have been 
postulated (Figure 2.4).169
R
Figure 2.4: Possible intermediates in the TEMPO oxidation.
For this particular conversion, the co-oxidant chosen was b/s-acetoxyiodobenzene 
(BAIB) as this can play a dual role of co-oxidant and proton source. Acetic acid is 
generated during a ligand exchange reaction between BAIB and the substrate and, 
for this reason, it is thought that this reaction is likely to follow the disproportionation 
route. Treatment of the protected 3'-amino nucleoside (11) with TEMPO/BAIB in 
50% aqueous acetonitrile produced the desired 5'-carboxylic acid (3) in a 40% yield. 
The compound precipitated from the reaction liquors upon formation and required 
no further purification. The disappearance of the two distinctive H5' proton signals 
from the 1H NMR spectrum and shift of the C5' peak from 62.7 ppm to 172.5 ppm in 
the 13C spectrum allowed for easy characterisation of the compound.
Although a yield of less than 50% of the protected amino acid was obtained, the fate 
of the other half of the material remains uncertain. Analysis of the reaction liquors 
showed only the presence of the expected by-products, acetic acid and 
iodobenzene. It has been identified that hypervalent iodine compounds, such as 
BAIB, can potentially act as an ozone equivalent and mediate carbon double bond 
cleavage in the presence of water.174 No physical evidence was found to support 
this theory through analysis of the reaction by-products. However, it has been 
demonstrated that the double bond in the thymidine base is susceptible 
ozonolysis.175
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A second thymidine monomer was designed with protection of the S'-carboxylic acid 
group and free 3'-amino to allow for coupling in solution (Figure 2.5). Although 
monomers with 5'-methyl ester protecting groups have been reported in the 
literature and utilised in coupling reactions performed in solution,157 removal of these 
groups and regeneration of the acid can be extremely difficult and require harsh 
conditions. In addition, the methyl group does little to aid the solubility of these polar 
compounds. In order to enable synthesis of longer oligomers, a protecting group 
that would behave in an orthogonal fashion to the Fmoc group was required. 
Therefore, the benzhydryl group was chosen as removal requires only a simple 
hydrogenation reaction. It was also anticipated that this protecting group would 
improve the compound’s solubility in much the same way as a trityl group.
Benzhydry testerMethylester
Figure 2.5: 5'-Carboxylic acid protecting groups (T=thymine).
Synthesis of the benzhydryl-protected monomer (Scheme 2.4) began with the 
previously discussed AZT (2) and oxidation of the 5'-hydroxyl group to give 
thymidine 3'-azido acid (12). Oxidation was carried out using the same 
TEMPO/BAIB procedure described previously. Purification at this stage proved 
difficult due to the surprising solubility of the compound in most organic solvents and 
attempts to purify the azido acid (12) by trituration with diethyl ether and hexane 
gave only a sticky solid. As the high polarity of this compound was expected to 
make chromatographic purification difficult, it was decided to carry the crude azido 
acid through to the next step involving preparation of the benzhydryl derivative (13).
Many methods for the introduction of the benzhydryl protecting group can be found 
in the literature ranging from reaction of carboxylic acids with diphenylmethyl 
phosphates,176 silver carboxylates with diphenylmethyl chloride177 and oxidation of 
benzophenone hydrazone to generate the active intermediate
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diphenyldiazomethane.178 The simplest and most efficient route to introduce this 
protecting group seemed to be using the latter of these methods, however diazo 
compounds are well known to be explosive and undergo degradation upon 
storage179. It was therefore decided to follow a simple one-pot procedure devised by 
Curini ef al. in which the reactive diphenyldiazomethane intermediate was 
generated in situ by oxidation with Oxone® and reacted immediately.180
TEMPO, BAIB, HO. 
1:1 MeCN:water
Benzophenone hydrazone, 
Oxone, 1% I2/DCM, 
Wet alumina, DCM 
59% over 2 steps
H2S, 15% Et3N/Pyr 
88%
Scheme 2.4: route to 5'-protected thymidine amino acid (14).
Thus, a cooled solution of the azido acid (12) and benzophenone hydrazone in the 
presence of catalytic iodine was treated with Oxone® supported on wet alumina.181 
Once the reaction was judged to be complete by tic, the unwanted solids were 
filtered off and a crude residue obtained after removal of the reaction solvents. 
Purification was carried out by simple column chromatography to give benzhydryl 
ester (13) in a 59% yield. The formation of benzhydryl ester (13) was confirmed by 
1H NMR spectroscopy as the spectrum recorded showed the appearance of 
aromatic peaks integrating as 11 protons. The singlet peak of the individual 
hydrogen atom could not be distinguished clearly due to overlap with the aromatic 
protons.
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The final step in the route was reduction of the azide moiety; however, a simple 
hydrogenation could not be used in this case due to the sensitivity of the protecting 
group to these conditions. Many other methods exist in the literature for the 
reduction of azides including reductions with lithium aluminium hydride,182 lnCI3183 
and Fe/AICI3 or Fe/BiCI3.184 However, use of heavy metals can lead to problems 
with purification and the harsh conditions sometimes required are not compatible 
with nucleosides.
The most attractive methods for the reduction of azides in nucleoside chemistry are 
those which offer mild conditions with a simple work-up and purification procedure. 
These include the Staudinger reduction,1851,3-propanedithiol186 reduction and 
hydrogen sulfide reduction.187 Although the Staudinger reduction provides an 
extremely efficient route to amines from azides, it had been found previously in the 
group that the iminophosphorane intermediate can be difficult to hydrolyse and 
removal of the triphenylphosphine oxide by-product can prove problematic. It was 
therefore decided to reduce the azide using hydrogen sulfide gas (Figure 2.6). The 
major by-product of this reaction is elemental sulfur which, if required, can be 
removed by extraction of the desired compound into water; sulfur has extremely 
poor solubility in aqueous solvents.
Figure 2.6: Mechanism of azide reduction by H2S.
Reduction of the protected azido acid (13) was performed by bubbling H2S through 
a solution of the nucleoside and provided the amino acid monomer (14), after 
purification by flash chromatography in an 88% yield. Generation of the amino
compound was confirmed by 1H NMR through a significant upfield shift of the H3' 
peak from 4.36 ppm in the starting material (13) to 3.76 ppm in the product (14). 
Use of the monomers (3) and (14) for coupling in solution will be discussed in 
Chapter 3.
2.3 Synthesis of a 5-methvlcvtidine-derived 0-amino acid monomer
It was decided to synthesise a monomer derived from cytidine for a number 
reasons. Firstly, we wanted a monomer that would base pair with guanosine; it was 
thought that even though there is a methyl group present at the 5-position and so 
this is not a ‘true’ cytidine base, this should have no affect on the ability of the base 
to participate in standard Watson-Crick hydrogen bonding. Secondly, we wanted to 
examine the feasibility of using AZT as a common intermediate in the synthesis of 
both pyrimidine nucleoside p-amino acids, thereby reducing the number of steps 
required to make the cytidine derivative.
NHBz
DMTO.
NHFmoc
Figure 2.7: Synthesis of the 5-methylcytidine derived p-amino acid monomer (16)
(DMT= 4, 4'-dimethoxytrityl).
The route to a 5-methyl-2'-deoxycytidine derived P-amino acid monomer (16, 
outlined in Figure 2.7) was designed using a similar strategy to that of the thymidine 
compound. AZT (2) was used as a common intermediate in both synthetic routes 
and it was thought that a functional group conversion carried out at the 4-carbonyl of 
the thymidine base would offer an efficient route to a cytosine derived P-amino acid 
analogue. A more detailed breakdown of the initial steps in this synthesis is shown 
in Scheme 2.5.
AZT (2) was synthesised by the previously discussed route and the 5'-hydroxyl 
group was protected with a 4, 4'-dimethoxytrityl (DMT) group. The 5'-protected AZT 
derivative (17) was easily accessed through an SN1 reaction with DMT chloride in
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the presence of dimethylaminopyridine (DMAP) in anhydrous pyridine (Scheme 
2.5). This afforded the desired compound (17) in an 87% yield after purification. The 
identity of (17) was confirmed by 1H NMR by the appearance of characteristic 
aromatic peaks and a singlet at 3.76 ppm corresponding to the 6 protons of the 
methoxy groups.
o
DMTO.
(18)
Scheme 2.5: Route to fully protected 3'-azido-2',3'-dideoxy-5-methylcytidine (15).
The first known synthesis of a 5-methylcytidine derivative from thymidine was 
carried out by Fox et al. in 1959.188 In this procedure, thiation of the 4-position, 
using phosphorus pentasulfide, and subsequent displacement with ammonia 
afforded the nucleoside in good yield. However, these conditions are considered to 
be quite harsh and since this publication many other milder methods for carrying out 
the same conversion have been developed. These include sulfonylation- 
amination,189 chlorination-amination190 and triazolation-amination.191 From a survey 
of the literature, the latter seemed to be the most commonly used method for the 
conversion and the most efficient. Based on this evidence, it was decided to follow 
this route.
Initial attempts at the triazolation-amination route proved to give disappointing 
results. For example, a synthesis reported by Gogoi et al., where triazolation was
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carried out by use of phosphoryl trichloride and 1,2,4-triazole (Scheme 2.5, pink), 
followed by amination gave a maximum yield of 50%187 and the reported yield of 
96% was not achieved even after multiple attempts. An alternative method utilizing 
p-chlorophenyl phosphodichloridate (Scheme 2.5, blue), published in 1981 by Sung 
had reported slightly lower yields, but was found to be much more reliable in 
practice.192 Thus, the 5'-protected AZT intermediate (17) was stirred with 1,2,4- 
triazole and p-chlorophenyl phosphodichloridate in pyridine for three days to give 
the 4-triazole intermediate. This was immediately treated with an ammonia/1,4- 
dioxane solution to give the S'-azido-Z'.S'-dideoxy-S-methylcytidine derivative (18). 
After purification, a yield of 88% was obtained which falls in line with the reported 
yield of 85%. The conversion was confirmed by the appearance of a broad singlet in 
the 1H NMR spectrum at 8.21 ppm corresponding to the two protons of the NH2 
group and loss of one mass unit in the high resolution mass spectrum.
Protection of the newly formed exocyclic amine of (18) required a group that would 
behave orthogonal to the Fmoc group for the protection of the sugar 3'-amino group 
later in the synthesis. The A/-benzoyl group is well established in both PNA193 and 
oligonucleotide194 synthesis and was deemed suitable to withstand any of the 
conditions that would subsequently be used in this synthesis.Thus, S’-azido^', 3- 
dideoxy-5-methylcytidine (18) was treated with benzoyl chloride in pyridine and after 
simple work-up and purification the AM-benzoylated compound (15) was obtained 
in 70% yield. Although the appearance of more aromatic peaks was observed in 
both the^ and 13C NMR spectrum it was difficult to ascertain from this alone if the 
correct compound had been formed. However, an accurate high resolution mass 
spectrum was obtained which confirmed that the benzoyl group was indeed present.
From this point the synthetic route was planned to proceed in a similar manner to 
that which had been developed for the preparation of the thymidine amino acid (3) 
(Scheme 2.6). Therefore compound (15), with protection on both the exocyclic 
amine and 5r-hydroxyl group, was subjected to reduction by simple hydrogenation. 
However, this reaction failed to give any of the amine product expected. Thus, it 
was decided to employ the previously used H2S method of reduction which gave the 
3'-amino nucleoside (19) in a 78% yield, after purification by flash chromatography. 
The identity of the product was confirmed by the appearance of a broad singlet in 
the 1H NMR spectrum at 8.29 ppm corresponding to 2 protons. However, all 
attempts to remove the DMT protecting group at this point resulted only in 
degradation of the product presumably by cleavage of the glycosidic bond. It was,
62
therefore, decided to continue the synthesis with the 5'-protecting group intact as 
shown in scheme 2.6.
Protection of the newly formed amine with an fmoc group was, therefore, carried out 
in the same manner as discussed previously for the thymidine amino acid (10). The 
fully protected nucleoside (20) was afforded in near quantitative yield. Successful 
protection was confirmed by the peak shift for H3' in the 1H NMR spectrum, from 
3.77 ppm in the starting material,! to 3.93 ppm in the product and the appearance of 
the characteristic Fmoc peaks at 4.50 ppm and 4.98 ppm. Treatment of compound 
(20) with tosic acid in THF, to remove the 5-DMT protection, proceeded smoothly 
and the 5'-deprotected nucleoside (21) was afforded in good yield ready for the final 
oxidation step. The product was confirmed by loss of 13 protons from the aromatic 
region of the 1H NMR.
NHBz
NHBz
DMTO.
DMTO.
H2S, 15% Et3N/Pyr 
78%
K2CO3, Fmoc-CI,
2:1 1,4-clioxane:Water 
99%
NHBz NHBz
0 TsOH, THF DMTO. 
76%
NHFmoc
(21)
NHFmoc
(20)
Scheme 2.6: Synthesis of 3'-A/-protected amino nucleoside.
Unfortunately, at this stage, attempts to generate the final protected amino acid (16) 
using the preferred method of TEMPO oxidation failed (Figure 2.8). The presence of
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the hydrophobic Fmoc group rendered compound (21) completely insoluble in 
aqueous acetonitrile, the optimal solvent system required for this oxidation.
NHBz NHBz
TEMPO, BAIB, 
1:1 MeCN:Water
NHFmoc
(21) NHFmoc
(16)
Figure 2.8: Oxidation.
This unexpected set back prompted an investigation into other methods of 
oxidation. Although mild metal free methods of oxidation are preferred within the 
area of nucleoside chemistry, some traditional transition metal based procedures 
remain an option. Oxidations utilising KMn04 are not usually considered suitable for 
nucleoside transformations due to the harsh conditions required,195 but pyridinium 
dichromate has been shown to be useful in the oxidation of certain nucleosides.196 
More popular methods of oxidation incorporating the use of heavy transition metals 
include RuCI3 with persulfate197 and 02 insertion over Adams catalyst (R02) in 
aqueous NaHC03198 However, transition metal based procedures have a number of 
potential problems associated with them. These include problems with the co­
ordination of metal catalysts to the nucleobase, making complete removal of the 
catalyst difficult to achieve. Despite these potential issues, the RuCI3 and Pt02 
methods remain widely used in nucleoside chemistry. However, when attempts 
were made to oxidise the 3'-protected amino nucleoside (21) using RuCI3 and 
potassium persulfate no oxidation was observed.
Due to the problems associated with metal based oxidations, organic, metal-free 
methods have increased in popularity. A disadvantage of a lot of these oxidations is 
that they are often not selective for the oxidation of primary alcohols over secondary 
and the product formed is usually an aldehyde so a further oxidation is required to 
generate the carboxylic acid. A popular method of oxidation in organic chemistry is 
the Swern oxidation involving the use of activated DMSO in combination with an 
electrophiles.199 Common electrophiles used include oxalyl chloride,200 acetic 
anhydride201 and thionyl chloride.202 Moffat et al. have shown that this type of 
reaction using DMSO in combination with DCC is a good way of generating
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aldehydes in nucleoside chemistry203,204 and this functionality can then be further 
oxidised to the carboxylic acid.
R R
HO R
Figure 2.9: Intermediates formed during the Dess-Martin oxidation with water (pink)
and without water (blue).
Another popular method for carrying out metal free oxidations is the Dess-Martin 
procedure. This method employs a cyclic periodane and offers an efficient route to 
an aldehyde with short reaction times and simple purification. The Dess-Martin 
periodane is highly selective for the oxidation of alcohols over other oxidisable 
groups, for example furan rings and sulphides. However, it is not selective for 
primary alcohols over secondary.205 The mechanism of the oxidation proceeds firstly 
via a ligand exchange at the iodine centre (Figure 2.9) followed by a proton 
exchange between the substrate and one acetate ligand and elimination of the 
newly oxidised product. It has been found that the addition of water to the reaction 
can accelerate the rate of oxidation as substitution of a second acetate ligand by a 
hydroxyl group takes place. It is thought the electron-donating ability of the hydroxyl 
group causes a lengthening of the remaining iodine-acetate bond (Figure 2.9). As a 
consequence of this the rate of proton exchange between the acetate ligand and 
substrate is increased and hence the oxidised substrate is released more rapidly.206
Attempts to oxidise using standard conditions of the Moffat and Dess-Martin 
procedures successfully produced the aldehyde product. However, no clear 
oxidation to the acid could be achieved. It was therefore decided to return to an 
earlier stage of the synthesis, namely the DMT protected azide (15), and investigate 
an alternative route (Scheme 2.7).
Removal of the DMT protecting group from the azido derivative (15) proved difficult, 
as there was a narrow window between complete removal and product degradation, 
presumably through cleavage of the glycosidic bond. When the compound was 
subjected to treatment with tosic acid, reaction times of longer than 10 minutes 
resulted in a significant reduction in yield and therefore the reaction required careful
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monitoring. Fast efficient workup and rapid purification were also required to obtain 
the best yields. The S'-deprotected nucleoside (22) was obtained in 81% yield and 
its formation was confirmed by 1H NMR through the loss of 13 aromatic proton 
signals.
NHBz
DMTO.
TsOH, THF 
81%
(15)
NHBz
(22)
TEMPO, BAIB, 
NaHC03,
1:1 MeCN, Water 
83%
NHBz
H2S, 15% Et3N/Pyr
Scheme 2.7: Alternative synthesis of 2', 3'-dideoxy-5-methylcytidine (3-amino acid
(24).
Oxidation of the 5'-position of nucleoside (22) was now successfully carried out 
using TEMPO. However, due to the apparent sensitivity of the compound to the 
presence of acid, it was decided to carry out the reaction under the conditions 
required for syn-proportionation. This was achieved by addition of NaHC03 to bring 
the reaction mixture to a higher pH. The oxidised product (23) was obtained as a 
brown powder in 83% yield, after trituration from a mixture of acetone and diethyl 
ether. Successful oxidation was confirmed by a loss of the two signals in the region 
of 3.76-4.02 ppm in the 1H NMR of the starting material (22) corresponding to the 
two H5' protons.
Insolubility of azido acid (23) in many solvents, including those favoured for 
hydrogenation, meant that simple palladium-catalysed reduction of the azide moiety
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was a less attractive option here. Therefore, reduction was carried out using H2S as 
previously described. The high polarity of the amino acid was anticipated to make 
purification by flash chromatography very difficult so the crude product (24) was 
instead partially purified by dissolution in water to precipitate the elemental sulfur. 
The identity of the amino acid (24) was confirmed by high resolution mass 
spectrometry.
NHBz NHBz
'O K2CO3, Fmoc-CI 
2:1 1,4-dioxane: H20 
17%
NHFmoc
(16)
Scheme 2.8: Protection of 3'-amino group.
Initial attempts to protect the S'-amino group of (24) with an Fmoc protecting group 
under the same conditions employed with the thymidine amino acid (10) gave only a 
diprotected Fmoc derivative which was confirmed by both NMR and mass 
spectrometry. This was a surprising result as no di-protection had been observed in 
the synthesis of the analogous thymidine compound. It appeared that the second 
Fmoc group had been incorporated at the A/-4-position, although there was no 
physical evidence to support this theory. The reaction was therefore attempted with 
only 1 equivalent of Fmoc-chloride at reduced temperature. Although this change in 
the conditions slowed down the rate of reaction, significant formation of di-protected 
product was again observed and it was decided to stop the reaction before 
completion. The mixture of starting material, mono-protected and di-protected 
products was separated by flash chromatography and a yield of 17% of the mono- 
protected target compound (16) was obtained (Scheme 2.8). The product was 
confirmed by the appearance of characteristic Fmoc peaks at 4.53 ppm and 
4.70 ppm in the 1H NMR spectrum.
Although the desired protected p-amino acid (16) had been successfully 
synthesised, the low yields obtained from the final protection step suggests that 
methods for the introduction of the Fmoc group into these p-amino acids requires 
further study. In addition, related work performed in parallel within the group 
suggested that the benzoyl group may not be entirely suited to the synthesis and
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deprotection of the p-peptides. This is discussed in more detail with regard to the 
synthesis of the adenine derived (3-amino acids. The use of this 2',3'-dideoxy-5- 
methylcytidine (3-amino acid monomer (16) for assembly of oligomers in solution will 
be discussed in Chapter 3.
2.4 Synthesis of an adenosine-derived B-amino acid monomer
2.4.1 Proposed route and strategy for base protection
It was clear that a logical extension of this project would be to synthesise p-amino 
acids of the purine nucleosides. 2'-Deoxyadenosine was chosen as the next target 
as it is well known in nucleoside chemistry that guanosine derivatives can be 
notoriously difficult to manipulate. It was hoped that designing an efficient route to 
the 2'-deoxyadenosine p-amino acid would provide us with a basis for a route to the 
2'-deoxyguanosine p-amino acid. It was also hoped that, in the future, interactions 
of homo-oligomers of the adenosine and previously prepared, thymidine-derived P- 
amino acids could be examined.
i) (Tf0)20, Pyr, DCM 
ii) H20BzCI, Pyr
i) (TfOzO, Pyr. DCM 
ii) UN3, DMF
NHFmoc
Figure 2.10: Proposed route to an adenosine derived p-amino acid (PG= protecting
group, E3z= Benzoyl).
The major difference between the synthesis of the purine and pyrimidine p-amino 
acids is that, in the case of the purines, an anhydronucleoside cannot be utilised as
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an intermediate for the introduction of the azido group. This makes the synthesis of 
the purine monomers longer and more complex than the pyrimidine monomers. 
Based on the knowledge gained during the synthesis of the pyrimidine monomers 
and research into other nucleoside derived structures, an initial route to the 
adenosine-derived p-amino acid was designed (Figure 2.10). In the chosen, route a 
strategy employed by Herdewijn for the inversion of stereochemistry at C3' was 
deemed to be the most suitable for this synthesis.207 The initial inversion of 
stereochemistry requires activation of the 3'-hydroxyl group followed by 
displacement induced by neighbouring group participation from a 5’-benzoyl 
protecting group. This gives an unusual bicyclic intermediate which upon treatment 
with water is opened up to give inversion of configuration at C3\
The successful implementation of the reaction scheme shown in figure 2.10 
depended on the choice of a suitable protecting group for the exocyclic amino group 
of adenine. It had to be efficiently introduced and stable to the conditions required 
for subsequent removal of the 5'-benzoyl group. Previous work in the group had 
shown that benzoyl protection of the base is not entirely suited to the synthesis of 
the nucleoside p-amino acid oligomers as it can be difficult to remove from the final 
products without some degradation of the peptide bonds. It was therefore decided to 
examine two groups which could be removed under milder conditions, the 
allyloxycarbonyl (Alloc) and phenoxyacetyl (PAC) group (Figure 2.11).
Allyloxycarbonyl (Alloc) Phenoxyacetyl (PAC)
Figure 2.11: Protecting groups.
In order to determine which of these protecting groups would be best suited to the 
route devised, it was decided to synthesise both 5'-benzoyl-A/-6-protected 
nucleosides (27 and 28).
Protection of the A^-position of the adenine base was initially investigated using the 
Alloc group following the literature procedure of Hayakawa et al. (pink, Scheme
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2.9).208 This procedure gave a very poor yield (11%) of the /^-protected nucleoside 
(25). Importantly, though, it was shown that the Alloc protecting group was stable to 
the preferred conditions (MeOH/1 M (aq) NaOH) required for the subsequent 
removal of the 5'-benzoyl protecting group. In comparison, the PAC group (blue, 
Scheme 2.9) was introduced in a slightly higher yield (30%). However, removal of 
the S’-benzoyl group with MeOH/ 1M (aq) NaOH resulted in significant loss of the 
PAC group from the base. With the Alloc group proving to be more suitable for the 
synthetic route, a more efficient method for the introduction of the Alloc group was 
required since the route devised by Hayakawa et a/.gave repeatedly poor yields in 
our hands.
i) (SiMe3)2NH, (NH4)2S04, 
1,4-dioxane
ii) /V-methylimidazole, 
allylchlorofomate
iii) MeOH. NH3, 11% h
i) TMS-CI, Triazole, 
phenoxyacetyl chloride, 
Pyr
ii) water, 30%
OH
PG=Alloc (25) 
PG=PAC (26)
BzCI, Pyr BzCI, Pyr
MeOH, 1M NaOH
MeOH. 1M NaOHOH
PG=Alloc
PG=PAC
PG=Alloc (27)
PG=PAC (28)
Scheme 2.9: Evaluation of the Alloc and PAC groups for protection of the exocyclic 
amino group of adenine (Alloc= allyloxycarbonyl, PAC= phenoxyacetyl).
A common reagent used for transient protection of both the 3'- and 5'-hydroxyl 
groups in nucleoside chemistry is the Markiewicz (TIPS) reagent, 1,3-dichloro- 
1,1,3,3-tetraisopropyl disiloxane.209 This reagent is commercially available or can be
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prepared in a two step synthesis from trichlorosilane.210 Protection of the 2'- 
deoxyribose moiety with this group provides a stable intermediate, unlike the TMS 
protected derivative, which can be isolated and stored for future use. 2- 
Deoxyadenosine was thus treated with the Markiewicz reagent211 to provide the 3', 
5'-TIPS protected nucleoside (29) in 90% yield after purification. Protection was 
confirmed by the presence of a series of peaks between 1.11 and 1.30 ppm in the 
1H NMR spectrum corresponding to 28 protons. These peaks were attributed to the 
alkyl protons directly attached to a silicon atom.
The next challenge was to protect the exocyclic amino group of (29). Initially, this 
was carried out by treating the TIPS protected nucleoside (29) with a tetrazole- 
activated allyloxycarbonyl intermediate which had been prepared separately 
according to a procedure by Hayakawa.212 Subsequent removal of the silyl 
protecting group with TBAF afforded the product (25) in a 60% yield; however, 
multiple purifications by flash chromatography were required to obtain the product in 
sufficient purity for analysis.
Markiewicz reagent,
vr \
i) ETT, THE, Et3N, 
allylchloroformate. 
ii) TBAF, THF 
83% / i) tetrazole, THF, Et3N, allylchloroformate 
ii) TBAF, THF 
60%
Scheme 2.10: Synthesis of A/-6-allyoxycarbonyl-2,-deoxyadenosine (25).
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Due to safety issues with regards to the use of tetrazole in targe scale syntheses, it 
was decided to investigate a safer alternative which is commonly used as an 
activator in the synthesis of oligonucleotides, 5-(ethylthio)-1 H-tetrazole (ETT). 
Substitution of tetrazole with this safer alternative gave (25) in an improved yield of 
83%.In addition,the purification procedure was simplified with the product only 
requiring one flash column in order to be obtained in sufficient purity for analysis. 
However, due to reduced reactivity, longer reaction times were required. In both 
syntheses, the formation of product (25) was confirmed by the appearance of 
characteristic peaks in the 1H NMR spectrum corresponding to the alkene moeity of 
the allyioxycarbonyl group at 5.29 ppm and 5.39 ppm. These peaks were attributed 
to the terminal CH2 protons. The peak at 5.99 ppm was assigned to the alkenyl CH 
proton.
AZ-S-Allyloxycarbonyl^'-deoxyadenosine (25) could now safely be produced in large 
quantities ready for use in further synthesis.
2.4.2 Synthesis of adenosine-derived B-amino acid: Route A
As described previously (Figure 2.10), the synthetic route to the adenosine-derived 
|3-amino acid was to proceed firstly with benzoylation of the 5'-hydroxyl group of 
(25), followed by an inversion of the stereochemistry at C3' and finally displacement 
of this inverted hydroxyl group with azide to give the required S'-azido compound 
with overall retention of configuration.
Selective benzoylation at the 5'-position by treatment of the A^-protected nucleoside 
(25) with 1 equivalent of benzoyl chloride in pyridine, proceeded to give the desired 
compound (30) in 45% yield (Scheme 2.11). Although a small amount of 
benzoylation at the 3-position and dibenzoylation was observed, these side 
products did not account for the fate of the other 55% of the starting material and 
this still remains uncertain. Benzoylation was confirmed the appearance of 
characteristic aromatic peaks in the 1H NMR spectrum of (30) at 7.50 ppm, 7.64 
ppm and 7.90 ppm corresponding to the meta, para and ortho protons of the 
benzoyl group, respectively. When the 'H NMR spectrum was recorded in 
deuterated DMSO, a doublet corresponding to the 3'-OH could also clearly be seen 
and cross peaks with H3' were observed in a COSY spectrum of the compound. 
These both indicated that protection had indeed occurred at the 5-position rather 
than the 3'-position.
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^||_| Alloc
kjijAHoc
BzCI, Pyr
i) (TfO)20, Pyr, DCM 
ii) H20 
11%
Scheme 2.11: Inversion of stereochemistry at C3'.
The first inversion of stereochemistry was carried out according to Herdewijn’s route 
to 3’-azido-2\ 3'-dideoxyadenosine.207 The 5'-benzoylated compound (30) in a 5% 
solution of pyridine in DCM was cooled to -30°C and treated with a 10% triflic 
anhydride/DCM solution, followed by addition of water. An 11% yield of the desired 
5'-benzoyl-3'-xy/o-compound (31) was recovered after purification by flash 
chromatography. However, a 33% yield of the 3'-benzoyl-3'-xy/o by-product (32) 
was also obtained. These two compounds could be distinguished easily by 1H NMR 
methods; the 5'-benzoyl-3'-xy/o nucleoside (31) showed only a slight change in shift 
for the peak assigned to H3' relative to its position in the spectrum of the starting 
material i.e., from 4.67 ppm to 4.34 ppm. In contrast, the spectrum recorded of the 
3'-benzoyl-3'-xy/o nucleoside (32) exhibited a large downfield shift for this peak from 
4.67 ppm to 5.72 ppm.
The formation of the 3'-benzoyl-3'-xy/o by-product (32) is a direct result of the 
reaction mechanism. Neighbouring group participation by the 5'-benzoyl group in 
the starting material (30) displaces the activated 3'-hydroxyl group to form an 
unusual bicyclic intermediate (33) (Figure 2.12). This intermediate can then be 
opened in two ways, with the 3-0-benzoate being the favoured product. This is due
73
to the fact that the primary 5'-hydroxyl group is a better leaving group. A solution to 
this problem is to isomerise the undesired compound (32) back to the S’-benzoate 
(31) using a weak base such as sodium hydrogen carbonate. This can either be 
carried out in situ or after isolation of the 3'-benzoyl-3'-xy/o compound. The 
presence of a weak base catalyses the reformation of intermediate (33) and means 
that the less acidic 3'-hydroxyl group is protonated preferentially. The driving force 
for the reaction is the improved steric stability of the 5'-benzoate over the 3- 
benzoate. Isomerisation afforded the 5'-benzoyl-3'-xy/o nucleoside (31) in a 35% 
yield.
Figure 2.12: Mechanism of xylo nucleoside formation.
It was apparent from the poor yields obtained for this inversion that this may not 
have been the ideal method for the transformation and other methods will be 
discussed later on in this chapter.
The next step in the synthesis was the introduction of the azide moiety. This was 
carried out by activation of the 3'-xy/o-OH with triflate followed immediately by 
displacement with azide in a direct SN2 attack. This afforded the 3'-azido-5'-0- 
benzoyl-2'-deoxyadenosine derivative (34) in 65% yield after purification by flash 
chromatography (Scheme 2.12). The conversion was once again confirmed by the 
presence of a strong azide absorption in the IR spectrum at 2090cm'1.
Simple removal of the 5’-benzoyl group under basic hydrolytic conditions afforded 
3'-azido-2'-deoxyadenosine (35) in 58% yield, after washing with water, and no 
further purification was required. A small amount of product degradation was 
observed by tic, after treatment with the ion-exchange resin, which suggests that the 
glycosidic bond of this derivative could be extremely acid sensitive. Removal of the
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protecting group was confirmed by an upfield shift of the peak assigned to the H5' 
protons in the 1H NMR spectrum; from 4.57 ppm and 4.68 ppm in spectrum 
recorded for the the protected compound (34) to 3.82 ppm and 4.03 ppm in the 
product. There was also a disappearance of the distinctive ortho, meta and para 
protons of the benzoyl group.
Oxidation of the 5'-position was carried out under standard TEMPO/ BAIB 
conditions. As with the 5-methylcytidine analogue the adenosine derived azido acid 
(36) did not precipitate from the reaction liquors. However, it was found that the 
product could be isolated from the reaction by-products by dissolving the crude 
mixture in methanol and precipitating the acid product through addition of diethyl 
either. A crop of off-white powder was isolated and found to be the desired product. 
It was obtained in high purity and 72% yield. Successful oxidation was confirmed by 
the loss of the signals associated with the two H5* protons by 1H NMR 
spectroscopy.
MHAIIoc
(31) N3 (34)
i) 1M NaOH,
5:4:1 1,4-dioxane: water: MeOH 
ii) H+ resin 
58%
MhAI'oc muAIIoc
HO
Scheme 2.12: Synthesis of 2'-deoxyadenosine azido acid (36).
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Reduction of the azide moiety was again carried out by treatment with hydrogen 
sulfide gas. This reagent was chosen as it was uncertain what effect the presence 
of palladium would have on the allyloxycarbonyl protecting group which is known to 
be removed by treatment with tetrakis(triphenylphosphine)palladium in the presence 
of an allyl scavenger.
Scheme 2.13: Azide reduction.
Due to the polarity of the amino acid (37), purification by flash chromatography was 
not possible. The compound was, therefore, separated from the sulfur by-products 
by extraction into water and removal of the non-soluble solids by filteration. The 
formation of compound (37) was confirmed by mass spectrometry.
Although multiple attempts at protection of the 3'-amine with Fmoc were carried out, 
all failed. This combined with the low yields from the inversion step prompted the 
decision to plan and investigate other routes to the target compound.
2.4.3 Synthesis of adenosine-derived B-amino acid: Route B
A second strategy for inversion of stereochemistry at C3' involves oxidation via a 
Dess-Martin procedure followed by stereospecific reduction to give the 3'-xy/o- 
nucleoside. Stable 2'-deoxy-3'-ketonucleosides were first synthesised and isolated 
by Robins et al. in 1990.213 Previous efforts to prepare and isolate purine 3- 
ketonucleosides have often resulted in elimination of the nucleoside base due to the 
high acidity of the H2' protons.214
It was decided to follow a procedure described by Eisenhuth et al., published in 
2008, in which S'-amino^'-deoxyadenosine was synthesised via a 3'-ketonucleoside 
intermediate. However, in this case, the base had been protected with a benzoyl 
group.215 The research carried out by this group found that low temperature
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oxidation, followed by immediate reduction at -60°C gave a highly selective, high 
yielding route to a 3'-xy/o-nucleoside with minimal depurination observed. 
Application of this route to the Alloc-protected 2-deoxy-adenosine is shown in 
Scheme 2.14.
The first step in the synthesis was to introduce silyl protection at the 5-OH group in 
order to avoid oxidation at this position. The group chosen was the bulky t- 
butyldimethylsily! group (TBDMS). It was hoped that the size of this group would 
also assist with selectivity of the reduction later on in the synthesis, by partially 
blocking access to the top face of the molecule. Protection proceeded smoothly in 
56% yield; some S'-protection and 3', S'-diprotection was also observed which 
accounted for the major loss of yield in this reaction. Successful protection to give 
S’-protected nucleoside (38) was confirmed by the appearance of characteristic 
singlets, in the 1H NMR spectrum, at 0.01 ppm and 0.80 ppm. These correspond to 
the 6 protons of the methyl and 9 protons of the f-butyl group, respectively.
Oxidation and subsequent reduction of the 3'-position were carried out in 
succession in a ‘one-pot’ synthesis. Thus, the 5'-protected nucleoside (38) was 
treated with Dess-Martin periodane at 0°C and the progress of the reaction was 
easily be monitored by tic. After 30 mins, all the starting material appeared to have 
been consumed. The excess oxidant was quenched by the addition of /so-propanol, 
which also served as the solvent for the reduction of the S'-ketonucleoside. Fresh 
sodium borohydride was added to the reaction mixture at iow temperature. However 
as the reaction proceeded, formation of a large amount of unidentified by-product 
was observed by tic, as well as formation of the desired compound (39). After work­
up and isolation by flash chromatography, it was found that this by-product was in 
fact the nucleoside base that had been eliminated from the molecule. The identity of 
this by-product was confirmed by NMR as only peaks corresponding to the Alioc 
protons and H2 and H8 of the adenine base were observed.
It was thought, that in this case, the hydride anion acted as a base extracting one of 
the acidic 2'-protons and inducing base elimination. Although multiple attempts at 
this reaction were carried out, the literature yield of 77% reported for the analogous 
A/-benzoyl compound was never achieved. The maximum yield of (39) obtained in 
our hands was 17%. Although the starting material (38) and the 3'-xy/o-nucleoside 
(39) were practically indistinguishable by tic, a small upfield shift in the peak
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assigned to H3't from 4.62 ppm to 4.48 ppm confirmed that the stereochemical 
inversion had indeed been successful.
nhAIIoc
nha"oc
i) Dess-Martin periodane, 
DCM
ii) /so-propanol, NaBH4 
17%
NHai,0C
TBDMSO. PyPh2P, DIAD TBDMSO. 
NaN3, DMF
Scheme 2.14: Inversion of stereochemistry at C3' using Dess-Martin periodane
(TBDMS = f-butyldimethylsilyl)
Although a poor yield had been obtained from the inversion step, it was decided to 
continue with the synthesis according to the paper and introduce the 3'-azide group 
via a Mitsunobu reaction which employed NaN3 as the azide source. Although an 
attempt was made utilising the exact same conditions as reported by Eisenhuth et 
a/.,215 no reaction was observed here. This observation combined with the 
disappointing yield from the inversion step, brought us to the conclusion that no 
further time should be dedicated to this route.
2.4.4 Synthesis of adenosine-derived B-amino acid: Route C
Although the first two methods for inverting the C3' stereochemistry of 2'- 
deoxyadenosine proved to give unexpectedly poor results, a number of other 
methods still remained that we considered worth investigating including: hydride 
reduction of /yxo-epoxides,216 regioselective 2'-0-tosylation of adenosine followed
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by a 1,2-hydride shift217 and inversion by Mitsunobu chemistry.218 The latter of 
these methods appeared to offer the simplest route, without the need to obtain 
expensive reagents or complex starting materials. It was therefore decided to 
attempt this method first.
A publication by Lavandera et al. in which azide functionality had been introduced at 
both the 3'- and 5'-position was used as inspiration for the devised route218 As with 
the previous two syntheses, the initial step in the reaction sequence was protection 
of the 5'-hydroxyl group. Initially, it was decided to follow the route as described by 
Lavandera et al. and use the DMT protecting group (Scheme 2.15). Protection of 
(25) proceeded smoothly, although in an unusually low yield of 42% after 
purification. However, this resulted in more than enough of the tritylated nucleoside 
(40) to carry through the synthetic pathway. Successful protection was confirmed by 
1H NMR spectroscopy through the appearance of characteristic aromatic peaks and 
a singlet at 3.77 ppm, corresponding to the 6 protons of the methoxy groups.
Ml_| Alloc
DMT-CI, Pyr 
42%
MHAiioc
DMTO.
p-nitrobenzoic acid, PPh3, 
DEAD, THF 
82%
Alloc
DMTO.
Scheme 2.15: Inversion of stereochemistry at C3' using Mitsunobu conditions
(PNBz = p-nitrobenzoyl).
Inversion of the 3'-hydroxyl group was carried out in two steps, the first of which was 
an Sn2 reaction using p-nitrobenzoic acid. Formation of the 3’-p-nitrobenzoate ester
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(41) was carried out using standard Mitsunobu chemistry with the formation of 
triphenylphosphine oxide side product being the driving force for the reaction. The 
desired compound (41) was afforded in 82% yield, after purification by flash 
chromatography. The identity of (41) was confirmed by a downfield shift of the H3' 
proton peak from 4.71 ppm to 5.89 ppm and the appearance of characteristic 
aromatic peaks corresponding to the ortho and meta protons of the p-nitrobenzene 
ring. A small loss of the DMT group was observed during this reaction which was 
not completely unexpected due to the presence of p-nitrobenzoic acid.
Cleavage of the ester moiety was carried out under basic conditions using sodium 
methoxide and afforded the 3'-xy/o-2'-deoxyadenosine analogue (42) in 81% yield. 
Removal was confirmed by the loss of the aromatic peaks in the 1H NMR spectrum 
corresponding to the ortho and meta protons of the p-nitrobenzene ring and a shift 
of the H3' peak back upfield to 4.36 ppm.
NHW|0C
DMTO.
MsCI, DMAP, Pyr 
65%
MH/miqc
DMTO.
(43)
DMTO.
TsOH, THF
Scheme 2.16: Attempted synthesis of 3,-azido-2'-deoxyadenosine analogue (35).
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The newly inverted 3'-hydroxyl group was converted to a leaving group by treatment 
with methanesulfonyl chloride to allow for easy displacement by azide (Scheme 
2.16). Mesylation proceeded in 65% yield and provided the sulfonate ester (43). 
Sucessful mesylation was confirmed by 1H NMR with a downfield shift of the H3' 
peak from 4.36 ppm to 5.48 ppm and the appearance of a singlet at 3.07 ppm 
characteristic of the methyl protons of a SO2CH3 group. Displacement of the leaving 
group by azide was carried out in a simple SN2 fashion by heating compound (43) in 
the presence of LiN3. This afforded the desired S’-azido^'-deoxyadenosine 
derivative (44) in 72% yield. However, even after multiple washes and 
chromatographic purification, trace amounts of the reaction solvent (DMF) could still 
be seen in the ^ NMR spectra. Formation of the azide compound was confirmed by 
a strong absorption in the infrared spectrum at 2102cm'1 characteristic of an azide.
Attempts to remove the DMT group from compound (44) under mildly acidic 
conditions resulted only in degradation of the nucleoside, presumably by cleavage 
of the glycosidic bond. A tic of the reaction showed 3 distinct spots, one of which 
was the orange staining trityl group which runs with solvent front in the 5% 
methanol/DCM eluent system used. A second spot running slightly below the trityl 
group was found to be UV active but did not stain with anisaldehyde and a third 
lower running spot was not UV active but could be stained with anisaldehyde. It was 
thought that these were the base portion and the sugar portion of the nucleoside, 
respectively.
After such encouraging results with the Mitsunobu method of inversion, it was 
decided to re-think the S’-hydroxyl protection and examine groups that did not 
require acidic conditions for their removal. After a review of protecting groups used 
in nucleoside chemistry, the decision was made to use a f-butyldiphenylsilyl 
(TBDPS) group for protection of the 5'-position. This group was chosen due to its 
high selectivity for primary hydroxyl groups over secondary and its ease of removal 
under standard conditions with TBAF. It was hoped that the combination of these 
factors would help to maximise the overall yield of the synthetic pathway.
Protection of the 5-hydroxyl group of (25) with TBDPS chloride to give (45) 
proceeded without any discernable observation of S'-protection or 3', 5'-diprotection. 
However, due to contamination of the starting material (25) with 
tetrabutylammonium salts, only an approximation of the yield (70%) could be 
established (Scheme 2.17). Silylation was confirmed by the appearance of a singlet
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at the low chemical shift of 1.04 ppm in the 1H NMR spectrum, corresponding to the 
f-butyl protons; a signal at this position is characteristic of alkyl groups attached 
directly to a silicon atom. Further to this, aromatic peaks were observed 
corresponding to 10 protons. Introduction of the p-nitrobenzoate ester and cleavage 
were carried out in the same manner as previously described and afforded the 5'- 
TBDPS-3'-xy/o nucleoside (47) in 54% yield over 2 steps. Although the individual 
yields for these steps were slightly lower than the previous attempt with the 
analogous DMT protected derivatives, the yields from this method of inversion were 
still far superior to those that had been obtained from the Herdewijn and Eisenhuth 
routes.
TBDPS-CI, DMAP TBDPSO.
ca. 70%
p-nitrobenzoic acid, PPh3, 
DEAD, THF
72%
TBDPSO. OPNBzTBDPSO.NaOMe, MeOH
74%
Scheme 2.17: Inversion of stereochemistry at C3’ using Mitsunobu conditions
(TBDPS= f-butyldiphenylsilyl).
Mesylation of the 3'-xy/o-nucleoside (47) was carried out in the same manner as 
previously described and proceeded smoothly to give sulfonate ester (48) in an 82% 
yield (Scheme 2.18). This slight improvement in yield can possibly be attributed to 
the greater stability of the TBDPS group to the reaction conditions, when compared 
to the DMT group. Displacement of the mesylate group with azide, however, did not 
proceed as expected. Subjection of a solution of sulfonate ester (48) in DMF to UN3 
at 60°C for 7 hours resulted in not only introduction of the azido group, but also
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removal of the allyloxycarbonyl protection from the base. This problem was 
overcome by carrying out the reaction at a slightly elevated temperature (70°C 
rather than 60°C) over a shorter time period (2 hours rather than 7 hours). Isolation 
of the 3'-azido nucleoside (49) proved difficult due to the formation of emulsions 
during the extraction process and problems were encountered in isolating pure 
product from the reaction solvent DMF. Consequently, the yields from this step were 
greatly reduced. A 42% yield of the 3'-azido analogue (49) was isolated in high 
purity and successful reaction was confirmed by the presence of an azide stretch at 
2102cm 1 in the infrared spectrum. In addition, an upfield shift of the H3‘ peak from 
5.45 ppm to 4.49 ppm in the 1H NMR spectrum was observed. The presence of the 
Alloc group was also confirmed by 1H NMR spectroscopy by a characteristic 
multiplet at 5.91 ppm corresponding to the alkenyl CH and two apparent double 
quartets at 5.21 ppm and 5.33 ppm corresponding to the terminal alkenyl protons.
TBDPSO. TBDPSO.MsCI, DMAP, Pyr 
82%
70°C, 2h
TBDPSO.
TBAF, THF
Scheme 2.18: Synthesis of 3'-azido-2'-deoxyadenosine analogue (35).
Removal of the silyl protection was carried out by treatment of (49) with TBAF to 
afford the 3'-azido-2'-deoxyadenosine derivative (35) in 55% yield. Deprotection was
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confirmed by the loss of the peak at 0.98 ppm in the 1H NMR spectrum of the 
starting material (49) which had been attributed to the 9 protons of the f-butyl group.
It was decided at this point, in the interest of time and due to the problems 
experienced previously with the Fmoc protection step, to use the azide itself as a 
masked amine for the synthesis of the oligomers. This not only shortened the 
synthesis but also reflects the fact that good yields can be obtained for the reduction 
of the azide, under a variety of conditions. Therefore the last remaining step in this 
synthesis was oxidation of the 5'-position (Scheme 2.19).
AIIOC
TEMPO, BAIB, 
1:1 MeCN:Water 
79%
(36)
Scheme 2.19: Oxidation to produce final product (36).
Oxidation of the 5’-position to give the carboxylic acid using the standard 
TEMPO/BAIB conditions, previously described, gave the desired azido acid (36) in a 
pleasing, 79% yield. Isolation of pure compound was carried out by dissolution of 
the crude reaction residue in the minimum amount of DCM and precipitation of the 
desired acid (36) using diethyl ether. Successful oxidation was confirmed by the 
loss of the H5' protons seen at 3.82 ppm and 4.03 ppm in the 1H NMR spectrum of 
the starting material (35).
Although the protected amino acid derived from 2’-deoxyadenosine was not 
obtained as originally designed, the S’-azido^'-deoxyadenosine-S’-carboxylic acid 
compound (36) can still be utilised as a useful building block for the synthesis of p- 
peptides in solution. Coupling of this monomer will be discussed in Chapter 3.
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2.5 Conclusions
Fmoc amino acids of thymidine and 5-methyl“2'-cytidine were both successfully 
synthesised from the parent nucleoside thymidine utilising the widely studied, 
pharmaceutically active compound AZT as a common intermediate. Although there 
still remains room for improvement in the synthesis of the 5-methyl-2'-cytidine amino 
acid, in terms of introduction of a S'-AZ-protecting group, the route devised provided 
the compound in sufficient quantities and purity for coupling studies to be carried 
out. Further to this, a second thymidine derived monomer with benzhydryl protection 
of the 5'-carboxylic acid group has been successfully synthesised and this monomer 
was expected to be better suited to synthesis of (3-peptides in solution.
The synthesis of an Fmoc amino acid derived from 2'-deoxyadenosine proved 
problematic with difficulties encountered in both the inversion of stereochemistry at 
C3' and introduction of the azide moiety. However, these issues were overcome 
after investigating a variety of synthetic routes and protecting groups. Although the 
Fmoc-protected amino acid was not prepared, an alternative S'-azido-S'-carboxylic 
acid monomer was synthesised successfully which could be used instead in the 
solution synthesis of the (3-peptides.
It should be noted that a significant potential problem with these (3-amino acids, 
particularly those derived from 2'-deoxyadenosine, is the lability of the glycosidic 
bond. For this reason, it is important to avoid conditions that are even mildly acidic, 
and this should be taken into consideration in any subsequent work performed on 
2'-deoxyguanosine.
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Chapter 3: Results and Discussion 2
Synthesis of B-peptides
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3.1 Peptide synthesis: Project aims
The next goal in this project was to couple the nucleoside derived p-amino acid 
monomers discussed in chapter 2, utilising amide bond formation, to synthesise 
short p-peptides. Previous research within the group has shown that secondary 
structures can be observed in peptides as short as four residues in length and that 
this can be studied in detail by NMR.153 However, the oligomers synthesised 
previously from the thymidine derived p-amino acid possessed an amide 
functionality at what would be described as the ‘C-terminus’ of the peptide (blue, 
Figure 3.1). We wanted to extend this study and examine the feasibility of obtaining 
oligomers that would have a carboxylic acid C-terminus (pink, Figure 3.1) so that 
both secondary structure and cyclisation studies could be carried out.
Assembly of peptides can be carried out by two different methods: solid-phase 
peptide synthesis (SPPS) and solution peptide synthesis. Both methods were 
applied to the synthesis of these p-peptides and each will be discussed in turn 
within this chapter.
Previous work
n=2
Project target
Figure 3.1: Nucleoside p-peptides: Previous work (top) and project target (bottom)
(T= thymine and B=nucleobase).
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3.2 Solid-phase peptide synthesis (SPPS)
3.2.1 A brief overview of SPPS
The original method of solid-phase peptide synthesis was developed and reported 
by Merrifieid in 1963.219 The work exploited the use of an insoluble, yet porous, solid 
support containing a chlorobenzyi linker to which a Boc-protected amino acid could 
be covalently attached. The Boc group could then be removed from the first amino 
acid residue under acidic conditions and subsequently coupled to a second residue 
by amide bond formation. This simple, yet effective, procedure revolutionised 
peptide synthesis and began the development of the methods we use today.
An improved method developed by Merrifieid utilising Boc protection of the a-amino 
function and side chain benzoyl protection of all other nucleophilic centres, had a 
number of disadvantages associated with the use of strongly acidic conditions 
required to deprotect the amino acids and remove the peptide from the resin 220 The 
use of protecting groups which can all be cleaved by similar conditions lead to 
concomitant loss of a small proportion of side chain protecting groups and 
degradation of a small amount peptide-resin linkage at each stage in the cycle.
Loss of side-chain protection can result in the liberation of reactive groups which 
can participate in undesired side reactions, this results in failure sequences and 
consequently a reduction in final product purity. Cleavage of a small amount of 
peptide at each stage also results in a further cumulative loss of yield.
With these problems becoming apparent, a lot of the work into improved methods of 
solid-phase peptide synthesis has focussed on the development of mild conditions 
for the removal of the peptide from the resin and the development of orthogonal 
protecting group strategies to minimise peptide and side-chain protecting group 
cleavage.
The publication of the Fmoc group as a base-labile /V-terminal protecting group for 
amino acids, in 1972,221 promoted a huge leap in the development of mild acid-free 
deprotection conditions for solid-phase peptide synthesis. This group can be 
removed rapidly by treatment with an organic secondary base without any 
degradation of peptide bonds. For this reason it became, and still remains, an 
extremely popular terminal protecting group in peptide chemistry.
As a consequence of the discovery of base-labile protecting groups, such as the 
Fmoc group, that can be used in solid phase peptide synthesis a number of resin
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linkers have been developed that require only extremely mild acidic conditions to 
liberate the peptide. Many of these are based upon Merrifield’s original design and 
release the peptide with either a C-terminal carboxylic acid or amide.
Commonly used resins for the synthesis of peptides with a carboxylic acid terminus 
include the Wang resin,222 Rink acid resin223 and HMPB-BHA derived resins.224 The 
most commonly used resin for the generation of peptides with an amide terminus is 
the Sieber amide resin225. Removal of peptides from all of the resins discussed here 
requires only a 1-5% solution of TFA, which, compared to the conditions required to 
cleave peptides from the Merrifield resin (HF), offers less cause for concern over 
undesirable removal of side chain protection or peptide degradation.
OMe OH
Rink Acid Resin Wang Resin
HMPB-BHA Resin (X=H) 
HMPB-MBHA resin (X=CH3)
Sieber Amide Resin
Figure 3.2: Resins used in SRPS.
3.2.2 Peptide Synthesis by SPPS
Previous work within our group had focussed on the synthesis of short (3-peptides of 
the thymidine derived (3-amino acid synthesised on the Sieber amide resin. This 
resin was chosen due to the high acid-lability of the xanthen-9-amine linker which 
can be cleaved with exposure to a 1% TFA in DCM solution. As alluded to in 
Chapter 2, the glycosidic bond in nucleosides, particularly the purines, is extremely 
acid labile so exposure to acidic conditions must be kept to a minimum in order to
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maximise yield and purity of the peptides. For initial studies of secondary structure, 
the fact that this resin would result in an amide terminus was of no great concern. 
However, we wished to now carry out further studies of these peptides and assess 
their potential to form macrocycles. This required the synthesis of the same short (3- 
peptide structures but with a carboxylic acid terminus rather than an amide.
Previously within our group, a study had been carried out on three resins that could 
potentially provide peptides with a carboxylic acid terminus. These were the Wang 
resin, Rink acid resin and HMPB-BHA resin (Figure 3.2). These resins were of 
particular interest as the linkers require the mildest acidic conditions for removal of 
the peptide. It was found that the best results (60% coupling efficiency) were 
provided by the HMPB-BHA resin (which has a dialkyloxybenzyl linker) with a 
coupling reagent combination of PyBOP/DIPEA/DMAc. However, immediately after 
this study had been carried out, the HMPB-BHA resin was discontinued and 
replaced by a similar HMPB-MBHA resin (Figure 3.2). Even though the change to 
the linker was relatively small, the coupling conditions required reassessment in 
order to provide the best initial coupling yield possible.
There are numerous permutations of coupling reagents that can be used in SPPS. 
However, we chose to test the new resin with the 3 combinations of reagents that 
had given us the best coupling yields in the past. The results of this study are 
outlined in Table 3.1.
Activator/solvent/base Coupling efficiency*
PyBOP/DMAc/DIPEA No coupling
HBTU/DMAc/DIPEA 62%
HBTU/DMAc/DIPA 48%
Table 3.1: Coupling efficiency of the thymidine derived p-amino acid to HMPB- 
MBHA resin. *Coupling efficiency was determined by spectrophotometric 
measurement of the dibenzofulvene released upon Fmoc deprotection (see 
experimental section for details).
The results of this study indicated that the most suitable coupling combination for 
attachment of the first nucleoside residue to the resin had changed from a system 
utilising PyBOP/DMAc to a system requiring HBTU/DMAc. It is not apparent what 
effect is responsible for change in coupling efficiency with different reagents. A
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subsequent second coupling carried out under the same reaction conditions was 
found to be quantitative.
OH
Q—LINK-0-AA-NH2 Q—LINK-O-AA-NHFmoc
2 % DBU
Figure 3.3: SPPS cycle
With the identification of suitable coupling conditions for the peptide synthesis 
complete, assembling of a peptide three residues in length could now begin (50, 
Figure 3.4). The resin was swollen overnight in DCM and then drained and washed 
with DMAc. The thymidine (3-amino acid was pre-activated for 60 seconds with the 
coupling reagent system and subsequently added to the resin bed which was then 
agitated for five hours. The excess reagents were then rinsed from the resin and the 
process of capping un-reacted sites, followed by removal of the Fmoc group, were 
performed to enable the second coupling to take place. Once the peptide of desired 
length had been assembled the resin bed was rinsed with DMAc, DCM and 
methanol and dried under vacuum overnight. Re-swelling of the resin allowed for 
acidic cleavage of the peptide from the linker with a 1 % TFA solution in DCM (this 
process is outlined in Figure 3.3). The liquors were then removed from the peptide 
and analysis of the crude mixture carried out by mass spectroscopy.
(50)
Figure 3.4: peptide assembled by SPPS.
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It was found that the peptide had indeed been formed. However, the presence of a 
lot of other fragment peaks prompted us to investigate the purity of the oligomer by 
RP-HPLC (Figure 3.5). The HPLC trace of the peptide showed a pattern of 5 major 
peaks, which were isolated individually and analysed by mass spectroscopy.
A = 12.98min 
B - 14.68min 
C = 16.39min 
D - 17.30min 
E = 18.18min
A.. AJUi
Retention time (mins)
Figure 3.5: RP-HPLC trace of the peptide (50, for conditions refer to experimental)
The results from electrospray mass spectrometry confirmed that the first two major 
peaks (A +B) were failure sequences of the peptide. However, the final 3 major 
peaks (C, D +E) all gave the same molecular ion which was consistent with the full 
length trimer (mass 728). The fact that the trimer appeared as multiple peaks in the 
HPLC indicated that perhaps the peptide may have been forming distinct secondary 
structures in solution. Attempts to break down the suspected secondary structures 
and coalesce the 3 peaks by using a HPLC column heater resulted in partial 
success with the formation of two broadened peaks. Unfortunately, though, a single 
peak which would have aided purification and analysis was not achieved.
Due to the difficulties encountered with the purification of this short, fully 
deprotected peptide, this method of peptide synthesis was abandoned. This 
decision was also further justified when the synthesis of the 2'-deoxyadenosine (3- 
amino acid monomer, which was carried out in parallel with this work, revealed the 
extremely sensitive nature of the glycosidic bond of these modified nucleosides, 
such that they would be incompatable with even very acid labile linkers. The 
combination of these factors and the fact that we required only short oligomers, led 
us to the decision to explore peptide synthesis in solution as an alternative.
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3.3 Peptide synthesis in solution
3.3.1 Amide bond formation in solution
The synthesis of peptides in solution can be carried out utilising simple amide bond 
forming reactions. This method does have some advantages over SPPS; it can be 
carried out on larger scales and the intermediates can be isolated and analysed at 
each step. However, it also has some distinct disadvantages which include a longer 
and more cumbersome synthesis and problems associated with solubility of larger 
peptides due to the neutral nature of the backbone. As we required short peptides 
for this study, we felt that, in this case, the advantages of this method outweighed 
the disadvantages.
The formation of an amide bond is one of the most important reactions in organic 
chemistry and many different strategies have been devised to form these bonds 
between carboxylic acids and amines. A common problem of amide bond forming 
reactions in peptide chemistry is the possibility of amino acid racemisation once the 
acid moiety has been activated. This racemisation is induced by intramolecular 
oxazolone formation (Figure 3.6) and can cause severe problems when peptides 
are synthesised for biological purposes. However, as our nucleoside derived p- 
amino acids contain a conformationally constrained furan ring system, we reasoned 
that this potential side reaction was unlikely to occur.
Figure 3.6: Intramolecular oxazolone formation in activated amino acids.
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3.3.2 Coupling reagents
Some of the most commonly used reagents for amide bond formation in organic 
synthesis include: carbodiimide-type, phosphonium-type and uronium-type 
reagents.226
Within the area of peptide and oligonucleotide chemistry the most common 
carbodiimide-type coupling reagents employed are dicyclohexylcarbodiimide 
(DCC),227 di/'sopropylcarbodiimide (DIG)228 and 1-ethyl-3-(3- 
dimethylaminopropyl)carbodiimide (EDC).229 These reagents are usually used in 
combination with a nucleophilic catalyst such as A/,A/-dimethylaminopyridine 
(DMAP), 1-A/-hydroxybenzotriazole (HOBt) or 7-aza-1-A/-hydroxybenzotriazole 
(HOAt) (Figure 3.7).
DMAP HOBt HOAt
Figure 3.7: Nucleophilic catalysts used in carbodiimide coupling reaction.
The carbodiimide reagent reacts with the acid moiety and converts this to an acyl 
isourea species which can then undergo nucleophilic attack by the catalyst to form 
either an activated ester, in the case of HOBt and HOAt, or a reactive amide in the 
case of DMAP. In the absence of a nucleophilic catalyst, the acyl isourea species 
can undergo an undesired rearrangement to form the A/-acyl urea species which 
renders the acid unable to couple with its partner amine (Figure 3.8). The addition of 
the nucleophilic catalyst not only prevents this rearrangement from occurring but it 
also creates an extremely reactive ester which, when treated immediately with the 
partner amine, reacts at such a rate that almost no racemisation is usually 
observed.
A common problem with the use of carbodiimide coupling reagents is the removal of 
the urea by-products. However, recent years have seen the development of newer 
coupling agents, such as DIG which have enhanced solubility in organic solvents. 
These newer coupling agents are more suited to solid-phase synthesis as they can 
be easily removed through a series of washes.230
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Figure 3.8: Intramolecular rearrangement by carbodiimide activated acids.
Phosphonium-type peptide coupling reagents were first developed in the 1970’s by 
Castro et a/..231 232 These early coupling agents produced a large amount of 
racemised material. However, the discovery of HOBt as a racemisation 
suppressor227 led to the development of a new generation of coupling reagents 
which remain in frequent use today. The first of these reagents was benzotriazol-1- 
yloxyf/7's(dimethyl-amino)-phosphonium hexafluorophosphate (BOP)233 (Figure 3.9). 
At the time of its development, BOP was a popular coupling agent used throughout 
peptide and organic chemistry.234 However, the realisation that the by-product from 
this reagent (hexamethylphosphoramide, HMPA) was a potent human carcinogen 
lead to further modifications to produce new compounds that did not generate toxic 
by-products. The modifications to the BOP reagent resulted in the reagents that are 
known today as benzotriazol-1-yloxytri(pyrrolidino)-phosphonium 
hexafluorophosphate (PyBOP)235 236 and the HOAt derivative [(7-azabenzotriazol-1- 
yl)oxy]f/7's-(pyrrolidino)-phosphonium hexafluorophosphate (PyAOP).237238
N
NCP
X=CH PyBOP 
X=N PyAOP
Figure 3.9: Phosphonium type coupling agents.
The proposed mechanism of these phosphonium-type reagents proceeds initially 
with deprotonation of the acid which then attacks the positively-charged phosphorus
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causing elimination of the OBt (or OAt) portion of the molecule. This OBt anion then 
acts as a nucleophile attacking the carbonyl group of the newly formed phosphorus 
intermediate causing elimination of a phosphorus oxide by-product. The activated 
ester can then react with an amine to form an amide bond.
Uronium-type coupling reagents were first introduced in 1978 by Gross et al239 This 
group developed the reagent ©-(benzotriazoM-yO-I.I.S.S-tetramethyluronium 
hexafluorophosphate (HBTU) which remains in wide use today.239 240 It was 
initially thought that this reagent existed as the O-uronium salt. However, recent 
studies have shown that the active form of the compound is actually the N- 
guanidinium salt241 (Figure 3.10). Along with HBTU, the HOAt derived compound O- 
(7-azabenzotriazol-1 -yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HATU) is also frequently used.237 242 Although many uronium- 
derived coupling agents exist, HBTU and HATU are two of the most popular due to 
their commercial availabilities.
O-Uronium form of HBTU A/-Guanidinum form
X = CH HBTU 
X = N HATU
Figure 3.10: Uronium-type coupling reagents.
It is thought the mechanism of this class of reagents proceeds in a similar manner to 
that of the phosphonium-type reagents. Formation of a guanidinium ester of the 
carboxylic acid is subsequently followed by generation of an active OBt (or OAt) 
ester. This ester can then undergo nucleophilic attack by the partner amine 
generating the amide bond.
In general, the uronium based reagents tend to be more stable than the 
phosphonium based reagents and, for both classes of compound, the HOAt 
derivatives are found to be more reactive than their HOBt derivatives.243
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3.3.3 Synthesis of peptides in solution
After reviewing literature in the area, it was decided to follow a procedure devised 
by Chandrasekhar et al. in which thymidine derived p-amino acid monomers, very 
similar to our own, were coupled together to make a very short peptide of four units 
in length.157 The procedure utilised a HBTU/HOBt combination of coupling reagents 
to connect two thymidine-derived p-amino acid units through an amide bond. This 
nucleoside dimer was then used to synthesise a trimer and tetramer.
mTU/msi o ^ °T
'—....'"m902
_ n=1 and 2
Figure 3.11: A general synthesis of short peptides in solution using HBTU/HOBt 
(PG1 and PG2 = protecting groups and T= thymine)
We wished to adopt the same strategy (see Figure 3.11) for the synthesis of 
peptides in solution built up of the nucleoside derived p-amino acid monomers 
discussed in chapter 2. Initially, it was decided to explore the preparation of homo­
oligomers of the thymidine derived p-amino acids to assess the validity of this 
coupling method. Thus, the 5'-benzhydryl protected thymidine monomer (14) and 3'- 
Fmoc protected thymidine monomer (3) were coupled in solution to give fully 
protected 3’—>5’ amide linked dimer (51).
Ph2HCO T
i) HBTU, HOBt, DIPEA 
THF
ii) 14, DIPEA, THF, 40°C 
89%
(14)
NHFmoc
(3)
Ph2HCO H
(51)
'"'NHFmoc
Scheme 3.1: Coupling of thymidine derived p-amino acid monomers to make a fully
protected dimer.
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This reaction was carried out by first activating the carboxylic acid moiety of amino 
acid (3) by treatment with a combination of HBTU/HOBt/DIPEA over a period of 2 
hours. Addition of the second amino acid (14) in the presence of base enabled 
nucleophilic attack of the free S'-amine on the newly activated acid and formation of 
the amide bond. In the publication by Chandrasekhar, this step reportedly took 3 
days at ambient conditions and produced a 60% yield. However, we found that 
gentle heating at 40°C allowed our reaction to go to near completion in high yield 
(89% after purification by flash chromatography) within 1 hour. It is thought that this 
increase in yield and reduction in reaction time might be attributed to the enhanced 
solubility of our nucleoside derived (3-amino acids due to a different protecting group 
strategy.
Formation of the fully protected dimer (51) was confirmed by 1H NMR spectroscopy 
through the presence of two singlet peaks at 1.75 ppm and 1.91 ppm integrating to 
3 protons each, corresponding to the two thymine methyl groups. The observation 
of four NH protons, two at 9.22 ppm and 10.03 ppm corresponding to the two amide 
NH groups and the remaining two at 13.09 ppm and 13.12 ppm corresponding to 
the two imine protons of the thymine base, provided additional support that the 
dimer (51) had indeed successfully formed.
The next stage in the synthesis was to generate two different dimers; one with a 
free acid moiety at the 5'-end (i.e 52) and one with a free amine at the 3'-end (i.e. 
53, see Scheme 3.2). It was hoped that these two dimers could then be coupled 
together under the same conditions discussed previously to generate a fully 
protected peptide four units in length. Further to this, it was thought a dimer with a 
free S’-amine moiety could be coupled to an additional single thymidine (3-amino 
acid (3, Scheme 3.1) to generate a fully protected peptide three units in length.
T . O T
THF, Pd/C, H2 HO
T . O T
Ph2HCO NH
(51)
"""NHFmoc
N
H
(52)
T . O T
'"""NHFmoc
THF, DBU
Ph2HCO H
(53)
Scheme 3.2: Removal of protecting groups from the 3' and 5' end of nucleoside
dimer (51).
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Removal of the benzhydryl group from the carboxylic acid moiety was carried out 
under standard hydrogenation conditions. After 72 hours, the 5’-carboxylic acid 
dimer (52) was obtained. Purification by standard flash chromatography could not 
be carried out on this compound due to its high polarity. Instead a partial purification 
of the crude material was carried out by partitioning between methanol and hexane. 
The polar peptide was retained in the methanol and the less polar impurities were 
transferred into the hexane. As a consequence of the partially crude nature of the 
material, analysis by NMR was found to be extremely difficult. However, a good high 
resolution mass spectrum was obtained finding as mass of 737.2171 compared to 
the calculated mass of 737.2183.
Removal of the Fmoc group from the S'-end of the fully protected dimer (51), to 
generate the dipeptide (53) with a free amine moiety, was carried out in THF using 
1, 8-diazabicyclo-[5.4.0] undec-7-ene (DBU). Again the compound proved to be 
extremely polar so a partial purification was carried out as discussed previously by 
utilising a methanol/hexane extraction. A good high resolution mass spectrum of this 
compound was also obtained with a mass of 659.2490 being observed compared to 
the calculated mass of 659.2466.
Coupling of 5'-deprotected dimer (52) and 3'-deprotected dimer (53) was carried out 
under the same conditions as discussed previously in this chapter (Scheme 3.3).
The carboxylic acid of dimer (52) was first activated using HBTU/HOBt/DIPEA 
followed by subsequent addition of 3’-amino dimer (53) in a mixture of THF and 
di/sopropylamine. Once the reaction was judged to be complete, as determined by 
tic, the reaction solvents were removed and the tetramer (54) was precipitated from 
methanol as a pale brown amorphous solid in 20% yield. The reason for the poor 
yield, in this case, is unknown as analysis of the reaction liquors determined that no 
residual starting materials were present.
The complexity of this molecule meant that analysis by NMR methods would prove 
to be difficult. An effort was made to obtain a ^ NMR spectrum of this compound. 
However, it was found that, due to overlapping peaks, the structure could not be 
analysed with complete certainty and definitive peak assignments could not be 
made. Analysis of this compound by mass spectrometry also proved difficult due the 
reluctance of the molecule to ionise. However a low resolution mass spectrum could 
be obtained which gave the expected mass of the molecule (1377.2).
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Scheme 3.3: coupling of dimers (52) and (53) to generate tetramer peptide (54).
In addition to the thymidine derived tetramer (54), a shorter fully protected peptide 
three residues in length (55) was also synthesised. Coupling of the 3'-amino dimer 
(53) to 5'-carboxylic acid monomer (3) using the HBTU/HOBt/DIPEA conditions 
described previously for the synthesis of the tetramer, afforded the trimer in a 17% 
yield (Scheme 3.4). Again the peptide was precipitated from methanol as a pale 
brown amorphous solid and the fate of the rest of the material could not be 
accounted for.
Analysis of the fully protected tripeptide (55) by electrospray mass spectrometry 
proved to be problematic in this case. The trimer proved to be difficult to ionise and 
the high cone voltage required to induce ionisation also resulted in the loss of the 
benzhydryl group from the 5'-end of the molecule. The only observed mass ion peak 
in this case corresponded to the mass of the peptide less a fragment, giving 
974.1. It is highly probable that the uncharged and fully protected trimer would be 
better suited to anaylsis by the MALDI-TOF technique rather than electrospray 
mass spectrometry.
Analysis of the tripeptide (55) by 1H NMR again proved difficult due to overlapping 
peaks, but the spectrum was consistent with that expected for the product trimer. In 
particular, the aromatic protons of the benzhydryl and Fmoc groups could be seen 
over a range from 7.20 to7.70ppm and three singlet peaks corresponding to the 
thymine methyl groups were observed at 1.07 ppm, 1.11 ppm and 1.19 ppm.
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Scheme 3.4: Coupling of 5'-carboxylic acid monomer (3) to 3'-amino dimer (53) to
generate peptide trimer (55).
Due to the successful coupling of the thymidine derived p-amino acid monomers it 
was decided to investigate the coupling of the 5-methyl-2'-deoxycytidine derived 
monomer (16) and the 2'-deoxyadenosine derived monomer (36) to the 5'-protected 
thymidine derived amino acid (14). These reactions were carried out on a very 
small scale as a simple proof of principal study to investigate if the synthesis of 
mixed peptide sequences may be possible in future.
0 HO 0 * THF o 0 }, 0 ^ac-
NHo NHFmrv'
ho^.° , i) 16,HBTU, HOBt, DIPEA THF
(14)
oc
(16)
H
(56)
’"'NHFmoc
(14) (36)
i) 36,HBTU, HOBt, DIPEA
THF
ii) 14, DIPEA, THF, 40°C
Ph2HCO
0 J O frMoc
(57)
Scheme 3.5: Synthesis of mixed nucleoside dimers (56) and (57).
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For both mixed nucleoside dimers, (56) and (57), the conditions used were exactly 
the same as those described for the synthesis of the thymidine based peptides 
(Scheme 3.5). Due to the small scale of these reactions, the crude reaction products 
were directly analysed by electrospray mass spectrometry.
The coupling of the S'-protected thymidine derived amino acid (14) to 5-methyl-2'- 
deoxycytidine monomer (16) was indeed successful with detection of the mass ion 
for the mixed dimer (56) both in low and high resolution mass spectrometry. Even 
with the crude material, the mass detected at 1006.3392 was extremely close to the 
calculated value of 1006.3388.
The coupling of the same thymidine derived amino acid (14) to the 2'- 
deoxyadenosine derived monomer (36) was also successful. Again mass 
spectrometry was carried out on the crude mixture and gave a mass ion peak of 
800.2529 which is very close the calculated value of 800.2517.
Due to constraints of time, no further work could be carried out on either the 
thymidine based peptides or the mixed nucleoside based peptides.
3.4 Conclusions
Solid-phase synthesis of peptides made up of thymidine-derived (3-amino acid (3) 
was attempted but abandoned, due to complications both with the synthesis, 
particularly the sensitivity of the glycosidic bond, and the purification of the peptide. 
This ted us to investigate the coupling of nucleoside-derived (3-amino acid 
monomers in solution.
A synthesis of fully protected peptides made up of thymidine-derived (3-amino acid 
units was carried out successfully in solution. Peptides of two, three and four units in 
length were synthesised. This work was then expanded further to investigate 
coupling of a 5-protected thymidine (3-amino acid to a 5-methyi-2'-deoxycytidine (3- 
amino acid and a S'-azido^'.S'-deoxyadenosine (3-amino acid. This work resulted in 
the successful generation of two mixed nucleoside dipeptides. This short, proof of 
principle study indicates that, in the future, it may be possible to synthesise longer 
peptides of mixed sequences in solution.
Although peptides can clearly be prepared by this procedure there remains room for 
improvement as the yields of some of the coupling steps are fairly low. The work
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could also benefit from full NMR analysis to confirm the structures are indeed 
correct and to investigate if any secondary structures are being formed in the longer 
peptides. Removal of the protecting groups from the tri- and tetra-peptides could 
also allow cyclisation studies to be carried out in the future.
In general, the synthesis of peptides in solution remains a work in progress and 
future studies should include investigations into more efficient methods of 
purification and analysis. Purification of the fully protected peptides could easily be 
carried out by flash chromatography. However, removal of the protecting groups 
from either end of the peptide caused problems. Other methods of purification for 
these more polar peptides should be investigated such as preparative scale, 
reverse phase HPLC. Electrospray mass spectrometry is not suited to these large 
uncharged peptides and other methods such as MALDI-TOF should be investigated 
in order to obtain cleaner ionisation.
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Chapter 4: Experimental
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4.1 Techniques and reagents
NMR spectroscopy
All NMR spectra were recorded on a Broker AMX-400MHz machine. Chemical shifts 
are reported in ppm relative to an internal standard of tetramethylsilane (IMS) and 
coupling constants are reported in Hz. Some chemical shift values for aromatic and 
fluorenyl protons and carbons have been assigned using spectra simulations from 
ChemBioDraw Ultra 12.0.
Mass spectrometry
Electrospray spectra were recorded by Mr Allan Mills and Miss Moya McCarron at 
the University of Liverpool using a Micromass LCT machine via Electrospray 
Ionisation (El). All samples were recorded using the ionisation mode specified and 
were injected using a direct infusion syringe pump. HRMS= High Resolution Mass 
Spectrometry.
IR spectroscopy
All samples were recorded neat on a Jasco FT-IR 4100 spectrometer equipped with 
an ATR sample holder.
Analytical thin layer chromatography (tlcl
Tic was performed on UV254 sensitive, silica gel 60 coated, aluminium tic plates 
purchased from Merck. The developed chromatographs were visualised with a UV 
lamp (254 nm). Most tic plates were stained with p-anisaldehyde, with spots turning 
blue upon heating with the exception of those compounds containing a 5'-DMT 
group which produced an orange stain. Exceptions to this are tic plates containing 
carboxylic acid and amino compounds which were stained with bromocresol green 
and turned yellow and blue, respectively, on a pale blue background without the 
application of heat.
Flash column chromatography
The required quantity of silica gel (particle size 40-63 pM, supplied by BDH or 
Sigma Aldrich) was made into a homogenous slurry with the column eluent and 
applied to the column over a base layer of sand. The material to be purified was 
then introduced on to the column in a minimum volume of eluent or as a powder by 
pre-absorption onto silica. All fractions were collected and analysed by tic.
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Solvents
Unless stated solvents were purchased from Fisher Scientific or BDH. Anhydrous 
solvents were obtained as follows:
Sigma Aldrich Sure-seal™: N, N- dimethylformamide 1L, N, N- dimethyiacetamide 
1L, 1,4-dioxane 1L, pyridine 1L, dichloromethane 1L, methanol 1L, tetrahydrofuran 
100mL
VWR: methanol 25QmL, dichloromethane 250mL, tetrahydrofuran 250mL, pyridine 
250mL.
Link Technologies: acetonitrile 100mL 
General reagents
Unless stated general reagents were obtained from Sigma Aldrich, Fluka or BDH 
and used as supplied. Nucleosides were obtained from ChemGenes USA and were 
co-evaporated with the relevant reaction solvent before use. Hydrogen sulfide was 
obtained in a cylinder from Sigma Aldrich.
p-Anisaldehyde dip was prepared as follows: p-Anisaldehyde (6 mL) was mixed with 
sulphuric acid (8 mL), acetic acid (2.4 mL) and ethanol (218 mL) and stored at room 
temperature in darkness.
Bromocresol green dip prepared as follows: Bromocresol green (0.10 g) was 
dissolved in ethanol (250 mL) and 6M sodium hydroxide (3 mL) was added 
dropwise. This dip was stored at room temperature.
Lithium azide prepared as follows: Lithium sulfate (10.0 g, 90.9 mmol) and sodium 
azide (11.8 g, 181.9 mmol) were dissolved in water (40 mL) and warmed to 40°C. 
Ethanol (60 mL) was then added slowly and the reaction stirred for 10 mins. The 
solids were removed by Alteration under vacuum and the filtrate evaporated to 
dryness. This afforded lithium azide as a white powdery solid.
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4.2 Synthesis of nucleoside monomers
Preparation of 2', 3,-Anhvdro-5,-(4-0-methoxvbenzovl)thvmidine (8)156
o
Thymidine (2.00 g, 8.25 mmol) and PPh3 (3.20 g, 12.4 mmol) were dissolved in dry 
DMF (20 mL) and allowed to stir. To this was added p-methoxybenzoic acid (1.90 g, 
12.4 mmol) in dry DMF (5 mL). The flask was then cooled to 10 °C in an ice/water 
bath and DIAD (2.50 mL, 12.4 mmol) was added dropwise over 10 minutes, the 
reaction was then warmed to ambient temperature and allowed to stir for 15 
minutes. A further aliquot of PPh3 (3.20 g, 12.37 mmol) in dry DMF (5 mL) was then 
added and again the reaction cooled to 10 °C and DIAD (2.50 mL, 12.4 mmol) was 
added in the same manner as previous. The reaction mixture was then warmed to 
ambient temperature and allowed to stir for 2 hours. During this time an off -white 
precipitate formed and the reaction mixture was poured onto Et20 (250 mL) and 
cooled to 4°C overnight. The precipitate was then collected by filteration under 
vacuum and washed with plenty of Et20 (500 mL).
Yield: 2.50 g, 6.98 mmol, 84%
1H NMR (400MHz, DMSO-cf6) 5 1.73 (s, 3H, Thy-CH3), 2.53 (m, 4H, H2' + OCH3), 
2.61 (m, 1H, H2'), 4.30 (dd, 1H, J=6.44, 11.81 Hz, H5'), 4.48 (dd, 1H, J=5.21,
11.81 Hz, H5'), 4.57 (m, 1H, H4’), 5.40 (brs, 1H, H3'), 5.88 (apparent d, 1H, J= 3.75 
Hz, H1'), 7.00 (d, 2H, J=6.84 Hz, m-ArH), 7.56 (s, 1H, H-6), 7.86 (d, 2H, J=6.84 Hz, 
o-ArH).
13C NMR (100MHz, DMSO-d6) 5 13.3 (Thy-CH3), 33.1 (C2')t 55.9 (CH30), 62.6 
(C5'), 77.5 (C3'), 82.4 (C4'), 87.2 (CV), 114.4 (m-ArC), 116.5 (C5), 121.6 (/pso-ArC), 
131.7 (o-ArC), 136.9 (C6), 163.7 (C2), 165.3 (p-ArC), 171.2 (C4).
HRMS found m/z (ES+) 381.1064 ([M + Na]+ 100%); [C18H18N206 + Na]+ requires 
381.1063
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Preparation of a-Azido-S-deoxv-S-O-^-methoxvbenzovDthvmidine (9V156
2,)3,-Anhydro-5'-(4-0-methoxybenzoyl)thymidine (8, 2.89 g, 8.06 mmol) and UN3 
(1.18 g, 24.2 mmol) were dissolved in dry DMF (20 mL) and heated at reflux for 3 
hours. The orange reaction mixture was then poured onto 5% aqueous HCI (70 mL). 
This mixture was then extracted with EtOAc (3 x 100 mL) and the combined organic 
extracts washed with water (100 mL) followed by brine (100 mL). After drying over 
MgS04 all the solvent was removed in vacuo and the crude product was afforded as 
a yellow gum
1H NMR (400MHz, CDCI3) 5 1.72 (s, 3H, Thy-CH3), 2.34 (m, 4H, H2' + OCH3), 2.53 
(m, 1H, H2'), 4.22 (m, 1H, H4'), 4.32 (m, 1H, H3'), 4.53 (dd, 1H, J= 3.80, 12.33 Hz, 
H5'), 4.65 (dd, 1H, J=3.42, 12.33 Hz, H5'), 6.17 (apparent t, 1H, J=6.46Hz, H1'), 
6.93 (m, 2H, m-ArH ), 7.20 (s, 1H, H-6), 7.98 (m, 2H, o-ArH), 8.16 (brs, 1H, NH).
13C NMR (100MHz, CDCI3) 6 12.6 (Thy-CH3), 38.3 (C2'), 55.9 (CH30), 61.6 (C3'), 
63.7 (C5’), 82.6 (C4r), 85.7 (C1’), 99.9 (C5), 114.4 (m-ArC), 122.2 (/pso-ArC), 132.1 
(o-ArC), 135.2 (C6), 151.4 (C2), 163.7 (C4), 165.7 (p-ArC).
HRMS found m/z (ES+) 424.1243 ([M + Na]+ 100%); [C^H^NgOe + Na]+ requires 
424.1233
IR v max/cm'1 =1020.16, 1168.65, 1255.43, 1367.28, 1513.85, 1631.48, 1695.12, 
2103.96, 2923.56.
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Preparation of S'-Azido-S'-deoxythymidine (2, AZTV156
o
S'-Azido-S'-deoxy-S'-O-^-methoxybenzoyOthymidine (9,1.10 g, 2.74 mmol) was 
dissolved in methanol (15 ml) and NaOMe (590 mg, 11.0 mmol) in water (5 mL) 
was added. This mixture was then allowed to stir at ambient temperature for 68 
hours. Upon addition of a further quantity of water (5 mL) a white solid was seen to 
precipitate out (p-methoxybenzoic acid). The precipitate removed by filteration 
under vacuum and a further aliquot of water was added (5 mL), any residual white 
precipitate formed was removed. The aqueous filtrate was then washed with Et20 (2 
x 25 mL) and the two phases were separated. The aqueous layer was then allowed 
to stir with Amberlite ion exchange resin for 15 minutes. The resin was removed by 
filteration and all the solvents were removed in vacuo to give a yellow solid. The 
crude was purified by silica chromatography using a 20% methanol/ethyl acetate 
eluent system. Fractions containing product were concentrated to afford AZT as an 
off-white foam.
Yield: 640 mg, 2.39 mmol, 84%
'H NMR (400MHz, MeOD-d4) 6 1.90 (s, 3H, Thy-CH3), 2.24 (m, 2H, H2,)) 3.76 (dd, 
1H, J= 3.42, 12.15 Hz, H5'), 3.86 (m, 1H, H5’), 3.93 (m, 1H, H4'), 4.37 (m, 1H, H3'), 
6.19 (apparent t, 1H, J= 6.35 Hz, HV), 7.81 (s, 1H, H-6).
13C NMR (100MHz, MeOD-cL) 5 12.8 (Thy-CH3), 38.6 (C2'), 61.9 (C5'), 62.8 (C3'), 
86.5 (C4' + C1’), 112.0 (C5), 138.2 (C6), 152.7 (C2), 166.7 (C4).
HRMS found m/z (ES+) 290.0858 ([M + Na]+ 100%); [C1oH13N504 + Na]+ requires 
290.0865
IR vmax/cm1 = 1163.19, 1244.36, 1356.23, 1630.66, 1696.13, 2097.80, 2941.96.
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Preparation of S-Amino-S'-deoxvthvmidine (10) 156
3'-Azido-3'-deoxythymidine (2, 840 mg, 3.14 mmol) was dissolved in methanol 
(8 mL) and to this was added a 10% palladium on activated carbon catalyst (20 mg). 
The reaction vessel was then flushed with nitrogen three times, refilled with H2 and 
allowed to stir at ambient temperature and pressure for 4.5 hours. No starting 
material remained after this time so the reaction was stopped and the Pd catalyst 
removed by filteration under vacuum through Celite and washed with excess of 
methanol (100 mL). The solvent was then removed in vacuo to give the product as 
an off-white foam.
Yield: 555 mg, 2.3 mmol, 74%
1H NMR (400MHz, MeOD-cf4) 6 1.89 (s, 3H, Thy-CH3), 2.23 (m, 1H, H2'), 2.32 (m, 
1H, H2'), 3.33 (m, 1H, H3'), 3.73 (m, 1H, H4'), 3.80-3.89 (m, 2H, H5'), 6.21 (dd, 1H, 
J= 4.84, 6.93Hz, H1’), 7.87 (s, 1H, H-6).
13C NMR (100MHz, MeOD-d„) 6 12.8 (Thy-CH3), 42.1 (C2'), 52.0 (C3'), 62.5 (C5'), 
86.3 (CV), 89.0 (C4'), 111.6 (C5), 138.6 (C6), 152.9 (C2), 166.7 (C4).
HRMS found m/z (Cl + NH3) 242.1145 ([M +H]+ 100%); [C^H^NA + H]+ requires 
242.1140.
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Preparation of S'-AZ-O-FluoromethoxycarbonyD-S'-deoxythymidine (11) 156
O
3’-Amino-3’-deoxythymidine (10, 555 mg, 2.30 mmol) was dissolved in 1,4- 
dioxane:water (2:1, 9 ml), K2CO3 (635 mg, 4.60 mmol) was added and the reaction 
allowed to stir at ambient temperature for 30 minutes. This was then cooled to 0°C 
in an ice bath and Fmoc chloride (722 mg, 2.80 mmol) added to the reaction. The 
mixture was then removed from the ice bath and allowed to stir for 40 minutes at 
ambient temperature after which the solution appeared a thick semi opaque white 
colour. Water (10 mL) was added to the reaction and a white precipitate formed 
which subsequently turned into an off-white sticky solid. Therefore the solvents were 
decanted off and the solid redissolved in 1% methanol/ethyl acetate (10 mL). All the 
solvents were removed in vacuo to give an off white solid which was then 
redissolved in methanol (5 mL) and the remaining insoluble impurities were filtered 
off. The filtrate was concentated in vacuo and the crude product purified by silica 
chromatography using a 1% methanol/ethyl acetate eluent system. The fractions 
containing product were combined to afford a white crystalline solid.
Yield: 480 mg, 1.03 mmol, 45%
1H NMR (400MHz, MeOD-cf4) 6 1.86 (s, 3H, Thy-CH3), 2.29 (m, 2H, H2')> 3.70 (m, 
1H, H4’), 3.85 (m, 2H, H5'), 4.22 (t, 1H, J=6.46 Hz, Fmoc-HB), 4.28 (m, 1H, H3'), 
4.43 (m, 2H, Fmoc-HA), 6.20 (m, 1H, HV), 7.43 (m, 4H, Fmoc-HE,F), 7.65 (m, 2H, 
Fmoc-HD), 7.81 (m, 2H, Fmoc-HG), 7.91 (s, 1H, H-6).
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13C NMR (100MHz, MeOD-d,) 5 12.8 (Thy-CHa), 39.3 (C2')( 49.2 (Fmoc CB), 52.0 
(C3'), 62.7 (C5'), 68.0 (Fmoc CA), 86.2 (C1' + C4'), 112.2 (C5), 121.3, 126.5, 128.5, 
129.2 (Fmoc-CD,E,F,G), 138.5 (C6), 152.5 (C2), 166.3 (C4).
HRMS found m/z (ES+) 486.1651 ([M + Na]+ 100%); [C25H25N3O6 + Na]+ requires 
486.1641
Preparation of S-AZ-O-FluoromethoxycarbonvO-S'-azido-S-deoxythymidvI-S'-
carboxylic acid (3)156
3'-A/-(9-Fluoromethoxycarbonyl)-3'-amino -3'-deoxythymidine (11, 480 mg, 1.03 
mmol) was suspended in MeCN/water (1:1, 8 mL) and TEMPO (31 mg, 0.20 mmol) 
and BAIB (728 mg, 2.26 mmol) were added. This caused the suspension to turn 
bright orange in colour. The reaction was allowed to stir at ambient temperature for 
14 hours and after this time the reaction had separated into two distinct layers and a 
pale brown precipitate was seen to have formed. The precipitate was collected by 
filteration under vacuum and washed with an excess of Et20 (100 mL).
Yield: 200 mg, 0.42 mmol, 40%
1H NMR (400MHz, DMSO-cf6) 5 1.89 (s, 3H, Thy-CH3), 2.30 (br s, 2H, H2'), 4.22 (m, 
1H, Fmoc-HB), 4.30-4.50 (4H, m, H4' + H3' + Fmoc-HA), 6.34 (m, 1H, H1'), 7.35 (m, 
2H, Fmoc-HE), 7.46 (m, 2H, Fmoc-HF), 7.70 (d, 2H, J=8.35 Hz, Fmoc-HD), 7.80 (d, 
2H, J= 7.22 Hz, Fmoc -HG), 8.19 (s, 1H, 3’-NH), 11.38 (br s, 1H, NH).
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13C NMR (100MHz, DMSO-d6) 5 12.7 (Thy-CH3), 36.6 (C2’), 47.0 (Fmoc- CB), 54.8 
(C3')t 65.2 (Fmoc CA), 81.9 (C4'), 85.4 (CV),109.7 (C5), 120.4, 125.5, 127.4, 128.0 
(Fmoc-CD,E,F,G), 136.7 (C6), 141.1 (Fmoc-CH), 144.2 (Fmoc-CC), 150.8 (C2), 
164.0 (C4), 172.5 (C5').
HRMS found m/z (ES+) 500.1429 ([M +Na]+ 100%); [C25H23N3O7 +Na]+ requires 
500.1434.
Preparation of S-Azido-S'-deoxvthvmidine-S'-benzhvdrvI ester (131
S'-Azido-S'-deoxythymidine (2, 2.55 g, 9.54 mmol), TEMPO (297 mg, 1.90 mmol) 
and BAIB (6.89 g, 21.0 mmol) were suspended in an acetonitrile: water (1:1, 20 mL) 
mix and allowed to stir at ambient temperature for 1.5 hours. The solvents were 
removed by in vacuo and residual water removed by co-evaporation with acetone, 
this afforded the intermediate as a white sticky solid. 3'-Azido-3'-deoxythymidine-5'- 
carboxylic acid (12,1.00 g, 3.56 mmol) and benzophenone hydrazone (965 mg, 5.70 
mmol) were added to a flask suspended in an ice bath and DCM (20 mL) was 
added slowly with stirring. 1% Iodine in DCM (0.2 mL) was then added to the 
reaction and a mixture of Oxone™ (3.28 g, 5.34 mmol) and wet alumina (3.8 g) was 
added in portions over 30 mins. The reaction was then allowed to stir in an ice bath 
over 2 hours and all the solids removed by filteration and washed well with DCM 
(100 mL). The filtrate was concentrated in vacuo and the crude residue purified by 
silica chromatography using a 0-2% methanol/DCM eluent system. The desired 
product was afforded as a yellow foam.
Yield: 1.00 g, 2.09 mmol, 59%
1H NMR (400MHz, CDCI3) 6 1.84 (s, 3H, Thy-CH3), 2.13 (m, 1H, H2'), 2.45 (m, 1H, 
H2'), 4.36 (apparent dt, 1H, J= 2.21, 5.99 Hz, H3'), 4.46 (d, 1H, J= 2.21 Hz, H4'),
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6.37 (dd, 1H, J= 5.50, 8.18 Hz, HV), 7.22-7.40 (m, 11H, Ar-H), 7.80 (d, 1H, J=1.24 
Hz, H6).
13C NMR (100MHz, CDCI3) 6 12.9 (Thy-CH3). 37.0 (C2'), 64.2 (C3'), 79.2 (C4'), 86.9 
(C1'), 111.9 (C5), [128.8, 128.9, 129.0, 129.2, 129.3 (Ar-C)], 136.1 (C6), 150.6 (C2), 
163.93 (C4), 169.6 (C5')
HRMS found m/z (ES+) 470.1430 ([M + Na]+100%); [C23H21N5O5 + Na]+ requires 
470.1440
Preparation of S-Amino-S-deoxvthvmidine-S'-benzhvdryl ester (14)
o
3'-Azido-3'-deoxythymidine-5'-benzhydryl ester (13, 1.00 g, 2.09 mmol) was 
dissolved in a 15 % triethylamine/pyridine solution (20 ml_) and cooled to 0°C. 
Hydrogen sulfide was then bubbled through for 5 minutes after this time the reaction 
vessel was sealed and allowed to stir for 30 mins at 0°C. The solvents were 
removed in vacuo and the crude residue purified by silica chromatography using a 
1-5% methanol/DCM eluent system. The desired product was afforded as an off- 
white foam.
Yield: 780 mg, 1.85 mmol, 88%
1H NMR (400MHz, CDCI3) 6 1.81 (s, 3H, Thy-CH3), 2.13 (m, 1H, H2’), 2.23 (m, 1H, 
H2'), 3.76 (apparent dt, 1H, J= 3.79, 6.03 Hz, H3'), 4.40 (d, 1H, J= 3.79 Hz, H4'), 
6.43 (apparent t, 1H, J= 6.34 Hz, HV), 7.00 (s, 1H, Ph2CH), 7.29-7.39 (m, 10H, Ar- 
H), 7.94 (d, 1H, J= 1.20 Hz, H6)
13C NMR (100MHz, CDCI3) 5 12.9 (Thy-CH3), 40.4 (C2'), 55.9 (C3'), 78.6 (C4'), 86.8 
(CV), 111.4 (C5), [127.5, 128.9, 129.1, 129.1, 129.2 (Ar-C)], 136.4 (C6), 150.8 (C2), 
164.18 (C4), 170.9 (C5')
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HRMS found m/z (ES+) 444.1518 ([M + Na]+ 100%); + Na]+ requires
444.1535.
Preparation of 3,-Azido-3,-deoxv-5,-0-(4.4,-dimethoxvtritvl)thvmidine (17)192
3'-Azido-3'-deoxythymidine (2, 3.55 g, 13.2 mmol), Dimethoxytrityl chloride (5.60 g, 
15.9 mmol) and DMAP (162 mg, 1.33 mmol) were dissolved in anhydrous pyridine 
(50 mL) and anhydrous triethylamine (9.24 mL) added. The reaction was then 
allowed to stir at room temperature for 5 hours. After this time all solvents were 
removed in vacuo and the residue redissolved in DCM (50 mL), the organic layer 
was then washed successively with saturated NaHC03 solution (100 mL) and water 
(2 x 100 mL). The organics were then dried over MgS04 and all solvents removed in 
vacuo. The crude was purified by silica chromatography using a 0-5% 
methanol/DCM eluent system and fractions containing product were concentrated to 
afford an off-white foam.
Yield: 6.64 g, 11.7 mmol, 87%
'H NMR (400MHz, MeOH-c/4)5 1.46 (s, 3H, Thy-CH3), 2.42 (m, 1H, H2'), 2.51 (m, 
1H, H2') 3.35 (m, 2H, H5'), 3.76 (s, 6H, DMT-OCH3), 3.94 (m,1H, H4’), 4.46 (m, 1H, 
H3'), 6.17 (apparent t, 1H, J= 6.33 Hz, HV), 6.86 (m, 4H, DMT-H, o-OCH3), 7.20- 
7.46 (m, 9H, DMT-H, m-OCH3, 2, 3, 4), 7.65.(s, 1H, H-6).
13C NMR (100MHz, MeOD-d4) 6 12.6 (Thy-CH3), 38.8 (C2'), 56.1 (DMT-OCH3 x2), 
62.3 (C3'), 64.6 (C5'), 85.3 (C4'), 86.4 (CV), 88.6 (DMT-qC), 112.1 (C5), 114.7 
(DMT-C, o-CH3 x4), 125.9 (DMT-C4), 128.5 (DMT-C, m-OCH3 x4), 129.4 (DMT-C2),
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129.8 (DMT-C3), 137.1 (C6), 138.0 (DMT-C, p-OCH3 x2), 146.3 (DMT-C1), 150.5 
(C2), 160.8 (DMT-C, /pso-OCH3), 166.7 (C4).
HRMS found m/z (ES+) 592.2169 ([M + Na]+ 100%); [C31H31N506+ Na]+ requires 
592.2172.
IR y/max/cm1 = 1174.44, 1247.72, 1461.78, 1506.13, 1606.41, 1683.55, 2100.10, 
2937.06, 3037.34.
Preparation of S'-Azido^. 3,-dideoxv-5,-O-(4.4,-dimethoxvtritv0-5-methvlcvtosine
(18)187,192
Method 1
Triazole (2.66 g, 38.6 mmol) and phosphoryl chloride (0.78 mL, 8.42 mmol) were 
suspended in anhydrous MeCN (30 mL) and triethylamine (4.89 mL, 35.1 mmol) 
was added dropwise at 0°C. 3-Azido- 3'-deoxy-5'-0-(4,4'-dimethoxytrityl)thymidine 
(17, 2.00 g, 3.51 mmol) in anhydrous MeCN (20 mL) was then added dropwise to 
the mixture, warmed to room temperature and allowed to stir for 3 hours. The 
reaction was then cooled to 0°C, triethylamine (2 mL) and water (0.8 mL) added and 
the reaction allowed to stir for a further 10 mins. All the solvents were then removed 
in vacuo and the residue redissolved in EtOAc (50 mL). The organics were washed 
successively with water (2 x 50 mL) and brine (2 x 50 mL) then dried over MgS04. 
The resulting solution was evaporated to dryness then redissolved immediately in 
1,4-dioxane (20 mL) and concentrated ammonia ( 7mL) added, the reaction was 
then allowed to stir for 3 hours at room temperature. The solvents were removed in
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vacuo and the crude was purified by silica chromatography using a 2-5% 
methanol/DCM eluent system. The product was afforded as a pale brown foam.
Yield: 1.00 g, 1.76 mmol, 50%
Method 2
S'-Azido- 3'-deoxy-5f-0-(4,4'-dimethoxytrityl)thymidine (17, 2.00 g, 3.51 mmol), 
1,2,4-Triazole (727 mg, 10.5 mmol) and 2-chlorophenylphosphorodichloridate (0.86 
ml, 5.27 mmol) were dissolved in dry pyridine (20 mL) and allowed to stir under 
nitrogen at room temperature for 3 days. All pyridine was then removed in vacuo. 
The residues were then redissolved in 1,4-dioxane (20 mL) and concentrated 
ammonia was added (7 mL) this was then allowed to stir at ambient temperature for 
2 hours. All solvents were then removed in vacuo and the crude residues purified by 
silica chromatography using a 0-5% methanol/DCM eluent system. The product was 
afforded as a pale brown foam.
Yield: 1.76 g, 3.10 mmol, 88%
1H NMR (400MHz, CDCI3) 5 1.53 (s, 1H, 5-Me), 2.45 (m, 1H, H2'), 2.60 (m, 1H,
H2'), 3.34 (dd, 1H, J= 2.89, 10.90 Hz, H5'), 3.60 (dd, 1H, J= 2.83, 10.90 Hz, H5'),
3.8 (s, 6H, DMT-OCH3), 4.02 (m, 1H, H4'), 4.32 (m, 1H, H3'), 6,29 (apparent t, 1H, 
J=5.90 Hz, HT), 6.88 (m, 4H, DMT-H, 0-OCH3), 7.25-7.43 (m, 9H, DMT-H, /77-OCH3, 
2, 3, 4), 7.78 (s, 1H, H-6), 8.21 (s, 2H, NH2).
13C NMR (400MHz, CDCI3) 5 13.1 (5-CH3), 39.1 (C2'), 55.6 (C3' + DMT-OCH3 x2),
60.2 (C5'), 84.1 (C4'), 85.9 (C1'), 87.3 (DMT-qC), 102.9 (C5), 113.7 (DMT-C, o- 
OCH3 x2), 113.7 (DMT-C, 0-OCH3 x2), 127.6 (DMT-C4), 128.4 (DMT-C, m-OCH3 
x4), 130.4 (DMT -C3 x2 + DMT-C2 x2), 135.6 (DMT -C, p-OCH3), 135.7 (DMT-C, 
P-OCH3), 138.2 (C6), 144.6 (DMT-C1), 156.5 (C2), 159.1 (DMT-C, /pso-OCH3 x2),
166.2 (C4).
HRMS found m/z (ES+) 591.2339 ([M + Naf 100%); [C3iH32N605+ Na]+ requires 
591.2332.
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Preparation of A/^-Benzovl-a'-azido^'. a'-dideoxv-S-Q-K^-dimethoxvtritvD-S-
methvlcvtosine (15)192
o
3'-Azido-2', S’-dideoxy-S'-O^^'-dimethoxytrityO-S-methylcytosine (18, 1.76 g, 3.10 
mmol) was dissolved in anhydrous pyridine (15 mL) and cooled to 0°C. Benzoyl 
chloride (0.54 mL, 4.65 mmol) was then added dropwise and the reaction allowed to 
stir at room temperature overnight. The reaction was again cooled to 0°C and water 
(0.5 mL) added. After stirring for 5 mins, ammonia (0.5 mL) was added and the 
reaction mixture allowed to stir for a further 30 mins. All solvents were then removed 
in vacuo and the residue redissolved in EtOAc (50 mL). The organics were washed 
successivley with saturated NaHC03 (2 x 100 mL), water (2 x 100 mL) and brine (2 
x 100 mL). The organic layer was dried over MgS04 and all solvents removed. The 
crude was then purified by silica chromatography using a 10% methanol/DCM 
eluent system. The product was afforded as a white foam.
Yield: 1.46 g, 2.17 mmol, 70%
1H NMR (400MHz, CDCI3) 5 1.67 (s, 3H, 5-Me), 2.47 (m, 1H, H2’), 2.54 (m, 1H,
H2'), 3.34 (dd, 1H, J= 4.08, 10.95 Hz, H5’), 3.60 (dd, 1H, J=2.74, 10.95 Hz, H5'), 
3.80 (s, 6H, DMT-OCH3), 4.01 (m,1H, H4’), 4.36 (m, 1H, H3'), 6.28 (apparent t, 1H, 
J= 6.22 Hz, HV), 6.86 (m, 4H, DMT-H, o-OCH3), 7.24-7.55 (m, 14H, DMT-H, m- 
OCH3, 1, 2, 3, Bz-H), 7.80 (s, 1H, H-6)
13C NMR(400MHz, CDCI3) 5 13.4 (5-CH3), 38.7 (C2'), 55.6 (DMT-OCH3 x2), 60.7 
(C5'), 67.2 (C3'), 84.2 (C4'), 85.4 (C1'), 87.5 (DMT-qC), 112.6 (C5), 113.7 (DMT-C, 
o-OCH3 x2), 113.7 (DMT-C, o-CH3 x2), 127.6 (Bz o-C x2 + DMT-C4), 128.4 (DMT- 
C, m-OCH3 x2), 128.5 (DMT-C, m-OCH3 x2), 130.3 (Bz m-C), 130.4 (Bz m-C),
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130.4 (DMT-C2 x2), 132.8 (DMT-C3 x2, Bz p-C), 135.5 (DMT -C, p-OCH3), 135.5 
(DMT-C, p-OCH3), 136.8 (C6), 137.5 (C2), 144.5 (DMT-C1), 159.2 (DMT-C, ipso 
OCH3 x2), 160.0 (C4).
HRMS found m/z (ES+) 695.2585 ([M + Na]+ 100%); [038^6^0,5+ Na]+ requires 
695.2594.
Preparation of AM-Benzovl-S-amino^'. 3,-dideoxv-5,-0-(4.4,-dimethoxvtritvl)-5-
methvlcvtosine (19)
o
A/-4-Benzoyl-3,-azido-2', 3,-dideoxy-5'-0-(4,4'-dimethoxytrityl)-5-methylcytosine (15, 
500 mg, 0.80 mmol) was dissolved in anhydrous 15% triethylamine/pyridine (2 mL) 
and cooled to 0°C in an ice bath. Hydrogen sulfide gas was then bubbled through 
for 15 mins after which time the reaction vessel was sealed and allowed to stir at 
ambient temperature for a further 30 mins. All the reaction solvents were removed in 
vacuo and the crude residue was purified by silica chromatography using a 0-3% 
methanol/DCM eluent system. The product was afforded as a yellow foam.
Yield: 363 mg, 0.57 mmol, 78%
1H NMR (400MHz, CDCI3) 5 1.73 (s, 3H, 5-Me), 2.29 (m, 1H, H2'), 2.45 (m, 1H,
H2'), 3.37 (m, 1H, H5'), 3.57 (m, 1H, H5'), 3.77 (m, 2H, H4' + H3'), 3.82 (s, 6H, 
DMT-OCH3), 6.28 (apparent t, 1H, J= 6.56 Hz, HV), 6.88 (m, 4H, DMT-H, 0-OCH3), 
7.31-7.54 (m, 14H, DMT-H, m-OCH3, 2, 3, 4, Bz-H), 7.84 (s, 1H, H-6), 8.29 (br s,
2H, NH2).
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13C NMR (400MHz, CDCI3) 5 13.5 (5-CH3), 42.6 (C2'), 51.5 (C3'), 55.6 (DMT-OCH3 
x2), 62.9 (C5')t 85.6 (C4’), 87.1 (C1'), 87.3 (DMT-qC), 113.7 (C5 + DMT-C, o-OCH3 
x2), 113.7 (DMT-C, o-CH3 x2), 127.5 (Bz o-C x2 + DMT-C4), 128.4 (DMT-C, m- 
OCH3 x2), 128.5 (DMT-C, m-OCH3 x2), 128.5 (Bz m-C), 130.2 (Bz m-C), 130.5 
(DMT-C2 x2), 132.7 (DMT-C3 x2, Bz p-C), 135.8 (DMT-C, p-OCH3), 136.8 (C6), 
137.6 (C2), 144.8 (DMT-C4), 159.1 (DMT-C, ipso-OCH3 x2).
HRMS found m/z (ES+) 669.2667 ([M + Na]+ 100%); [C38H38N406+ Na]+ requires 
669.2689.
Preparation of A/-4-Benzovl-3,-(Fmoc)amino-2,. S'-dideoxv-S-Q-^^'-
dimethoxvtritvl)-5-methvlcvtosine (20)
A/-4-Benzoyl-3'-amino-2', 3'-dideoxy-5'-0-(4,4'-dimethoxytrityl)-5-methylcytosine (19, 
100 mg, 0.16 mmol) and potassium carbonate (43 mg, 0.32 mmol) were dissolved 
in a dioxane/water (2:1, 3 ml_) mix and allowed to stir at ambient temperature for 30 
mins. The reaction was then cooled to 0°C in an ice bath and Fmoc chloride (49 mg, 
0.19 mmol) was added. The reaction was allowed to stir in the ice bath for 2 hours 
after which time water (1 mL) was added and the reaction stirred for a further 5 
mins. All the reaction solvents were removed in vacuo and the crude purified by
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silica chromatography using a 0-2% methanol/DCM eluent system. The product was 
afforded as an off white solid.
Yield: 140 mg, 0.16 mmol, 99%
1H NMR (400MHz, CDCI3)6 1.58 (s, 3H, 5-Me), 2.44 (m, 2H, H2')t 3.40 (m, 1H, H5'), 
3.52 (m, 1H, H5'), 3.75 (s, 6H, DMT-OCH3), 3.93 (m, 1H, H3’), 4.19 (m, 1H, H4'), 
4.50 (m, 2H, Fmoc-HA), 4.98 (m, 1H, Fmoc-HB), 6.31 (m, 1H, HI'), 6.84 (m, 4H, 
DMT-H, oOCH3), 7.20-7.59 (m, 22H, Fmoc-HD, E, F, G + Bz-H +DMT-H ), 7.78 (s, 
1H, H-6), 8.47 (s, 1H, NH).
HRMS found m/z (ES+) 891.3351 ([M + Na]+ 100%); [C53H48N408+ Na]+ requires 
891.3370.
Preparation of AM-Benzovl-S-fFmoclamino^'. S'-dideoxv-S-methvIcvtosine (21)
o
A/-4-Benzoyl-3'-(Fmoc)amino-2', 3'-dideoxy-5'-0-(dimethoxytrityl)-5-methylcytosine 
(20, 140 mg, 0.16 mmol) was dissolved in THF (1 mL) and p-toluene sulphonic acid 
(31 mg, 0.18 mmol) in THF (1 mL) was added. The reaction was allowed to stir at 
ambient temperature for 2 hours and then all reaction solvents were removed in 
vacuo. The crude residue was purified by silica chromatography using a 0-3% 
methanol/DCM eluent system. The product was afforded as a white solid.
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Yield: 69 mg, 0.12 mmol, 76%
1H NMR (400MHz, DMSO-d6)6 2.01 (s, 3H, 5-Me), 2.27 (m, 2H, H2'), 3.59 (m, 1H, 
H5'), 3.69 (m, 1H, H5'), 3.85 (m, 1H, H3'), 4.12 (m, 3H, Fmoc-HA + H4'), 4.35 (m, 
1H, Fmoc-HB), 6.17 (m, 1H, HI'), 7.32-7.85 (m, 13H, Fmoc-HD, E, F, G + Bz-H), 
7.90 (s, 1H, H-6), 8.17 (s, 1H, NH).
HRMS found m/z (ES+) 589.2063 ([M + Naf 100%); [C32H3oN406+ Na]+ requires 
589.2063.
Preparation of AM-Benzovl-S'-azido^’. S'-dideoxv-S-methvIcvtosine (22)
o
A/-4-Benzoyl-3'-azido-2', 3,-dideoxy-5'-0-(dimethoxytrityl)-5-methylcytosine (15,
500 mg, 0.74 mmol) was dissolved in THF (3 ml_) and toluene-4-sulphonic acid (139 
mg, 0.81 mmol) was added. This was then allowed to stir at ambient temperature for 
5 minutes. All solvents were removed in vacuo and the crude residue purified by 
silica chromatography using a 0-10% methanol/DCM eluent system. The product 
was afforded as a white foam.
Yield: 220 mg, 0.59 mmol, 81%
1H NMR (400MHz, MeOH-d,)5 1.96 (s, 3H, 5-Me), 2.38 (m, 1H, H2'), 2.59 (m, 1H, 
H2'), 3.76-4.02 (m, 3H, H5\ H4'), 4.37 (m, 1H, H3'), 6.20 (m, 1H, H1'), 7.23 (s, 1H, 
H-6), 7.70-8.15 (m, 5H, Bz-H)
13C NMR (400MHz, MeOD-d4) 5 13.6 (5-Me), 39.4 (C2'), 61.9 (C5'), 67.8 (C3'), 86.3 
(C4’), 87.5 (Cl'), 127.3 (C5), 129.0 (Bz o-C x2), 129.9 (Bz m-C x2,), 130.1 (Bz p-C, 
Bz /pso-C), 130.2 (C6), 130.9 (C2), 142.1 (C4).
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HRMS found m/z (ES+) 393.1296 ([M + Na]+ 100%); [C17H18N604 + Naf requires 
393.1287.
Preparation of AM-Benzovl-S-azido^'. S'-dideoxv-S-methvIcvtosine-S'-carboxvIic
acid (23)
o
/V-4-Benzoyl-3'-azido-2', 3'-dideoxy-5-methylcytosine (22, 220 mg, 0.59 mmol) was 
dissolved in acetonitrile/water (1:1, 3 mL) and cooled to 0°C in an ice bath. TEMPO 
(19 mg, 0.12 mmol), BAIB (432 mg, 1.30 mmol) and sodium hydrogen carbonate 
(100 mg, 1.18 mmol) were then added and the reaction allowed to stir at 0°C for 2 
hours. The reaction was then removed from the ice bath and allowed to stir at room 
temperature for a further hour, all solvents were then removed in vacuo. The 
resulting residue was recrystallised from acetone and diethyl ether to give a pale 
brown solid.
Yield: 188 mg, 0.49 mmol, 83%
1H NMR (400MHz, DMSO-d6)5 1.75 (s, 3H, 2-Me), 1.98-2.20 (m, 2H, H2'), 4.02 (m, 
1H, H4’), 4.40 (m, 1H, H3'), 6.17 (m, 1H, HV), 7.10-7.47 (m, 5H, Bz-H), 8.19 (s, 1H, 
H-6).
13C NMR (400MHz, DMSO-c/6) 6 14.1 (5-Me), 24.7 (C2'), 65.2 (C3'), 85.2 (C4'), 86.6 
(Cl'), 125.8 (C5), 127.4 (Bz o-C x2), 128.4 (Bz m-C x2), 128.4 (Bz p-C, Bz ipso-C), 
129.5 (C6), 137.9 (C4), 146.0 (C5').
HRMS found m/z (ES ) 383.1110 ([M - H]‘ 100%); [CiyHigNeOs]' requires 383.1104.
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Preparation of AM-Benzoyl-S-amino^. S'-dideoxv-S-methylcvtosine-S'-carboxvIic
acid (24)
o
AM-Benzoyl-S'-azido^', S’-dideoxy-S-methylcytosine-S'-carboxylic acid (23,
180 mg, 0.47 mmol) was suspended in 15% triethylamine/pyridine (3 mL) and 
cooled to 0°C. H2S was then bubbled through the suspension for 20 minutes. After 
this time the reaction vessel was sealed and allowed to stir for 30 minutes at room 
temperature. All the solvents were then removed in vacuo and the resulting residue 
redissolved in water, solid sulphur was seen to precipitate out of solution. The 
solution was centrifuged and the supernatant fluid evaporated
(Note: This was not analysed by NMR due to residual sulphur present and therefore 
was used in a partially crude state for the next step. The product identity was 
confirmed by mass spectrometry)
Yield: 158 mg (Crude mixture, yield not calculated)
HRMS found m/z (ES ) 357.1214 ([M -H]' 100%); [CirH^Os]* requires 357.1199.
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Preparation of A/^-Benzovl-S-AZ-Fmoc-amino^'. S-dideoxv-S-methylcvtosine-S'-
carboxvlic acid (16)
A/-4-Benzoyl-3'-amino-2', S'-dideoxy-S-methylcytosine-S'-carboxylic acid (24,
566 mg, 1.58 mmol) and potassium carbonate (436 mg, 3.16 mmol) were dissolved 
in a dioxane/water (2:1, 3 ml_) solvent mixture and allowed to stir at room 
temperature for 30 mins. The reaction was then cooled to 0°C and Fmoc chloride 
(408 mg, 1.58 mmol) was added, this was then allowed to stir at the same 
temperature for 10 hours. Water (10mL) was then added to the reaction and stirred 
for a further 5 mins. All solvents were then removed in vacuo and the residue 
redissolved in DCM and purified by silica chromatography using a 0-20% 
methanol/DCM eluent system. The product was afforded as a pale yellow solid.
Yield: 160 mg, 0.28 mmol, 17%
1H NMR (400MHz, DMF-d7) 5 2.31 (s, 3H, 5-Me), 2.52 (m, 1H, H2'), 2.68 (m, 1H, 
H2'), 4.49 (m, 1H, H3'), 4.53 (m, 2H, Fmoc-HA), 4.70 (m, 2H, H4' + Fmoc-HB), 6.71 
(m, 1H, HI'), 7.31 (d, 2H, J = 7.59 Hz, Bz m-H), 7.50-7.97 (9H, m, Fmoc-HD, E, F,
G + Bz p-H ), 8.09 (d, 2H, J = 7.59 Hz, Bz o-H), 8.47 (s, 1H, H-6).
13C NMR (400MHz, DMF-d7) 6 13.4 (5-Me), 20.8 (C2'), 47.5 (Fmoc-CB), 56.9 (C3'), 
66.8 (Fmoc-CA), 86.2 (C4'), 87.5 (CV), 109.2 (C5), 120.4, 120.5, 121.7, 125.8 
(Fmoc-CD, E, F, G), 126.3 (C5), 127.5 (Bz o-C x2), 128.5 (Bz m-C x2), 128.8 (Bz p-
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C), 132.8 (C6), 141.5 (Fmoc-CH), 144.7 (Fmoc-CC), 156.9 (C4), 182.5 (Bz C=0), 
206.4 (C5' C=0).
HRMS found m/z (ES ) 579.1885 ([M -H]* 100%); [C32H27N4O7]' requires 579.1880.
Preparation of S'.S-TetraisopropvIsiloxane^'-deoxyadenosine (29)211
6 N
Si—O,
2'-Deoxyadenosine (10.0 g, 37.1 mmol) was co-evaporated three times with 
anhydrous pyridine ( 3 x 150 ml_) and then suspended in fresh anhydrous pyridine 
(80 mL). I.S-Dichloro-I.IAS-tetraisopropyldisiloxane (12.1 mL, 37.9 mmol) was 
added to the suspension dropwise and the reaction allowed to stir at ambient 
temperature for 18 hours. All the solvent was removed in vacuo and the residue 
redissolved in DCM (100 mL). The solution was then washed successively with 
saturated sodium hydrogen carbonate (200 mL), water (200 mL) and brine (200 
mL). The organic layer was dried over MgS04 and all solvents removed in vacuo. 
The crude residue was purified by silica chromatography using a 2-4% 
methanol/DCM eluent system. The desired product was afforded as a white foam.
Yield: 16.5 g, 33.3 mmol, 90%
1H NMR (400MHz, CDCI3) 5 1.30-1.11 (m, 28H, /so-Propyl H), 2.67 (m, 2H, H2'), 
3.90 (m, 1H, H4'), 4.06 (m, 2H, H5'), 4.95 (apparent-q, 1H, J= 7.97 Hz, H3'), 6.30 
(dd, 1H, J= 2.58 Hz, H1'), 8.04 (s, 1H, H8), 8.32 (s, 1H, H2).
13C NMR (100MHz, CDCI3) 5 [12.9, 13.2, 13.5, 13.7, 17.2, 17.3, 17.4, 17.5, 17.7, 
17.8, 17.9, (/so-propyl C)], 40.4 (C2'), 62.1 (C5'), 70.1 (C3r), 83.5 (C1'), 85.5 (C4'), 
120.6 (C5), 139.3 (C8), 149.4 (C2), 153.3 (C6), 155.8 (C4).
HRMS found m/z (ES+) 516.2435 ([M + Na]+ 100%); ^HagNsC^Sh + Na]+ requires 
516.2438
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Preparation of A/-6-Allvloxvcarbonvl-2,-deoxvadenosine (25)
Method A
Ethylthio-tetrazole (7.71 g, 59.3 mmol) was dissolved in a mixture of THF (150 ml) 
and triethylamine (8.25 mL, 59.3 mmol) and cooled to 0 °C in ice. Allyl 
chloroformate (6.30 mL, 59.3 mmol) was then added dropwise over a period of 10 
mins and the reaction was allowed to stir for 1 hour at 0 °C. The reaction was 
filtered through celite to remove solids and concentrated to 1/10th of its original 
volume by solvent evaporation. The intermediate formed was then added to a 
solution of S'^'-tetraisopropylsiloxane^'-deoxyadenosine (29, 9.75 g, 19.8 mmol) in 
anhydrous THF (150 ml) and heated to 70°C for 20 hours. After cooling all the 
solvent was removed in vacuo and the oily residue redissolved in DCM (200 mL). 
This was then washed successively with saturated sodium hydrogen carbonate (150 
mL), water (150 mL) and brine (150 mL) and the organic layer dried over MgS04. 
The solvents were removed in vacuo and fresh anhydrous THF (150 mL) was 
added. TBAF (49.4 mL, 49.4 mmol) was then added cautiously and the reaction 
allowed to stir at ambient temperature for 48hours. The solvents were then 
removed in vacuo and the crude residue purified by silica chromatography using a 
1-8% methanol/DCM eluent system. The desired product was afforded as a white 
foam.
Yield: 5.52 g, 16.5 mmol, 83%
Method B208
Triethylamine (1.4 mL, 10 mmol) was added dropwise to a 3% solution of tetrazole 
in acetonitrile (24.0 mL, 10.0 mmol) and the reaction cooled to 0°C in ice. Allyl 
chloroformate was then added dropwise over 10 mins and the reaction allowed to 
stir in an ice bath for 30 mins. The reaction was filtered through a pad of celite to
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remove solids and concentrated to 1/10th of its original volume in vacuo . The 
intermediate formed was then added to a solution of S'.S'-tetraisopropylsiloxane^'- 
deoxyadenosine (29, 1.30 g, 2.63 mmol) in anhydrous THF (35 mL) and heated to 
70°C for 2 hours. After cooling ail the solvent was removed in vacuo and the oily 
residue redissolved in ethyl acetate (75 mL). This was then washed with sodium 
hydrogen carbonate (75 mL) and the organic layer dried over MgS04. The solvents 
were removed in vacuo and fresh anhydrous THF (2 OmL) was added. TBAF (5.00 
mL, 5.00 mmol) was then added cautiously and the reaction allowed to stir at 
ambient temperature for 2 hours. The reaction solvents were then removed in vacuo 
and the crude residue purified by silica chromatography using a 2-8% 
methanoi/DCM eluent system. The desired product was afforded as a white foam.
Yield: 521 mg, 1.55mmol, 60%
Method C211
2-Deoxyadenosine (1.00 g, 3.71 mmol) was co-evaporated three times with 
anhydrous dioxane (3 x 20 mL). It was then suspended in dry dioxane (13 mL) 
along with hexamethyldisilazane (12.4 mL, 59.4 mmol) and ammonium sulphate 
(0.20 g, 1.51 mmol) and heated to 115°C. The resulting mixture was allowed to stir 
for 2 hours. All reaction solvents were then removed in vacuo to give an oily 
residue. The residue was co-evaporated twice with dry toluene (2 x 50 mL) and 
then redissolved in anhydrous DCM (40 mL). The solution was cooled in an ice bath 
and N-methylimidazole (0.83 mL, 10.4 mmol) and allylchloroformate (1.10 mL, 10.4 
mmol) were added, the resulting mixture was allowed to stir at ambient temperature 
for 42 hours. The reaction solvents were removed in vacuo and the residue 
redissolved in methanol (35 mL) and triethylamine (8 mL) and allowed to stir at 
ambient temperature for 15 hours. The solvents were removed in vacuo and the 
crude residue purified by silica chromatography using a 4-10% methanol/ DCM 
eluent system. The product was afforded as a white foam.
Yield: 150 mg, 0.44 mmol, 11%
1H NMR (400MHz, CDCI3) 5 2.44 (m, 1H, H2'), 2.99 (m, 1H, H2'), 3.84 (dd, 1H,
2.08, 12.77 Hz, H5'), 3.97 (dd, 1H, J= 1.90, 12.77 Hz, H5r), 4.25 (m, 1H, H4'), 4.77 
(m, 2H, CH2CH=CH2), 4.82 (m, 1H, H3'), 5.29 (apparent dq, 1H, 1.12, 10.40 Hz)
CH^CFb), 5.39 (apparent dq, 1H, J= 1.38, 17.18 Hz, CH=CH2 ), 5.99 (m, 1H, 
CH=CH2), 6.44 (dd, 1H, J= 5.68, 8.72Hz, H1'), 8.19 (s, 1H, H8), 8.74 (s, 1H, H2), 
8.85 (s, 1H, NH).
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13C NMR (100MHz, CDC!3) 5 41.2 (C2'), 63.4 (C5'), 67.2 (CH2CH=CH2), 73.1 (C3'), 
87.7 (C1'), 89.8 (C4'), 119.6 (CH=CH2), 131.9 (CH=CH2), 143.0 (C8), 150.3 (C5), 
150.5 (C6), 151.2 (C2), 152.5 (C4).
HRMS found m/z (ES+) 358.1113 ([M + Na]+ 100%); [C^H^NsOs + Na]+ requires 
358.1127
Preparation of AZ-S-Allvloxycarbonyl-S'-benzovl^'-deoxvadenosine (30)
A/-6-Allyloxycarbonyl-2'-deoxyadenosine (25, 630 mg, 1.88 mmol) was dissolved in 
anhydrous pyridine (3mL) and cooled in an ice bath. Benzoyl chloride (218 pi, 1.88 
mmol) in anhydrous pyridine (2 mL) was added dropwise over a period of 30mins. 
The reaction mixture was allowed to stir for a further 30 mins. Water (0.3 ml) was 
added to the reaction and the mixture allowed to stir for 5 mins, all reaction solvents 
were then removed in vacuo. The green residue was redissolved in DCM (20 mL) 
and washed with water (20 mL), the organic layer was dried over MgS04 and all 
solvents removed in vacuo. The crude residue was purified by silica 
chromatography using a 0-6% methanol/ DCM eluent system and the desired 
product was afforded as a white foam.
Yield: 370 mg, 0.84 mmol, 45%
’H NMR (400MHz, DMSO-d6) 5 2.45 (m 1H, H2’), 2.99 (m, 1H, H2'), 4.18 (m, 1H, 
H4'), 4.44 (dd, 1H, J= 5.92, 11.83 Hz, H5'), 4.56 (dd, 1H, J= 4.26, 11.83 Hz, H5')t 
4.67 (m, 3H, CH2CH=CH2 + H3'), 5.22 (apparent dq, 1H, J= 1.47, 10.55 Hz, 
CH=CH2), 5.41 (apparent dq, 1H, J= 1.69, 17.24 Hz, CH=CH2), 5.60 (d, 1H, J= 
4.36Hz, 3-OH), 5.98 (m, 1H, CH=CH2), 6.48 (apparent t, 1H, J=6.60Hz, HV), 7.50 
(m, 2H, m-Ar Bz), 7.64 (m, 1H, p-Ar Bz), 7.90 (m, 2H, o-Ar Bz), 8.60 (s, 1H, H8), 
8.62 (s, 1H, H2), 10.65 (br s, 1H, NH).
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13C NMR (100MHz, DMSO-cfe) 6 38.7 (C2'), 64.6 (C5'), 65.6 (CH2CH=CH2), 70.7 
(C3'), 84.0 (Cr), 84.4 (C4'), 117.9 (CH=CH2), 124.2 (C5), 129.0 (m-ArC), 129.5 (o- 
ArC), 129.6 (/psa-ArC), 133.2 (CH=CH2), 133.7 (p-ArC), 143.3 (C8), 150.0 (C6), 
151.7 (0=0 Alloc), 152.0 (C2), 152.2 (C4), 165.8 (C=0 Bz).
HRMS found m/z (ES+) 462.1392 ([M + Na]+ 100%); [C21H21N506 + Na]+ requires 
462.1390
Preparation of AZ-e-AllvloxycarbonvI-S - TBDMS^'-deoxvadenosine (38)
o
A/-6-Allyloxycarbonyl-2'-deoxyadenosine (25, 4.29 g, 12.8 mmol) and TBDMS 
chloride (2.70 g, 17.9 mmol) were dissolved in anhydrous pyridine (40 mL) and 
allowed to stir at ambient temperature for 16 hours. The pyridine was removed in 
vacuo and the resulting residue redissolved in ethyl acetate (100 mL) and washed 
successively with saturated sodium hydrogen carbonate (150 mL), water (150 mL) 
and brine (150 mL). The organic layer was dried with MgS04and evaporated to 
dryness. The crude residue was purified by silica chromatography using a 2-6% 
methanol/DCM eluent system and the desired product was afforded as a white 
foam.
Yield: 3.21g, 7.14mmol, 56%
1H NMR (400MHz, CDCI3) 6 0.01 (s, 6H, 2 x CH3), 0.80 (s, 9H, f-Bu), 2.57 (m, 2H, 
H2'), 3.78 (dd, 1H, J= 3.22, 11.20 Hz, H5'), 3.83 (dd, 1H, J= 3.94, 11.20 Hz, H5'), 
4.07 (apparent-q, 1H, J= 3.44 Hz, H4'), 4.62 (m , 1H, H3'), 4.67 (m, 2H, 
CH2CH=CH2), 5.18 (apparent dq, 1H, J= 1.17, 10.40 Hz, CH^hh), 5.30 (apparent 
dq, 1H, J= 1.40, 17.18 Hz, CH^Hz), 5.89 (m, 1H, CH=CH2), 6.47 (apparent t, 1H, 
J= 6.40Hz, H1’), 8.27 (s, 1H, H8), 8.65 (s, 1H, H2), 8.85 (brs, 1H, NH).
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13C NMR (400MHz, CDCI3) 5 -4.9 (CH3), 18.7 (C(CHZ)3), 26.3 (C(CH3)3), 41.7 (C2'), 
63.7 (C5'), 67.0 (CH2CH=CH2), 72.4 (C3')t 85.0 (CV), 87.7 (C4'), 119.4 (CH=CH2), 
122.5 (C5), 132.1 (CH=CH2), 141.5 (C8), 149.7 (C=0 Alloc), 151.0 (C6), 151.2 (C4), 
153.1 (C2).
HRMS found m/z (ES+) 472.1996 ([M + Na]+ 100%); [C2oH31N505 + Na]+ requires 
472.1992.
Preparation of A/-6-Allvloxvcarbonvl-5,-(4.4,-dimethoxvtritvl)-2,-deoxvadenosine (40)
o
ov
\
A/-6-Allyloxycarbonyl-2'-deoxyadenosine (25, 3.50 g, 10.4 mmol), dimethoxytrityl 
chloride (3.53 g, 10.4 mmol) and dimethoxyaminopyridine (127 mg, 1.04 mmol) 
were dissolved in anhydrous pyridine (100 mL) and allowed to stir at ambient 
temperature for 18 hours. All reaction solvent was removed in vacuo and the 
resulting crude residue purified by silica chromatography using a 1-4% 
methanol/DCM eluent system containing 1% triethylamine to basify the silica. The 
desired product was afforded as an off-white foam.
Yield: 2.85 g, 4.47 mmol, 42%
1H NMR (400MHz, CDCI3) 5 2.57 (m, 1H, H2’), 2.86 (m, 1H, H2'), 3.40 (m, 2H, H5'), 
3.77 (s, 6H, 2 x 0-CH3), 4.16 (apparent q, 1H, 4.32 Hz, H4'), 4.71 (apparent dt,
1H, J= 3.93, 6.02 Hz, H3'), 4.76 (m, 2H, CH2CH=CH2), 5.29 (apparent dq, 1H, J= 
1.21, 10.28 Hz, CH^hb). 5.40 (apparent dq, 1H, J=1.36, 17.10 Hz, ONChb), 5.99 
(m, 1H, CH=CH2), 6.47 (apparent t, 1H, J= 6.38 Hz, HV), 6.81 (m, 4H, ArH), 7.13- 
7.39 (m, 9H, ArH), 8.10 (s, 1H, H8), 8.68 (s, 1H, H2), 8.77 (s, 1H, NH).
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13C NMR (100MHz, CDCI3) 5 40.6 (C2'), 55.6 (O-CHs), 64.0 (C5'), 67.0 
(CH2CH=CH2), 72.8 (DMT q-C), 85.0 (C1'), 86.5 (C4'), 113.5 (ArC), 113.5 (ArC), 
119.4 (CH=CH2), 122.8 (C5), [127.4, 128.2, 128.3, 129.2, 129.5, 130.3 (ArC)], 132.1 
(CH=CH2), 135.9 (ArC), 141.5 (C8), 144.8 (ArC), 149.7 (ArC), 151.1 (C6), 153.1 
(C4), 158.9 (C2).
HRMS found m/z (ES+) 660.2415 ([M +Na]+100%); [C35H35N5O7 + Na]+ requires 
660.2434.
Preparation of A/-6-Allvloxvcarbonvl-5-TBDPS-2,-deoxvadenosine (45)
A/-6-Allyloxycarbonyl-2'-deoxyadenosine (25, 7.90 g including TBAF salts) and 
dimethylaminopyridine (575 mg, 4.30mmol) were dissolved in anhydrous pyridine 
(60 mL) and fert-butyldiphenylsilyl chloride (3.06 mL) was added dropwise. The 
reaction mixture was allowed to stir at ambient temperature under nitrogen for 4 
hours after which time no starting material remained. The reaction solvents were 
removed in vacuo and the residue redissolved in DCM (70 mL). The organic 
solution was washed successively with a saturated sodium hydrogen carbonate 
solution (100 mL), water (100 mL) and brine (100 mL). The organic layer was dried 
over MgS04 and evaporated to dryness. The residue was purified by silica 
chromatography using a 0-4% methanol/DCM eluent system. The product was 
afforded as a white foam.
Yield: 3.10 g, due to starting material impurities accurate yield not recorded.
1H NMR (400MHz, CDCI3) 6 1.04 (s, 9H, f-Bu), 2.59 (m, 1H, H2'), 2.76 (m, 1H, H2'), 
3.85 (dd, 1H, 3.86, 11.36 Hz, H5'), 3.94 (dd, 1H, J= 4.75, 11.36 Hz, H5'), 4.13
(apparent q, 1H, J= 4.04 Hz, H4'), 4.74 (m, 3H, CH2CH=CH2 + H3’), 5.25 (apparent 
dq, 1H, J= 1.20, 10.40 Hz, CH^ii), 5.37 (apparent dq, 1H, J= 1.45, 17.40 Hz,
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CH=CH2), 5.96 (m, 1H, CH=CH2), 6.50 (apparent t, 1H, J= 6.48 Hz, H1'), 7.37 (m , 
6H, ArH), 7.62 (m, 4H, ArH), 8.19 (s, 1H, H8), 8.70 (m, 1H, H2), 8.84 (brs, 1H, NH).
13C NMR (100MHz, CDCI3) 6 19.6 (C(CH3)3), 27.3 (C(CH3)3), 40.9 (C2'), 64.2 (C5')t 
67.0 (CH2CH=CH2), 72.3 (C3'), 85.0 (CV), 87.5 (C4'), 119.4 (CH=CH2), 122.6 (C5),
132.1 (CH=CH2), [133.0, 133.1, 135.8, 135.9, (ArC)], 141.4 (C8), 149.7 (C=0 Alloc),
151.1 (C6), 151.2 (C4), 153.1 (C2).
HRMS found m/z (ES+) 596.2286 ([M + Na]+ 100%); [CaoHagNsOsSi + Na]+ requires 
596.2305.
Preparation of A/-6-Allvloxvcarbonvl-5-benzovl-3,-xWo-2,-deoxvadenosine (31) (and
A/-6-allvloxvcarbonvl-3,-benzovl-3,-xWo-2,-deoxvadenosine. 32)
/N/-6-Allyloxycarbonyl-5'-benzoyl-2'-deoxyadenosine (30, 5.15 g, 11.7 mmol) was 
dissolved in a mixture of anhydrous DCM (50 ml_) and Pyridine (2.5 mL) and cooled 
to -30°C. A solution of triflic anhydride (1.45 mL, 8.64 mmol) in anhydrous DCM 
(14.5 mL) was then added dropwise over 30 minutes. The reaction was warmed to 
ambient temperature and water (25 mL) was added. The reaction mixture was 
allowed to stir for 1 hour before a further portion of water (50 mL) was added and 
the layers formed were separated. The organic layer was dried over MgS04 and 
evaporated to dryness. The crude residue was purified using silica chromatography 
using a 0-2.5% methanol/DCM eluent system to afford both products as yellow 
foams
Yield: 583 mg, 1.32 mmol, 11%
1H NMR (400MHz, DMSO-d6) 5 2.27 (m, 1H, H2'), 2.68 (m, 1H, H2'), 4.17 (m, 1H, 
H4'), 4.34 (m, 2H, H3' + H5'), 4.47 (m, 3H, CH2CH=CH2 + H5'), 5.50 (apparent dq, 
1H, J= 1.39, 10.54 Hz, CH=CH2), 5.23 (apparent dq, 1H, 1.62, 17.26 Hz,
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CH=CH2), 5.70 (d, 1H, J= 4.48 Hz, 3’-OH), 5.80 (m, 1H, CH=CH2), 6.29 (dd, 1H, J= 
1.68, 8.24 Hz, H1'), 7.33 (m, 2H, m-ArH), 7.47 (m, 1H, p-ArH), 7.77 (m, 1H, o-ArH), 
8.46 (s, 1H, H8), 8.51 (s, 1H, H2), 10.49 (br s, 1H, NH).
13C NMR (100MHz, DMSO-d6) 6 40.9 (C2'), 64.4 (C5'), 65.6 (CH2CH=CH2), 69.7 
(C3'), 82.5 (C4'), 83.4 (C1'), 117.9 (CH=CH2), 123.8 (C5), 129.1 (m-ArC), 129.5 (o- 
ArC), 129.8 (/pso-ArC), 133.2 (CH=CH2), 133.7 (p-ArC), 143.2 (C2), 149.9 (C6), 
151.6 (C=0 Alloc), 151.9 (C8), 152.2 (C4), 166.0 (C=0 Bz).
HRMS found m/z (ES+) 462.1393 ([M + Na]+ 100%); [C21H21N506 + Na]+ requires 
462.1390.
O
Yield: 1.70 g, 3.87 mmol, 33%
1H NMR (400MHz, DMSO-c/6) 5 2.93 (m, 1H, H2'), 3.06 (m, 1H, H2'), 3.80 (m, 2H, 
H5'), 4.37 (m, 1H, H4'), 4.70 (m, 2H, CHUCH^H^, 4.99 (t, 1H, J= 5.58 Hz, 5'-OH), 
5.24 (apparent dq, 1H, J= 1.52, 10.52 Hz, CH^ji), 5.42 (apparent dq, 1H, J=
1.62, 17.22 Hz, CH=CH2), 5.72 (apparent t, 1H, J= 4.14 Hz, H3'), 5.97 (m, 1H, 
CH=CH2), 6.52 (dd, 1H, J= 2.56, 7.52 Hz, H1’), 7.50 (m, 2H, m-ArH), 7.65 (m, 1H, p- 
ArH), 7.80 (m, 2H, o-ArH), 8.54 (s, 1H, H8), 8.59 (s, 1H, H2), 10.65 (br s, 1H, NH).
13C NMR (400MHz, DMSO-d6) 5 38.1 (C2'), 59.5 (C5'), 65.5 (CH2CH=CH2), 73.4 
(C3'), 83.8 (CV + C4’), 117.9 (CH=CH2), 124.0 (C5), 129.1 (m-ArC), 129.4 (o-ArC), 
129.8 (/pso-ArC), 133.2 (CH=CH2), 133.7 (p-ArC), 142.2 (C2), 149.9 (C6), 151.7 
(C=0 Alloc), 151.9 (C8), 152.2 (C4), 165.2 (C=0 Bz).
HRMS found m/z (ES+) 462.1400 ([M + Na]+ 100%); [C21H21N506 + Na]+ requires 
462.1390
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Isomerisation of /V-e-AllvloxvcarbonvI-S'-benzovl-S-xWo^-deoxvadenosine (32) to
N -6-allvloxvcarbonvl-5,-benzovl-3,-xWo-2,-deoxvadenosine (31)
A/-6-Allyloxycarbonyl-3'-benzoyl-3'-xy/o-2'-deoxyadenosine (32, 1.70 g, 3.87 mmol) 
was dissolved in methanol (125 mL) and solid sodium hydrogen carbonate (260 mg, 
3.09 mmol) was added. The reaction mixture was allowed to stir at ambient 
temperature for 2 hours. The reaction solvents were removed in vacuo and the 
resulting crude residue purified by silica chromatography using a 1-6% 
methanol/DCM eluent system. The desired product was afforded as an off-white 
foam.
Yield: 600 mg, 1.36 mmol, 35%
Analysis as for A/-6-allyloxycarbonyl-5,-benzoyl-3'-xy/o-2'-deoxyadenosine (31).
Preparation of A/-6-Allvloxvcarbonvl-5,-TBDMS-3,-xWo-2,-deoxvadenosine (39)
A/-6-Allyloxycarbonyl-5'-TBDMS-2'-deoxyadenosine (38, 1.37 g, 3.05 mmol) 
dissolved in anhydrous DCM (10 mL) was added to a cooled (0 °C) solution of Dess 
Martin periodane (15% wt in DCM, 19.4 mL, 6.86 mmol) and allowed to stir for 30 
mins. The reaction was allowed to warm to ambient temperature before being 
allowed to stir for 12 hours. Isopropanol (8 mL) was added and the reaction was
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cooled to -60°C. Sodium borahydride (230 mg, 6.10 mmol) was added. After stirring 
for 2 hours the reaction was allowed to warm to ambient temperature and acetone 
added (10 mL). The resulting mixture was then poured into ethyl acetate (100 mL) 
and washed successively with saturated sodium hydrogen carbonate (100 mL), 
water (100 mL) and brine (100 mL). The organic layer was dried over MgS04 and 
all reaction solvents were removed in vacuo. The crude residue was purified by 
silica chromatography using a 2-4% methanol/DCM eluent system and the desired 
product was afforded as a pale yellow foam.
Yield: 236 mg, 0.52 mmol, 17%
1H NMR (400MHz, CDCI3) 5 -0.02 (s, 3H, CH3), 0.00 (s, 3H, CH3), 0.81 (s, 9H, t- 
Bu), 2.50 (m, 1H, H2'), 2.81 (m, 1H, H2'), 3.95 (m, 2H, H5'), 4.02 (apparent q, 1H,
J= 5.12 Hz, H4'), 4.48 (m, 1H, HS'), 4.71 (m, 2H, CH2CH=CH2), 5.23 (apparent dq, 
1H, J- 0.80, 10.36 Hz, ONChh), 5.35 (apparent dq, 1H, J= 1.12, 17.16 Hz, 
CH=CH2), 5.95 (m, 1H, CH=CH2), 6.21 (dd, 1H, J= 2.42, 9.06 Hz, H1'), 8.21 (s, 1H, 
H8), 8.54 (s, 1H, NH), 8.69 (s, 1H, H2).
13C NMR (100MHz, CDCI3) 5 -4.9 (2 x CH3), 18.7 (C(CH3)3), 26.2 (C(CH3)3), 41.3 
(C2'), 62.5 (C5'), 67.1 (CH2CH=CH2), 71.5 (C3'), 84.6 (C1'), 85.1 (04'), 119.5 
(CH=CH2), 123.2 (C5), 132.0 (CH=CH2), 143.2 (C8), 150.1 (C=0 Alloc), 150.3 (C6), 
151.0 (C4), 152.6 (C2),
HRMS found m/z (ES+) 472.1974 ([M + Na]+ 100%); [C2oH31N505 + Na]+ requires 
472.1992.
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Preparation of A/-6-Allvloxvcait>onvl-5,-dimethox>rtritvl-3,-xWo(para-nitrobenzovl)-2
deoxvadenosine (41)
o
A/-6-Allyloxycarbonyl-5'- dimethoxytrityl-2'-deoxyadenosine (40, 2.85 g, 4.47 mmol), 
p-nitrobenzoic acid (1.49 g, 8.94 mmol) and triphenylphosphine (2.34 g, 8.94 mmol) 
were suspended in anhydrous THF (60 mL) and DEAD (40% in toluene, 3.89 mL, 
8.94 mmol) was added dropwise. The reaction was allowed to stir at ambient 
temperature for 2 hours and after this time all solvents were removed in vacuo. The 
crude residue was purified by silica chromatography using a 0-2% 
methanol/chloroform eluent system with 1% triethylamine to basify the silica. The 
desired product was afforded as a pale yellow solid.
Yield: 2.90 g, 3.69 mmol, 82%
1H NMR (400MHz, DMSO-cfe) 5 3.07 (m, 1H, H2'), 3.27 (m, 1H, H2'), 3.36 (m, 2H, 
H5'), 3.65 (s, 3H, 0-CH3), 3.67 (s, 3H, O- CH3), 4.65 (m, 3H, CH2CH=CH2 + H4'), 
5.23 (apparent dq, 1H, J= 1.69, 10.38 Hz, CH=CH2), 5.40 (apparent dq, 1H, J= 
1.47, 17.22 Hz, CH=CH2), 5.89 (m, 1H, H3'), 5.97 (m, 1H, CH=CH2), 6.53 (dd, 1H, 
J= 2.60, 7.48Hz, H1'), 6.71 (m, 4H, ArH DMT), 7.09-7.31 (m, 9H, ArH DMT), 7.69 
(m, 2H, ArH PNBz), 8.23 (m, 2H, ArH PNBz), 8.44 (s, 1H, H8), 8.50 (s, 1H, H2), 
10.63 (s, 1H, NH).
13C NMR (100MHz, DMSO-d6) 5 37.0 (C2'), 55.2 (0-CH3), 55.2 (0-CH3), 61.3 (C5'),
65.5 (CH2CH=CH2), 74.0 (C3'), 81.4 (C4'), 84.0 (CV), 86.0 (DMT q-C), 113.4 (ArC),
113.5 (ArC), 117.9 (CH=CH2), 123.9 (ArC), 124.0 (C5), [129.1, 129.9, 130.6, 131.0, 
131.7, (ArC)], 131.8 (CH=CH2), [134.8, 135.2, 135.4 (ArC)], 142.2 (C8), 152.2 (C6), 
156.9 (C6), 158.3 (C4), 158.4 (C2), 165.3 (C=Q PNBz).
137
HRMS found m/z (ES+) 809.2568 ([M + Na]+100%); [C42H38N6O10 + Na]+ requires 
809.2547.
Preparation of A/-6-AHvloxvcarbonvl-5,-dimethoxvtritvl-3,-xWo-2 -deoxvadenosine
(42)
A/-6-Allyloxycarbonyl-5'-dimethoxytrityl-3'-xy/o(para-nitrobenzoyl)-2'-deoxyadenosine 
(41, 2.80 g, 3.56 mmol) and sodium methoxide (384 mg, 7.12 mmol) were dissolved 
in anhydrous methanol (200 mL) and allowed to stir at 0°C for 25 mins. The reaction 
solvents were removed in vacuo and the resulting residue redissolved in DCM (100 
mL). The organic solution washed twice with water (2 x100 mL). The organic layer 
was dried over MgS04 and evaporated to dryness. The crude residue was purified 
by silica chromatography using a 0-2% methanol/DCM eluent system containing 1% 
triethylamine to basify the silica. The desired product was afforded as a pale yellow 
foam
Yield: 1.85 g, 2.9 mmol, 81%
1H NMR (400MHz, DMSO-d6) 6 2.38 (m, 1H, H2'), 2.77 (m, 1H, H2’), 3.20 (m, 1H, 
H5'), 3.35 (m, 1H, H5'), 3.70 (s, 3H, 0-CH3), 3.71 (s, 3H, O-CHs), 4.24 (apparent dt, 
1H, J= 3.58, 7.42 Hz, H4’), 4.36 (apparent q, 1H, J= 4.28 Hz, H3'), 4.66 (m, 2H, 
ChkCH^Hs), 5.24 (apparent dq, 1H, J= 1.50, 1052 Hz, CH=CH2), 5.42 (apparent 
dq, 1H, J= 1.72, 17.22 Hz, CH^j^), 4.36 (d, 1H, 4.36 Hz, 3'-OH), 5.98 (m, 1H,
CH=CH2), 6.48 (dd, 1H, J= 1.72, 8.48 Hz, H1'), 6.80 (m, 4H, ArH), 7.24 (m, 7H, 
ArH), 7.39 (m, 2H, ArH), 8.46 (s, 1H, H8), 8.65 (s, 1H, H2), 10.67 (s, 1H, NH).
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13C NMR (100MHz, DMSO-c/6) 5 40.9 (C2'), 55.3 (0-CH3), 63.5 (C5')t 65.5 
(CH2CH=CH2), 69.6 (C3'), 83.5 (CV), 84.3 (C4')t 85.8 (DMT q-C), 113.3 (ArC), 
113.4 (ArC), 117.9 (CH=CH2), 126.9 (C5), 131.8 (CH=CH2), [133.2, 135.8, 136.0 
(ArC)], 142.9 (C8), [145.3, 149.9, 151.6 (ArC)], 151.8 (C=Q Alloc), 152.2 (C6), 
156.9 (C4), 158.3 (C2).
HRMS found m/z (ES+) 660.2431 ([M + Na]+100%); [C35H35N5O7 + Na]" requires 
660.2434.
Preparation of A/-6-Allvloxvcarbonvl-5,-dimethoxvtritvl-3,-xWo(mesvl)-2-
deoxvadenosine (43)
A/-6-Allyloxycarbonyl-5,-dimethoxytrityl-3'-xy/o-2'-deoxyadenosine (42,1.85 g, 2.90 
mmol) and dimethylaminopyridine (1.77g, 14.55 mmol) were dissolved in anhydrous 
pyridine (70 mL) and methanesulphonyl chloride (676 pi, 8.73 mmol) was added 
dropwise. The reaction was allowed to stir at ambient temperature for 2 hours. After 
this time all reaction solvents were removed in vacuo. The crude residue was 
purified using a 0-3% methanol/chloroform eluent system and the desired product 
was afforded as a pale yellow foam.
Yield: 1.30 g, 1.90 mmol, 65%
1H NMR (400MHz, DMSO-d6) 5 2.87 (m, 1H, H2'), 3.07 (m, 4H, S02CH3 + H2'), 3.21 
(dd, 1H, J= 4.06, 10.03 Hz, H5'), 3.39 (dd, 1H, J= 7.36, 10.03 Hz, H5’), 3.72 (s, 6H,
2 x O-CH3), 4.50 (m, 1H, H4'), 4.66 (m, 2H, CH2CH=CH2), 5.24 (apparent dq, 1H, J= 
1.47, 10.54 Hz, CH=CH2), 5.42 (apparent dq, 1H, J= 1.65, 17.24 Hz, CH^hU), 5.48
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(m, 1H, H3'), 5.98 (m, 1H, CH=CH2), 6.55 (dd, 1H, J= 2.40, 7.92 Hz, H1'), 6.83 (m, 
4H, ArH), 7.26 (m, 7H, ArH), 7.40 (m, 2H, ArH), 8.26 (s, 1H, H8), 8.32 (s, 1H, H2), 
10.71 (brs, 1H, NH).
13C NMR (100MHz, DMSO-d6) 6 37.8 (C2'), 38.6 (SOaCHa), 55.3 (0-CH3), 60.8 
(C5'), 65.6 (CH2CH=CH2), 80.2 (C3'), 81.8 (C4'), 83.0 (C1'), 113.1 (ArC), 113.4 
(ArC), 117.9 (CH=CH2), 124.3 (C5), [129.2, 130.0, 130.1 (ArC)], 131.8 (CH=CH2), 
[133.2, 133.5, 135.5 (ArC)], 144.9 (C=Q Alloc), 141.6 (C8), 149.7 (C6), 150.0 (C4), 
156.9 (C2).
HRMS found m/z (ES+) 738.2236 ([M + Na]+ 100%); [CaeHarNsOg + Na]+ requires 
738.2210.
Preparation of /V-e-AllvloxvcarbonvI-S'-TBDPS-S'-xWofoara-nitrobenzovI)^ -
deoxvadenosine (46)
o
A/-6-Allyloxycarbonyl-5'-TBDPS-2'-deoxyadenosine (45, 6.14 g, 10.7 mmol), p- 
nitrobenzoic acid (3.57 g, 21.4 mmol) and triphenylphosphine (5.61 g, 21.4 mmol) 
were dissolved in anhydrous tetrahydrofuran (100 ml) under a nitrogen 
atmosphere. A solution of DEAD (40% in toluene, 9.31 mL, 21.4 mmol) was added 
dropwise with stirring and the reaction was allowed to stir at ambient temperature 
for 3 hours. All solvents were removed from the reaction in vacuo and the crude 
residue was purified by silica chromatography using 100% ethyl acetate. The 
product was afforded as an off white foam.
Yield: 5.60 g, 7.75 mmol, 72%
'H NMR (400MHz, CDCI3) 6 0.92 (s, 9H, f-Bu), 3.00 (m, 1H, H2'), 3.10 (m, 1H, H2'), 
4.08 (m, 2H, H5'), 4.55 (m, 1H, H4'), 4.73 (m, 2H, CH2CH=CH2), 5.26 (apparent dq,
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1H, 1.17, 10.44 Hz, CH^hb), 5.38 (apparent dq, 1H, J= 1.46, 17.18 Hz,
CH=CH2), 5.95 (m, 2H, CH=CH2+ H3'), 6.50 (dd, 1H, J= 1.86, 7.18 Hz, HV), 7.19- 
7.75 (m, 12H, ArH),8.14 (m, 2H, ArH), 8.21 (s, 1H, H8), 8.61 (s, 1H, H2), 8.90 (brs, 
1H , NH).
13C NMR (100MHz, CDCI3) 5 19.4 27.0 (C(CH3)3), 39.4 (C2'), 60.8 (C5'),
67.1 (CH2CH=CH2), 73.7 (C3'), 84.0 (CV), 85.3 (C4'), 119.5 (CH=CH2), 122.8 (C5), 
[128.2, 129.0, 130.3, 131.4 (ArC)], 132.0 (CH=CH2), 132.9 (ArC), 134.6 (ArC), 141.0 
(C8), 149.0 (C=0 Alloc), 153.0 (C6), 157.2 (C4), 163.6 (C2), 171.6 (C=0 PNBz),
HRMS found m/z (ES+) 745.2424 ([M + Na]+ 100%); [CayHssNeOaSi + Na]+ requires 
745.2418.
Preparation of /V-e-Allvloxycarbonyl-S-TBPRS-S'-xWo^-deoxvadenosine (47)
A/-6-Allyloxycarbonyl-5'-TBDPS-3'-xy/o(para-nitrobenzoyl)-2-deoxyadenosine (46, 
5.60 g, 7.75 mmol) was dissolved in anhydrous methanol (350 mL) and cooled to 
0°C in an ice bath. Sodium methoxide powder (419 mg, 7.76 mmol) was then added 
and the solution allowed to stir at 0°C for 10 minutes. The reaction solvents were 
removed in vacuo and the residue redissolved in DCM (150 mL) and washed with 
water (3 x 100 mL). The organic layer was dried over MgS04 and all solvent was 
removed in vacuo. The crude residue was purified by silica chromatography using a 
1-4% methanol/DCM eluent system. The product was afforded as a white foam.
Yield: 3.29 g, 5.74 mmol, 74%
1H NMR (400MHz, CDCI3) 5 1.04 (s, 9H, f-Bu), 2.54 (m, 1H, H2’), 2.86 (m, 1H, H2'), 
3.99-4.14 (m, 3H, H5' + H4'), 4.52 (apparent q, 1H, J= 2.89 Hz, H3'), 4.77 (apparent 
dt, 2H, J= 1.28, 5.84 Hz, CH2CH=CH2), 5.29 (apparent dq, 1H, J= 1.16, 10.44 Hz,
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CHMChh), 5.41 (apparent dq, 1H, J= 1.44, 17.16 Hz, CH^hh), 5.99 (m, 1H, 
CH=CH2), 6.25 (dd, 1H, J= 2.28, 9.04 Hz, H1'), 7.36 (m, 6H, ArH), 7.63 (m, 4H, 
ArH), 8.28 (s, 1H, H8), 8.70 (s, 1H, H2).
13C NMR (100MHz, CDCI3) 6 19.5 (C{CH3)3), 27.2 (C(CH3)3), 41.2 (C2'), 63.1 (C5'), 
67.1 (CH2CH=CH2), 71.3 (C3'), 84.7 (CV), 85.3 (C4'), 119.5 (CH=CH2), 128.0 (ArC),
123.3 (C5), [128.0, 130.1, 130.2 (ArC)], 132.0 (CH=CH2), 133.3 (ArC), 135.9 (ArC),
143.3 (C8), 150.2 (C=Q Alloc), 150.2 (C6), 151.1 (C4), 152.5 (C2).
HRMS found m/z (ES+) 596.2281 ([M + Na]+ 100%); [CaoHssNsOgSi + Na]+ requires 
596.2305.
Preparation of /V-e-Allvloxycarbonyl-S-TBPRS -S-xWofmesvl)^-deoxvadenosine
(48)
A/-6-Allyloxycarbonyl-5,-TBDPS-3'-xy/o-2-deoxyadenosine (47, 2.26 g, 3.94 mmol) 
and dimethylaminopyridine (2.40 g, 19.70 mmol) were dissolved in anhydrous 
pyridine (150mL) under nitrogen. Methanesulphonyl chloride (915 pi, 11.82 mmol) 
was then added dropwise and the reaction allowed to stir at ambient temperature for 
2 hours. All reaction solvents were then removed in vacuo and the crude residue 
purified by silica chromatography using a 0-3% methanol/DCM eluent system. This 
afforded the product as an off-white foam.
Yield: 2.10 g, 3.22 mmol, 82%
1H NMR (400MHz, CDCI3) 5 1.08 (s, 9H, f-Bu), 2.87 (s, 3H, S02CH3), 2.95 (m, 2H, 
H2'), 4.01 (m, 2H, H5'), 4.28 (m, 1H, H4'), 4.76 (apparent dt, 2H, J= 1.30, 5.80Hz, 
CH2CH=CH2), 5.28 (apparent dq, 1H, J= 1.17, 9.22 Hz, CH^hb), 5.40 (apparent 
dq, 1H, J= 1.45,17.18 Hz, CH^hh), 5.45 (apparent q, 1H, J= 2.97 Hz, H3'), 5.97
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(m, 1H, CH=CH2), 6.52 (apparent t, 1H, J= 5.10 Hz, HV), 7.41 (m, 6H, ArH), 7.67 
(m, 4H, ArH), 8.18 (s, 1H, H8), 8.44 (br s, 1H, NH), 8.73 (s, 1H, H2).
13C NMR (100MHz, CDCI3) 6 19.5 (C(CH3)3), 27.2 (C(CH3)3), 38.9 (SOzCHa), 40.2 
(C2'), 61.2 (C5'), 67.0 (CH2CH=CH2), 78.5 (C3')f 83.4 (C1'), 83.6 (C4'),119.4 
(CH=CH2), 122.4 (C5), 128.3 (ArC), 132.9 (CH=CH2), [133.9, 135.9, 136.3, (ArC)], 
141.0 (C8), 150.2 (C=0 Alloc), 151.1 (C6), 151.3 (C4),153.3 (C2).
HRMS found m/z (ES+) 674.2069 ([M + Na]+ 100%); [C3iH37N507SiS + Na]+ requires 
674.2081
Preparation of AZ-e-AllvloxycarbonvI-S'-benzovl-S’-azido^'. S^dideoxvadenosine (34)
A/-6-Allyloxycarbonyl-5,-benzoyl-3'-xy/o-2'-deoxyadenosine (31, 1.18 g, 2.69 mmol) 
was dissolved in anhydrous DCM (30 mL) and pyridine (3 mL) and cooled to -30°C. 
Triflic anhydride (680 pi) was then added dropwise. The reaction was allowed to 
warm to ambient temperature over 30mins. A solution of lithium azide (1.32 g, 27.0 
mmol) in anhydrous DMF (10 mL) was then added and the reaction allowed to stir at 
ambient temperature for 2 hours. Water (50 mL) was added to the reaction and the 
two layers were separated. The organic layer was washed with water (50 mL) and 
then dried over MgS04. The crude residue was purified by silica chromatography 
using a 0-2% methanol/DCM eluent system the desired product was afforded as a 
yellow solid.
Yield: 800 mg, 1.72 mmol, 65%
1H NMR (400MHz, CDCI3) 5 2.67 (m, 1H, H2'), 3.25 (m, 1H, H2'), 4.31 (apparent q, 
1H, J= 4.80 Hz, H4’), 4.57(dd, 1H, J= 4.56, 12.20 Hz, H5'), 4.68 (dd, 1H, J= 4.16, 
12.20 Hz, H5'), 4.77 (m, 3H, CH2CH=CH2 + H3'), 5.29 (apparent dq, 1H, J= 1.18,
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10.46 Hz, CH=CH2), 5.40 (apparent dq, 1H, J= 1.44, 17.18 Hz, CHCH2), 5.99 (m, 
1H, CH=CH2), 6.34 (dd, 1H, J= 5.08, 7.00 Hz, HI'), 7.39 (m, 2H, m-ArH), 7.55 (m, 
1H, p-ArH), 7.93 (m, 2H, o-ArH), 8.12 (s, 1H, H8), 8.69 (s, 1H, H2), 8.85 (br s, 1H, 
NH).
13C NMR (400MHz, CDCI3) 5 37.4 (C2'), 61.2 (C3'), 63.8 (C5’), 67.0 (CH2CH=CH2),
82.9 (C4'), 85.2 (CV), 119.5 (CH=CH2), 123.1 (C5), 128.9 (n?-ArC), 129.5 (/pso- 
ArC), 129.9 (o-ArC), 132.1 (CH=CH2), 133.8 (p-ArC), 142.2 (C8), 150.0 (C=0 Alloc),
150.9 (C6), 151.2 (C4), 153.2 (C2), 166.4 (C=0 Bz).
HRMS found m/z (ES+) 487.1456 ([M + Na]+ 100%); [C21H2oN805 + Na]+ requires 
487.1454
IR v max/ cm'1 = 1074.16, 1211.08, 1270.86, 1469.49, 1616.06, 1718.26, 1756.76, 
2090.46, 3313.11
Preparation of A/-6-Allvloxvcarbonvl-5,-dimethoxvtritvl-3,-azido-2,. 3’-
deoxvadenosine (44)
A/-6-Allyloxycarbonyl-5'-dimethoxytrityl-3'-xy/o(mesyl)-2-deoxyadenosine (43, 1.30 
g, 1.82 mmol) and lithium azide (552 mg, 10.9 mmol) were dissolved in anhydrous 
DMF (40 ml) and allowed to stir at 60°C for 7 hours. Water (1 mL) was added and 
after cooling to ambient temperature all solvents were removed in vacuo. The crude 
residue was purified by silica chromatography using a 0-2% methanol/ chloroform 
eluent system. The product was afforded as a yellow oil
Yield: 720 mg, 1.08 mmol, 72%
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HRMS found m/z (ES+) 685.2495 ([M + Na]+ 100%); [C35H34N806 + Na]+ requires 
685.2499.
Preparation of AZ-e-Allvloxycarbonyl-S'-TBPRS -3,-azido-2,. S-deoxvadenosine (49)
A/-6-Allyloxycarbonyl-5'-TBDPS -S'-xy^mesyl)^-deoxyadenosine (48, 1.48 g, 2.27 
mmol) and lithium azide (555 mg, 11.4 mmol) were suspended in anhydrous DMF 
(40 mL) under a nitrogen atmosphere and heated to 70°C. The reaction was 
allowed to stir for 2 hours and then removed from the heat and allowed to cool. The 
reaction solvents were removed in vacuo and the crude residue redissolved in DCM 
(100 mL). The organic solution was washed with successively a saturated sodium 
hydrogen carbonate solution (100 mL), water (100 mL) and brine (100 mL). The 
organic layer was dried over MgS04 and evaporated to dryness. The crude residue 
was purified by silica chromatography using a 2% methanol/DCM eluent system. 
The product was afforded as a white foam.
Yield: 640 mg, 1.07 mmol, 47%
1H NMR (400MHz, CDCI3) 5 0.98 (s, 9H, f-Bu), 2.51 (m, 1H, H2'), 2.91 (m, 1H, H2'), 
3.74 (dd, 1H, J= 3.76, 11.44 Hz, H5'), 3.89 (dd, 1H, J= 4.64, 11.44 Hz, H5'), 4.00 
(apparent q, 1H, J = 4.24 Hz, H4'), 4.49 (m, 1H, H3'), 4.69 (apparent dt, 2H, J= 1.31, 
5.83Hz, CH2CH=CH2), 5.21 (apparent dq, 1H, J= 1.23, 11.54 Hz, CH=CH2), 5.33 
(apparent dq, 1H, J= 1.44, 16.44Hz, CH=CH2), 5.91 (m, 1H, CH=CH2), 6.29 
(apparent t, 1H, J= 6.20 Hz, HV), 7.26-7.38 (m, 6H, ArH), 7.55 (m, 4H, ArH), 8.09 
(s, 1H, H8), 8.32 (br s, 1H, NH), 8.62 (s, 1H, H2).
13C NMR (100MHz, CDCI3) 5 19.6 (C(CH3)3), 27.2 (C(CH3)3), 37.7 (C2'), 60.9 (C3'), 
63.6 (C5’), 67.0 (CH2CH=CH2), 84.9 (CV), 85.3 (C4'), 119.4 (CH=CH2), 122.9 (C5),
145
128.1 (ArC), 128.2 (ArC), 132.1 (ChNCHh), [132.8, 133.0, 135.8 (ArC)], 141.6 (C8), 
149.8 (C=0 Alloc), 151.1 (C6), 151.0 (C4), 153.2 (C2).
HRMS found m/z (ES+) 621.2385 ([M + Na]+ 100%); [C3oH34N804Si + Na]+ requires 
621.2370.
Preparation of A/-6-allvloxvcarbonvl-3,-azido-2^ S'-dideoxvadenosine (35)
Removal of Benzoyl protecting group
AZ-e-Allyloxycarbonyl-S'-benzoyl-S'-azido^'-deoxyadenosine (34, 800 mg, 1.72 
mmol) was dissolved in a dioxane: water: methanol mix (5:4:1, 30 ml_) and cooled in 
ice. 1M (aq) Sodium hydroxide (3.5 ml) was then added and the reaction allowed to 
stir for 30 mins. Amberlite™ ion exchange resin (1 g) was added to the reaction 
mixture to achieve neutral pH. The resin was then removed by filteration and all 
solvents removed in vacuo. The crude residue was redissolved in DCM (20 ml), 
washed with water (20 ml_) and the organic layer dried over MgS04. The reaction 
solvents were removed in vacuo to afford a yellow foam.
Yield: 360 mg, 1.00 mmol, 58%
Removal of TBDPS protecting group
A/-6-Allyloxycarbonyl-5'-TBDPS -3’-azido-2' 3'-deoxyadenosine (49, 600 mg, 1.00 
mmol) was dissolved in anhydrous THF (7 ml_) and TBAF (1.20 mL, 1.20 mmol) 
was added dropwise. The reaction was allowed to stir at ambient temperature for 2 
hours then all solvents were removed in vacuo. The residue was redissolved in 
dichloromethane (50 mL) and washed with water (2 x 50 mL). The organic layer was 
dried over MgS04 and all solvents were removed in vacuo. The crude residue was
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purified by silica chromatography using a 2% methanol/DCM eluent system. The 
product was afforded as a white foam.
Yield: 201 mg, 0.56 mmol, 55%
1H NMR (400MHz, CDCI3) 5 2.47 (m, 1H, H2'), 3.11 (m, 1H, H2'), 3.82 (m, 1H, H5'), 
4.03 (m, 1H, H5'), 4.23 (m, 1H, H4'), 4.63 (apparent dt, 1H, J= 2.29, 6.09 Hz, H3'), 
4.76 (m, 2H, CH2CHCH2), 5.29 (m, 1H, CH=CH2). 5.40 (m, 1H, CH=CH2). 5.99 (m, 
1H, CH=CH2), 6.32 (dd, 1H, J= 5.82, 8.34 Hz, HV), 8.21 (s, 1H, H8), 8.72 (s, 1H, 
H2), 9.63 (br s, 1H, NH).
13C NMR (100MHz, CDCI3) 6 38.2 (C2'), 62.5 (C3'), 63.5 (C5’), 67.0 (CH2CH=CH2), 
86.8 (C4'), 87.2 (CV), 119.6 (CH=CH2), 123.6 (C5), 132.0 (CH=CH2), 142.8 (C8), 
150.5 (C=0 Alloc), 150.6 (C6), 151.4 (C4), 152.6 (C2).
HRMS found m/z (ES+) 383.1188 ([M + Na]+ 100%); [C14H16N804 + Na]+ requires 
383.1192
IR v max/ cm'1 = 1099.23, 1211.08, 1465.63, 1585.20, 1616.06,1754.90, 2103.96, 
2942.84, 3251.40.
Preparation of AZ-e-AllvloxycarbonvI-S-azido^'. S'-dideoxvadenosine-S-carboxylic
acid (36)
A/-6-Allyloxycarbonyl-3'-azido-2'-deoxyadenosine (35, 360 mg, 1.00 mmol), TEMPO 
(31.0 mg, 0.20 mmol) and BAIB (730 mg, 2.20 mmol) were suspended in an 
acetonitrile: water mixture (1:1,4mL) and allowed to stir at ambient temperature for 
4 hours. All solvents were removed in vacuo and the product was redissolved in a 
minimum amount of methanol. The pure product was obtained by precipitation from
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the methanol solution using diethyl ether. The desired product was afforded as an 
off white powder.
Yield: 270 mg, 0.72 mmol, 72%
1H NMR (400MHz, MeOD) 5 1.48 (m, 1H, H2'), 1.69 (m, 1H, H2'), 3.45 (d, 1H, J= 
3.40 Hz, H4'), 3.57 ( apparent dt, 2H, J= 1.41, 5.89 Hz, CH2CH=CH2), 3.70 (m, 1H, 
H3'), 4.09 (apparent dq,1H, J= 1.32, 10.50Hz, CH=CH2), 4.25 (apparent dq, 1H, J= 
1.57, 17.24 Hz, CH=CH2), 4.86 (m, 1H, CH=CH2), 5.42 (apparent t, 1H, J=6.32 Hz, 
HI’), 7.41 (s, 1H, H8), 7.55 (s, 1H, H2).
13C NMR (400MHz, MeOD) 5 36.9 (C2'), 64.1 (C3'), 65.5 (C5), 65.9 (CH2CH=CH2), 
82.6 (C4'), 85.3 (CV), 117.2 (CH=CH2), 132.2 (CH=CH2), 142.7 (C2), 149.5 (C6), 
151.7 (C4), 152.0 (C8).
HRMS found m/z (ES+) 375.1165 ([M + H]+ 100%); [CuH^NgOsr requires 
375.1165.
IR v max/cnV1= 1029.80, 1095.37, 1222.65, 1326.79, 1415.49, 1554.34, 1581.34, 
1727.91, 1766.48, 2102.03, 2989.12, 3185.83.
Preparation of /^/-6-Allvloxvca^bonvl-3,-amino-2,. S'-dideoxvadenosine-S-carboxylic
acid (37)
AZ-e-Allyloxycarbonyl-S’-azido^’-deoxyadenosine-S'-carboxylic acid (36, 210 mg, 
0.56 mmol) was dissolved in an anhydrous 15% triethylamine/pyridine solution (15 
mL) and cooled to 0°C. Hydrogen sulphide was bubbled through the mixture for 10 
mins then the reaction vessel sealed and allowed to stir in an ice bath for a further
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30 mins. All reaction solvents were removed in vacuo to afford a brown solid. Kept 
as crude.
HRMS found m/z (ES+) 371.1070 ([M + H]+100%); [CmH^NbOs]" requires 
371.1080.
Preparation of A/-6-Phenoxvacetvl-2,-deoxvadenosine (26)
2'-Deoxyadenosine (0.50 g, 1.99 mmol) was co-evaporated with anhydrous pyridine 
(3 x 10mL) and dried thoroughly under vacuum. The white solid was then 
suspended in anhydrous pyridine (8 mL) and thmethylsilylchloride (1.77 mL, 14.0 
mmol) was added dropwise. The reaction was stirred at ambient under nitrogen for 
2 hours. In a separate flask triazole (192 mg, 2.79 mmol) was dissolved in 
anhydrous pyridine (5 mL) and cooled to 5°C in an ice bath. Phenoxyacetal chloride 
(385 pL, 2.79 mmol) was then added dropwise and the reaction allowed to stir at 
ambient temperature under nitrogen for 10 minutes. This was then added to the 
solution containing the protected nucleoside and the reaction allowed to stir at 
ambient temperature under nitrogen for 18 hours. Water (1 mL) was added to the 
reaction mixture after cooling in an ice bath. The reaction was stirred for a further 
hour. All reaction solvents were then removed in vacuo, the residue was then 
redissolved in water (10 mL) and extracted with DCM (3x10 mL). The combined 
organics were dried over MgS04 and the solvents removed in vacuo. The crude 
residue was purified by silica chromatography using a 5-10% methanol/DCM eluent 
system. The product was afforded as a white solid.
Yield: 220 mg, 0.57 mmol, 30%
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1H NMR (400MHz, DMSO-d6) 5 2.35 (m, 1H, H2'), 2.77 (m, 1H, H2'), 3.58 (m, 2H, 
H5'), 3.90 (m, 1H, H4’), 4.44 (m, 1H, H3'), 5.03 (s, 2H, C(0)CH20Ph), 5.37 (brs, 1H, 
3'-OH), 6.46 (apparent t, 1H, J= 6.72 Hz, HV), 6.96 (m, 3H, ArH PAC), 7.31 (m, 2H, 
ArH PAC), 8.68 (s, 1H, H8), 8.70 (s, 1H, H2) 10.93 (br s, 1H, NH).
13C NMR (100MHz, DMSO-d6) 5 39.6 (C2'), 61.9 (C5'), 67.5 (C(0)CH20Ph), 71.0 
(C3'), 84.1 (CV), 88.3 (C4'), 114.9 (ArC), 121.4 (ArC), 123.7 (C5), 129.8 (ArC),
143.3 (C8), 151.8 (C6), 151.9 (C4), 158.1 (C2), 167.7 (C=0).
HRMS found m/z (ES+) 408.1289 ([M + Na]+ 100%); [C^H^NgOs + Na]+ requires 
480.1284.
Preparation of /V-e-Phenoxvacetvl-S'-benzovl^'-deoxvadenosine (28)
A/-6-Phenoxyacetyl-2'-deoxyadenosine (220 mg, 0.56 mmol) was dissolved in 
anhydrous pyridine (1.5 mL) under a nitrogen atmosphere and cooled in an ice bath. 
Benzoyl chloride (0.07 mL, 0.56 mmol) in anhydrous pyridine (0.5 mL) was added to 
the stirred solution over a period of 30 mins and the reaction was then stirred in ice 
for a further 10 minutes. Water (0.1 mL) and ammonia (1 drop) were then added to 
the reaction mixture and stirring continued for 10 minutes. All solvents were 
removed in vacuo and the crude residue was redissolved in DCM (10 mL). The 
organic solution was then washed with water (10 mL) and dried over MgS04. The 
solution was then evaporated to dryness in vacuo. The crude residue was purified 
by silica chromatography using a 0-4% Methanol/DCM eluent system. The product 
was afforded as a white powdery solid.
Yield: 75 mg, 0.15 mmol, 26%
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1H NMR (400MHz, CDCI3) 5 2.66 (m, 1H, H2')t 3.03 (m, 1H, H2'), 4.35 (m, 1H, H4'), 
4.64 (m, 2H, H5'), 4.86 (m, 3H, CfOJCJHbOPh + H3'), 6.46 (apparent t, 1H, J= 6.28 
Hz, H1'), 7.05 (m, 3H, ArH), 7.32-7.62 (m, 5H, ArH), 7.96 (m, 2H, ArH), 8.16 (s, 1H, 
H8), 8.69 (s, 1H, H2), 9.41 (brs, 1H, NH).
13C NMR (100MHz, CDCI3) 5 40.1 (02'), 64.1 (05'), 68.4 (C(O)0H2OPh), 72.0 (03'), 
85.2 (01' + 04'), 115.3 (ArC), 122.8 (05), 128.9 (ArC), 130.0 (ArC), 130.2 (ArC), 
133.8 (ArC), 142.4 (08), 150.9 (06), 151.8 (04), 152.9 (02).
HRMS found m/z (ES+) 490.1710 ([M + Naf 100%); [C^H^NsOs + Naf requires 
490.1703.
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4,3 Solid-phase peptide synthesis
Techniques and reagents
High Performance Liquid Chromatography (HPLC)
HPLC was performed on an automated Glison HPLC system equipped with an 
autoinjector, a photodiode array detector and a dual hydraulic pump. 
Chromatographic data was handled using UniPoint version 3.0 and absorptions 
measured at 254nm.
Separations were performed on a reverse-phase 250mm x 4.6mm Gemini 5u C18 
110A column supplied by Phenomenex®. A gradient of 0-60% MeCN/[40% 
MeCN/60% 0.1M Trithethylammonium bicarbonate (TEAS)] was used for the 
thymidine tripeptide (50) over a period of 45 minutes.
UV spectroscopy
Spectra were recorded at the stated wavelengths on a Hewlett Packard 8452A 
spectrodiode array in 1 cm quartz cuvettes.
Reagents
4-Hydroxymethyl-3-methoxyphenoxybutyric acid-4-methylbenzhydrylamine (HMPB- 
MBHA) resin (0.82 mmol/g loading) was purchased from Novabiochem. O- 
(BenzotriazoM-yI)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) was 
provided by Fluka through Sigma Aldrich.
TNBS Test:
The TNBS test was performed using the following reagents:
Reagent A: 10% v/v DIPEA/DMF 
Reagent B: 1% v/v TNBS/DMF
Approximately 10 resin beads were extracted from the drained resin bed and placed 
in a microcentrifuge tube. One drop of each reagent solution was then added to the 
beads and the tube was left to stand for 5 minutes. The colour of the beads was 
noted as; red - positive, free amino groups present, successful deprotection. Yellow 
- negative, no free amino groups, unsuccessful deprotection or successful coupling.
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General procedure for solid-phase synthesis of S'-carboxylic acid peptides:
Couplings were performed on HMPB-MBHA resin (210 mg, 0.17 mmol loading) and 
initial coupling was carried out at 25% capacity.
Coupling Component Quantity
1 Fmoc amino acid 20.0 mg, 0.04 mmol
0.2 M HBTU in DMAc 240 pL, 0.05 mmol
DIPEA 8.30 pL, 0.05 mmol
2+ Fmoc amino acid 50.0 mg, 0.11 mmol
0.2 M HBTU in DMAc 525 pL, 0.11 mmol
DIPEA 18.0 pL, 0.11 mmol
Table 1: coupling conditions
Swelling of the resin and coupling of first nucleoside monomer residue:
The dry HMPB-MBHA resin was swollen overnight in three times the resin bed 
volume of DCM. The swelling solvent was removed and the resin washed with 
DMAc (x3). The thymidine derived p-amino acid (3, 20.0 mg, 0.04 mmol) was 
dissolved in 0.2 M HBTU/DMAc (240 pL, 0.05 mmol) and DIPEA (8.30 pL, 0.05 
mmol) and the solution was allowed to pre-activate for 60 seconds. This solution 
was then added to the resin along with a further aliquot of DMAc (150 pL) and 
agitated on an orbital shaker for 5 hours. The coupling solution was then removed 
and the resin washed with DMAc (5 x 0.25 mL).
Capping unreacted sites:
Excess capping solution (Ac20, DMAc, collidine, 1:8:1) was added to cover the resin 
and the reaction vessel was agitated on an orbital shaker for 10 minutes. The resin 
was then washed thoroughly with DMAc (5 x 0.25 mL).
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Removal of then-terminal Fmoc group:
Excess deprotection solution (2% DBU v/v in DMAc) was added to cover the resin 
and the reaction vessel agitated on an orbital shaker for 10 minutes. The 
deprotection solution was removed and the resin washed with DMAc (5 x 0.25 ml). 
A TNBS test was then performed to confirm the removal of the Fmoc protecting 
group through the detection of the newly generated NH2 groups.
Further residue couplings:
The cycle of coupling, capping and deprotection was continued according to the 
above procedures for further nucleoside residues. For all residues apart from the 
first, coupling times were reduced to 30 minutes and a TNBS test was performed to 
confirm successful couplings. The quantities for subsequent couplings are shown in 
Table 1. When all required couplings had been performed and the final deprotection 
step carried out the resin was dried. Drying of the resin was carried out by washing 
the resin bed with excess DMAc (x5), DCM (x5) and MeOH (x5) and the application 
of vacuum for 30 minutes. The resin was then stored in a vacuum dessicator for 24 
hours.
Cleavage of the peptide from the solid support:
The dried resin was swollen in excess DCM for 30 minutes and washed with fresh 
DCM (3 x 0.50 mL). The resin was then covered with the cleavage solution (1% v/v 
TFA in DCM) and agitated on an orbital shaker for 2 minutes. The cleavage solution 
was removed and retained. This procedure was repeated a further 9 times. Any 
residual peptide was washed from the resin bed with excess DCM (x3) and MeOH 
(x3) then the combined cleavage solutions were evaporated to dryness under 
reduced pressure to give peptide (50).
(50)
When analysed and purified by HPLC, the peptide product (50) was found to be 
contained in those fractions with retention times of 16.39, 17.30 and 18.18 minutes.
HRMS found m/z (ES‘) 728.2299 ([M -H]‘ 100%); [Csc^NcAs]' requires 728.2276 
for peak at retention time 16.39 minutes.
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HRMS found m/z (ES_) 728.2281 ([M -H]" 100%); [C3oH34N90133' requires 728.2276 
for peak at retention time 17.30 minutes.
HRMS found m/z (ES‘) 728.2298 ([M -H]‘ 100%); [C3oH34N9013]" requires 728.2276 
for peak at retention time 18.18 minutes.
Coupling efficiency UV assay:
The HMPB-MBHA resin (50 mg) was swollen in DCM overnight and then washed 
with excess of the chosen solvent DMAc/DMF (x5). Coupling of the first amino acid 
residue, using selected coupling reagents, was carried out according to the 
standard procedure discussed previously and all unreacted sites capped. The resin 
was then washed with excess DMAc/DMF (x5), DCM (x5) and MeOH (x5) and dried 
overnight in a vacuum dessicator. Once dried the resin was agitated with the 
deprotection solution (2 ml_) for 30 minutes and the solution removed into a 25 mL 
volumetric flask. This was then made up to the 25 ml mark with MeCN. Aliquots (1 
mL) of this solution were then further diluted to 25 ml for assay in the 
spectrophotometer.
A reference sample was prepared in the same manner with 2 mL of the 2 % DBU 
solution that had not been in contact with the resin. The UV spectra of these 
solutions were recorded and the absorption at 294 nm was noted in order to 
establish the coupling efficiency of a particular combination of resin and reagents.
The concentration of the initial 25 mL solution was then calculated from the UV 
absorbance and the percentage of coupling could be derived by comparing this to 
what the expected concentration would be for 100 % coupling.
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4.4 Solution synthesis of peptides
Preparation of fully protected thymidine dimer (51)
HOBt (118 mg, 0.88 mmol), HBTU (666 mg, 1.76 mmol) and di-/sopropylethyl amine 
(230 pi, 1.32 mmol) were dissolved in anhydrous THF (1 mL). 3'-A/-(9- 
Fluoromethoxycarbonyl)-3'-deoxythymidyl-5'-carboxylic acid (3, 504 mg, 1.05 mmol) 
dissolved in anhydrous THF (1 mL) was then added to the mixture and the reaction 
allowed to stir at ambient temperature for 2.5 hours. 3'-Amino-3'-deoxythymidine-5'- 
benzhydryl ester (14, 370 mg, 0.88 mmol) in anhydrous THF (1 mL) was then added 
to the reactionmixture followed by di-/sopropylethylamine (230 pi, 1.32 mmol). The 
reaction was warmed to 40°C and allowed to stir for 1 hour. The reaction was 
removed from the heat, allowed to cool then all solvents were removed in vacuo to 
give a brown sticky gum. The crude residue was purified by silica chromatography 
using a 3-5% methanol/DCM eluent system to give the product as a pale brown 
foam.
Yield: 688 mg, 0.78 mmol, 89%
’H NMR (500MHz, Pyr-d5) 5 1.75 (s, 3H, Thy-CH3), 1.91 (s, 3H, Thy-CH3), 2.49 (m, 
2H, H2'), 2.60 (m, 2H, H2'), 4.18 (m, 1H, Fmoc-CH), 4.62 (m, 2H, Fmoc-CFh), 4.72 
(m, 1H, H4'), 4.92 (m, 1H, H3'), 5.13 (m, 1H, H4'), 5.20 (m, 1H, H3'), 6.68 (m, 1H, 
HV), 6.83 (m, 1H, HV), 7.07-7.77 (m, 18H, Fmoc-H, Benzyhyryl-H), 7.98 (s, 1H, H- 
5), 8.02 (m, 2H, Fmoc-H), 8.27 (s, 1H, H-5), 9.22 (d, 1H, NH-amide, J= 6.50 Hz),
10.03 (d, 1H, NH-amide, J= 7.00 Hz), 13.09 (br s, 1H, NH-imine), 13.12 (br s, 1H, 
NH-imine).
13C NMR (125MHz, Pyr-d5) 5 12.3 (Thy-CH3), 12.4 (Thy-CH3), 36.5 (C2'), 37.2 (C2'), 
43.0 (Fmoc-CH), 53.0 (C3'), 55.7 (C3'), 67.0 (Fmoc-CH2), 78.5 (Benzhydryl-H), 82.2
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(C4'), 83.6 (C4'), 86.1 (CV), 89.5(01'), 111-2 (Ar-C), 111.4 (05), 116.4 (05), 119.9 
(Ar-C), [120.3, 125.0, 126.4, 127.0, 127.2, 127.7, 128.2, 128.3, 128.4 (Ar-C)], 134.7 
(06), 135.9 (06), 143.6 (02), 143.7 (02), 151.0 (04), 156.4 (04), 164.3 (Fmoc 
0=0), 170.0(05'), 170.9(05').
HRMS found m/z (ES+) 903.2989 ([M + Na]+ 100%); ^sFUNeOn + Na]+ requires 
903.2966.
Removal of Fmoc group from fully protected thymidine dimer (53)
o o
The fully protected thymidine dimer (51, 300 mg, 0.34 mmol) was dissolved in 
anhydrous THF (3 mL) and DBU (56.0 pi, 0.37 mmol) was added. The reaction was 
allowed to stir at ambient temperature for 30 mins and all solvents were then 
removed in vacuo. The crude gum was dissolved in DOM (10 mL) and washed with 
water (3x10 mL). The organic layer was dried over MgS04 and all solvents 
removed in vacuo. The crude gum was then redissolved in methanol (10 mL) and 
washed with hexane (4x10 mL) to remove non polar impurities. The impure 
product was afforded as a pale brown foam.
HRMS found m/z (ES+) 659.2490 ([M + H]* 100%); [CaaHasNeOc,]* requires 
659.2466.
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Removal of benzhvdrvl group from fully protected thymidine dimer (52)
The fully protected thymidine dimer (51, 150 mg, 0.17 mmol) was dissolved in 
anhydrous THF (2 mL) and a micro spatula of 10% Pd/C powder was added. The 
reaction vessel was sealed, evacuated and flushed with nitrogen twice followed 
hydrogen twice. The reaction was allowed to stir at room temperature and pressure 
under hydrogen for 72 hours. The system was flushed with fresh nitrogen and then 
the reaction mixture was filtered through celite. All the solvents were removed in 
vacuo to give a crude solid which was washed with diethyl ether (10 mL). The 
solvent was decanted from the solid and this solid redissolved in methanol (10 mL) 
and washed with hexane (3x10 mL). The solvent was removed in vacuo to afford 
the impure product as a pale brown solid.
HRMS found m/z (ES+) 737.2171 ([M + Na]+ 100%); [CasH^NUOn + Na]+ requires 
737.2183.
Preparation of fully protected thymidine trimer (55)
HOBt (8.0 mg, 0.06 mmol), HBTU (45.0 mg, 0.12mmol) and di-/sopropylethyl amine 
(15.0 pi, O.OQmmol) were dissolved in anhydrous THF (1mL). 3’-N~(9- 
FluoromethoxycarbonyO-S’-deoxythymidyl-S’-carboxylic acid (3, 34.0 mg, 0.07 
mmol) in anhydrous THF (0.5 mL) was then added and the reaction allowed to stir
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at ambient temperature for 2 hours. Dipeptide 53 (39.0 mg, 0.06 mmol) in 
anhydrous THF (0.5 mL) was then added followed by di-/sopropylethyl amine (15.0 
pi, 0.09 mmol) and the reaction was warmed to 40°C and stirred for 2.5 hours. All 
solvents were removed in vacuo and the residue was redissolved in a minimum 
amount of methanol.A precipitate was seen to form as a pale brown solid and was 
isolated by filteration.
Yield: 11.0 mg, 0.009 mmol, 17%
LRMS found m/z (ES+) [M-C^hU + Na]+ 974.1 ([M + Na]+ 100%)
Synthesis of fully protected thymidine tetramer (54)
HN HN
Ph2HCO
N O N cr N cr N
^NHFmoc
HOBt (10.0 mg, 0.07 mmol), HBTU (55.0 mg, 0.15 mmol) and di-/sopropylethyl 
amine (19pl, 0.11 mmol) were dissolved in anhydrous THF (1 mL). Dipeptide 52 (62 
mg, 0.09 mmol) in anhydrous THF (0.5 mL) was then added and the reaction 
allowed to stir at ambient temperature for 2.5 hours. Dipeptide 53 (48 mg, 0.07 
mmol) in anhydrous THF (0.5 mL) was then added followed by di-/sopropylethyl 
amine (19 pi, 0.11 mmol) and the reaction was warmed to 40°C and allowed to stir 
for 2.5 hours. All reaction solvents were removed in vacuo and the residue 
redissolved in a minimum amount of methanol. A precipitate was seen to form as a 
pale brown solid and was isolated by filteration.
Yield: 20.0 mg, 0.014 mmol, 20%
LRMS found m/z (ES+) 1377.29 ([M + Na]+ 100%)
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Preparation of fully protected thymidine-cytosine dimer (56)
HOBt (8.0 mg, 0.06 mmol), HBTU (44.0 mg, 0.11 mmol) and di-/sopropylethyl amine 
(15.0 pi, 0.09 mmol) were dissolved in a mixture of anhydrous THF (1 mL) and 
anhydrous acetonitrile (0.5 mL). A/-4-Benzoyl-3'-A/-Fmoc-amino-2', 3'-dideoxy-5- 
methylcytosine-5'-carboxylic acid (16, 25.0 mg, 0.07 mmol) in anhydrous THF (0.5 
mL) was then added and the reaction mixture allowed to stir at ambient temperature 
for 2.5 hours. S'-Amino-S'-deoxythymidine-S'-benzhydryl ester (14, 24.0 mg, 0.06 
mmol) in anhydrous THF (0.5 mL) was then added followed by di-/sopropylethyl 
amine (15 pi, 0.09 mmol) and the reaction was warmed to 40°C and allowed to stir 
for 2.5 hours. All solvents were removed in vacuo and the crude residue was 
purified by silica chromatography using a 2-3% methanol/DCM eluent system. The 
product was afforded as a beige foam.
Yield: 25 mg, 0.025 mmol, 42%
HRMS found m/z (ES+) 1006.3392 ([M + Maf 100%); [C55H49N7OH + Na]+ requires 
1006.3388.
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Preparation of fully protected thymidine-adenosine dimer (57)
o
HOBt (21.0 mg, 0.16 mmol), HBTU (118 mg, 0.31 mmol) and di-/'sopropylethyl 
amine (41.0 pi, 0.23 mmol) were dissolved in a mixture of anhydrous THF (1 mL) 
and anhydrous acetonitrile (1 mL). A/-6-Allyloxycarbonyl-3'-azido-2', 3'- 
dideoxyadenosine-5'-carboxylic acid (36, 70.0 mg, 0.19 mmol) in anhydrous THF 
(0.5 mL) was then added and the reaction mixture allowed to stir at ambient 
temperature for 2 hours. 3'-Amino-3'-deoxythymidine-5'-benzhydryl ester (14, 65.0 
mg, 0.15 mmol) in anhydrous THF (0.5 mL) was then added followed by di- 
/sopropylethyl amine (41.0 pi, 0.23 mmol), the reaction was warmed to 40°C and 
allowed to stir for 4 hours. All reaction solvents were removed in vacuo and the 
crude residue was analysed by mass spectrometry.
HRMS found m/z (ES+) 800.2529 ([M + Na]+ 100%); [C37H35NHO9 + Na]+ requires 
800.2517.
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